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Abstract 
 
This dissertation focuses on structural and functional studies related to the interaction 
between proteins and nucleic acids and their applications. The work reported here 
includes two projects. The first part of the thesis is on the mutational and combinatorial 
analysis of HIV-1 nucleocapsid protein (NCp7). Sixteen mutants of NCp7 were 
constructed and over-expressed in E. coli. The dissociation constants (Kd) between the 
mutant proteins and the major packaging signal in HIV-1, SL3 RNA, were measured using 
tryptophan fluorescence titration assay and/or isothermal titration calorimetry (ITC) 
assay. Most mutants show tolerance of the mutation but some mutants, including F16A, 
I24A and K14E-E21K, suffered moderate to significant loss of affinity for SL3 RNA, 
indicating the roles of the affected residues in the interaction between NCp7 and SL3. 
The second part focuses on the development of methods for aptamer discovery. Two 
prototype platforms were set up to imitate the two main-stream next-generation 
sequencing (NGS) technologies, bridge amplification based and emulsion PCR based NGS 
technologies. Proof-of-principle experiments were carried out and optimized to evaluate 
the practicality of these platforms in high-throughput and multiplexed aptamer 
discovery. 
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Part I.   Mutational and Combinatorial 
Analysis of HIV-1 Nucleocapsid Protein 
(NCp7) 
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Chapter 1. Introduction 
 
This dissertation focuses on structural and functional studies related to the interaction 
between proteins and nucleic acids and their applications. Work on two projects is 
reported in the following chapters in two parts. The first part of the thesis is on the 
mutational and combinatorial analysis of HIV-1 nucleocapsid protein, also known as 
NCp7. It covers the topics of construction of HIV-1 NCp7 mutants via site-directed 
mutagenesis, characterization of the mutant and wild type proteins, affinity assays for 
NCp7 variants with HIV-1 SL3 RNA, including tryptophan fluorescence titration and 
isothermal titration calorimetry.  The following is a general introduction to these topics. 
 
1.1. AIDS and HIV 
 
Acquired Immunodeficiency Syndrome (AIDS) is a disease that affects human immune 
system. It progressively breaks down the patient’s immune system and makes the 
victims more vulnerable to infections and tumors. AIDS is categorized as a bloodborne 
infectious disease and a sexually transmitted disease (STD) because it can be passed on 
by an exchange of bodily fluids [1]. Since its first public report in 1981 by the USCDC [2], 
AIDS has quickly escalated from an epidemic into a global pandemic.  In 2010, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) estimated in its annual global report 
that there were 33.3 million people living with the disease at the end of 2009, including 
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2.6 million people that were newly infected in the year of 2009. The disease killed 1.8 
million people in 2009, including 260,000 children of age 15 or younger. At present, 
AIDS has a prevalence of 0.8% in global adult population aged 15-49 [3]. These numbers 
are likely to increase further as researchers still have found no cure for AIDS after 
almost thirty years of hard work [4]. 
 
Human Immunodeficiency Virus (HIV) has been recognized as the causative agent of 
AIDS. It’s a retrovirus, meaning its genetic information is carried by RNA instead of DNA. 
HIV uses reverse transcriptase to transcribe its RNA to DNA, which in turn integrates 
into the host’s DNA [5]. HIV can be divided into two species, HIV-1 and HIV-2, with HIV-1 
being more infective and prevalent [6, 7]. As of today, we have been able to control the 
disease with an antiretroviral drug cocktail regimen, by targeting multiple stages of 
HIV’s replication cycle [8-10]. But current treatments are unable to eradicate the 
dormant virus integrated in the genomic DNA of the host. Moreover, HIV virus is known 
for its high mutation rate [11-15]. So new anti-HIV drugs and vaccines are needed to 
attack resistant strains, reduce side effects, improve the effectiveness of therapies and 
prevention methods, as well as to control treatment cost [16-20]. 
 
1.2. HIV Replication cycle 
 
Understanding HIV’s replication cycle has been key to the treatment of AIDS. Many 
details have been revealed about HIV and other retroviruses. As depicted in Figure 1-1 
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(D’Souza and Summers, 2005 [21]), a typical replication cycle of HIV-1 can be roughly 
divided into 9 steps: 
 
Step 1: Attachment. The surface subunit of HIV-1’s Env protein, gp120, recognizes and 
binds to the CD4 receptors on the surface of HIV-1’s host cells (T cells, 
macrophages and dendritic cells) [22]. The binding to CD4 induces a 
conformational change of gp120 [23, 24], leading to its high-affinity binding to 
chemokine receptors, including CCR5 and CXCR4 [25, 26], which function as co-
receptors for HIV-1 on the host cell surface. 
 
Step 2: Fusion. Interactions of gp120 with co-receptors trigger a cascade of 
conformational changes of Env that result in activation of the trans-membrane 
subunit of Env, gp41 [27]. The free energy released when gp41 undergoes 
conformational change then induces the fusion of virion and cell membranes 
[28]. The HIV-1 capsid core containing its genetic material is then released into 
the cytoplasm of the host cell. 
 
Step 3: Uncoating and Reverse Transcription. After viral entry, the HIV-1 capsid core 
disassembles, in which the capsid proteins (CA) are dissociated from the HIV-1 
nucleoprotein complex. This event is called uncoating. Uncoating of the capsid 
core is accompanied with the formation of subviral particles called reverse-
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transcription complexes (RTCs) and pre-integration complexes (PICs) [29, 30], in 
which the positive strand of viral RNA is transcribed to double-stranded DNA [5]. 
 
Step 4: Integration. The PICs containing the double-stranded proviral DNA are 
transported through the nuclear membrane. The proviral DNA is then inserted 
into the genomic DNA of the host with the help of the viral integrase [31]. The 
integrated proviral DNA is replicated together with the host genome but lies 
dormant in the latent stage of the replication cycle until being activated or 
induced by cellular or viral signals [32, 33]. 
 
Step 5: Transcription and Translation. Utilizing the host’s transcription machinery, HIV-1 
viral transcription from proviral DNA is initiated and driven by cellular 
transcription factors and the viral trans-activating protein Tat [34]. In the early 
stage, most mRNA is spliced and used to encode viral accessory proteins Tat, Rev 
and Nef. Full-length viral RNA is later transported to the cytoplasmic ribosome 
for translation with the help of Rev protein. Three viral polyproteins, Gag, Gag-
Pol and Env, are synthesized in the cytoplasm and at the endoplasmic reticulum. 
These polyproteins are later processed by proteolytic cleavage to generate 
structural and functional viral proteins [35]. 
 
Step 6: Genome Recognition. After the viral Gag and Gag-Pol polyproteins are 
synthesized, they recognize the full length viral RNA by the interaction between 
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the NC domain of Gag protein and the packaging signal at the 5’-end of viral RNA. 
Upon recognition of the viral RNA, Gag polyproteins assemble into multimeric 
structures around the RNA molecule and localize to the cell membrane [36]. 
 
Step 7: Assembly. As Gag polyproteins accumulate on the inner surface of the plasma 
membrane, they recruit the Env polyproteins, which are transported from the ER 
onto the cell surface via the secretory pathway, and start the assembly process 
of virus particles [35]. An immature particle is first formed with a relatively stable 
capsid core of spherical shape [37]. 
 
Step 8: Budding. The assembly of immature virion particles induces the formation of a 
bud on cell membrane and eventually the departure of the bud from host cell 
membrane. During this process, the virion particle acquires a plasma membrane-
derived lipid envelope that incorporates Env polyproteins and is tightly 
associated with a layer of Gag polyproteins. Budding offers a non-lytic approach 
for virus egress and allows the host cell to remain viable and continue to 
produce more progeny virions [37]. 
 
Step 9: Maturation. The freshly budded virion particle is immature and non-infectious. 
During and immediately after budding, the virion undergoes a dramatic 
morphologic change known as maturation. This step involves proteolytic 
cleavage of the Gag and Gag-Pol polyproteins and a large-scale rearrangement of 
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the cleavage products resulting in the structural transition of the virus core from 
a spherical to a conical shape [37-39]. 
 
1.3. Gag Polyprotein and NC (Nucleocapsid) Domain 
 
The HIV-1 genome contains nine open reading frames (ORFs), as shown in Figure 1-2 
(Freed, 1998 [36]). Three of these ORFs encode the Gag, Pol and Env polyproteins, which 
are later processed by viral and cellular proteases to generate individual structural 
proteins and enzymes [35]. The other six ORFs encode six accessory proteins that have 
regulatory or protective roles in the viral replication cycle [35, 40]. 
 
The 55kD Gag polyprotein is a major structural protein of HIV-1. During the maturation 
step of the viral replication cycle, it is proteolyzed into four proteins, MA (matrix), CA 
(capsid), NC (nucleocapsid) and p6, which make up the virion core containing the viral 
genomic RNA [35]. The Gag protein has important roles in many steps of HIV-1’s 
replication cycle, including viral particle assembly, localization, budding, maturation, 
early post-entry steps and reverse transcription [36]. 
 
Many of the Gag polyprotein’s functions are associated with the NC (nucleocapsid) 
domain or the mature NC protein [36, 41-56]. The most significant function of the NC 
domain or NC protein is to recognize the viral genomic RNA for correct virus packaging 
in a sequence-specific manner [57-61]. In the gag precursor, the NC domain is 
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responsible for full discrimination of genomic from non-genomic RNA via several RNA-
NC interactions [62-66]. NC also interacts with viral RNA or proviral DNA in a sequence-
nonspecific manner. In a HIV-1 virion particle, there are 2000 to 3000 gag precursors 
coating the dimeric viral RNA, equivalent to about one NC protein per every seven 
nucleotides [42, 67]. This Histone-like coating pattern of NC protects viral RNA or 
proviral DNA from nuclease digestion [46]. The NC domain or mature NC protein can 
destabilize sequence-nonspecific nucleic acid duplex [52], facilitate nucleic acid strand 
annealing and complex nucleic acid secondary structure rearrangements [52], 
chaperone viral RNA’s conformational rearrangement [68], activate viral RNA’s 
dimerization [69],  anneal the primer tRNA onto the genomic RNA for reverse 
transcription [70], and facilitate efficient minus- and plus-strand transfer in reverse 
transcription [71]. NC protein promotes primer-specific synthesis of proviral DNA and 
reduces non-specific self-primed reverse transcription of viral and cellular RNAs. NC also 
contributes to the high mutation rate of HIV-1 by enhancing the incorporation of 
mutations during minus strand DNA elongation [42]. 
 
NC also interacts with various viral and cellular proteins to perform its multiple 
functions. NC domain is essential to the self association of Gag polyprotein. It works in 
concert with MA and p6 domains as the driving force behind Gag multimerization and 
the assembly process of HIV-1 [72, 73]. NC is directly involved in the recruitment of HIV-
1 reverse transcriptase (RT) into nucleoprotein complexes. In collaboration with Vif, NC 
enhances RT processivity to promote synthesis of full-length cDNA [44, 74, 75]. NC is 
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also reported to regulate the timing of reverse transcription by inhibiting premature 
cDNA synthesis by RT during virion assembly [76, 77]. NC is required for incorporation of 
Vpr into the viral particle. Moreover, NC improves RNA recognition by Vpr through 
interaction with the C-terminus of Vpr [78, 79]. NC protein can stimulate the integration 
of HIV-1 proviral DNA by HIV-1 integrase [80, 81]. By directly binding F-actin, NC domain 
mediates the association of Gag precursor with the host cell cytoskeleton and plays a 
role in virus assembly and budding [82]. NC domain binds cellular protein Alix and 
cooperates with p6 domain on Gag precursor to recruit cellular proteins, such as HP68, 
Tsg101, EF-1α, Staufen, VAN and many other cellular proteins, which are proved or 
hypothesized to participate in viral assembly, budding, morphogenesis and other steps 
of HIV-1 replication cycle [55, 83, 84]. The cellular protein APOBEC3G, which is shown to 
have an anti-retroviral activity, is encapsidated into virus-like particles through a direct 
interaction with NC [49, 85]. Drugs to attack the nucleocapsid have the potential to 
interfere with critical functions at many stages of the viral replication cycle [45, 86]. 
 
The mature HIV-1 nucleocapsid protein contains 55 amino acid residues (see Figure 1-3) 
and has an apparent molecular weight around 7kD, hence the name NCp7. NCp7 has a 
highly conserved amino acid sequence among HIV-1 strains, as shown in Figure 1-4 (Lin 
and Borer, unpublished data [87]), and has several distinct structural features: 
 
(1) NC or NCp7 contains two conserved CCHC zinc finger motifs in the form: Cys-X2-
Cys-X4-His-X4-Cys (X is any amino acid residue) [88-90]. This CCHC type zinc finger 
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motif is highly conserved among retroviral nucleocapsid proteins and is relatively 
rare among cellular zinc finger proteins in which CCHH or CCCC motifs are more 
common [91, 92]. In coordination with zinc ions in a 1:1 stoichiometry, these zinc 
fingers maintain a unique backbone structure and play an essential role in viral 
genomic RNA packaging and infectivity. The zinc fingers, especially the intact N-
terminal zinc finger, are required for the binding specificity and target selectivity 
of NC for viral genomic RNA [93, 94]. Intact structure of the zinc fingers is 
required for the temporal control of reverse transcription by NC throughout the 
virus replication cycle [76, 77].  Mutations within the zinc fingers are usually 
inhibitory. Zinc finger mutations can impair intracellular HIV-1 Gag localization, 
virion biogenesis and maturation and infectivity [95]. Mutations that render NC 
incompetent for zinc binding can destroy the capacity to recognize and package 
genomic RNA [91, 96, 97]. Zinc finger interactions contribute to NC’s nucleic acid 
chaperone activity by facilitating efficient minus- and plus-strand transfer and 
nucleic acid annealing [71, 98, 99]. The conserved aromatic and hydrophobic 
residues, including F16, I24, A25 of zinc finger 1 and W37, Q45, M46 of zinc 
finger 2, are displayed on the protein surface and form a hydrophobic core that 
could serve as the nucleic acid interactive site [89]. Besides interaction with viral 
RNA, the zinc fingers are also found to directly interact with other proteins such 
as Vpr [78]. The N-terminal zinc finger (F1 in Figure 1-3) is more conserved 
among retroviruses and is proved more essential than the C-terminal zinc finger 
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(F2 in Figure 1-3), whereas F2 serves an accessory role in NC’s chaperoning 
activity [99-103].  
 
(2) One important feature of NC domain or NCp7 is its high content of basic residues. 
At neutral pH, NCp7 carries a net charge of +9. The basic residues in NC are 
important for virus budding. The mutation of basic residues in NC can cause a 
pronounced decrease in virus release from cultured cells [56]. The first zinc 
finger of NC is flanked on both sides by a highly conserved and basic consensus 
sequence, RXXRK, where X represents any amino acid residue. This motif is also 
present in other retroviruses and many non-retroviral RNA-binding proteins and 
is probably responsible for the unique hybridization properties of NC proteins, 
which enhance RNA dimerization, tRNA annealing to the RNA primer binding and 
the turnover rates of the interaction of a ribozyme with its RNA substrate [104, 
105]. Basic residues in those motifs as well as the first zinc finger have been 
shown to be required for speciﬁc binding of NC to HIV-1 RNA. In particular, R7, 
R32 and K33 are the most essential basic residues for the interaction between 
NCp7 and viral RNA [102, 104]. There’s an overall proportional relationship 
between the basicity of NC mutants and their non-specific RNA binding activity 
[104, 106]. Basic residues in NC domain are required for Gag-Gag interactions 
and Gag multimerization. But the specific interaction between Gag and viral RNA 
is more dependent on the protein tertiary structure than on the basic residues 
[107, 108].  
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(3) The linker region between the two zinc fingers has a highly conserved short basic 
sequence, 29RAPRKKG35. Most notably, the proline residue at position 31 occurs 
only in the trans conformation and induces a bend in the otherwise flexible 
linker that is likely to bring the two fingers into close proximity. Mutations that 
could destabilize the structure of the linker region are detrimental to the 
infectivity of virion particles. Substitution of Pro31 by D-Pro31 causes spatial 
rearrangement of the linker backbone, which leads to a severe reduction of viral 
RNA dimerization in vitro [109]. The mutation P31L inhibits incorporation of Gag-
Pol polyprotein and tRNALys3 into virion particles and results in a total loss of RT 
activity and the formation of non-infectious and immature viral particles [109, 
110]. The overall structure, rather than the basicity, of  the central globular 
domain of NC, which consists of the two zinc fingers and the linker region,  has 
been shown to be critical to the structure and infectivity of virions [108]. 
 
(4) Another characteristic of NC is that it contains one and only one tryptophan 
residue (Trp37), whose side chain resides in a hydrophobic core between the two 
zinc motifs and is key to NC’s interaction with viral RNA. Tight and saturated 
binding of RNA molecule onto NC can quench the natural fluorescence of Trp37 
by over 90%. Therefore the tryptophan fluorescence in NCp7 can be used to 
monitor and measure the binding of viral RNA to NC in in vitro assays [111]. 
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Its multitude and significance in function and its sequence conservation and distinct 
structure make the NC domain or mature NC protein an attractive target for anti-HIV 
drug discovery. Even though there hasn’t been an approved NC inhibitor as anti-HIV 
drug because of lack of selectivity and efficacy in drug candidates so far [112, 113], 
researchers have been actively working on finding an effective anti-HIV drug that targets 
NC domain or NCp7 [45, 86, 114-119]. Investigation of the structure-function 
relationship in the interaction between NCp7 and viral RNA would shed light on the 
rational design of anti-HIV drugs. 
 
Mature NCp7 interacts with nucleic acids in vitro in a similar manner as NC domain does 
in vivo [120, 121].  Synthetic or recombinant NCp7 protein has been widely used as a 
model for structural and functional studies on NC and NC domain [57, 102, 104, 121-
124]. Therefore in this project I used recombinant NCp7 mutant and wild type proteins 
over-expressed in E. coli as targets to investigate the interactions between them and 
viral RNA in vitro. 
 
1.4. SL3 Packaging Signal 
 
The HIV-1 genome contains two copies of a 9.7-kb RNA molecule in a dimeric form, 
which are coated with nucleocapsid proteins [125]. Besides serving as the HIV-1 genome, 
the full length viral RNA also functions as an mRNA to encode the Gag and Gag-Pol 
polyproteins [126]. Many functions of NC domain or NCp7 involve interactions between 
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NC and the viral RNA. NC demonstrates both specific and non-specific interactions with 
RNA. The non-specific interaction can be attributed largely to its high basicity, whereas 
the specific interaction likely results from the structure of NC domain and/or the 
sequence and structure of viral RNA, especially the 5’-untranslated region (5’-UTR) on 
the viral RNA.  
 
The 5’-untranslated region (5’-UTR) on the viral RNA is the most conserved part of the 
HIV-1 genome and contains multiple distinct secondary structures, as shown in Figure 1-
5 [57, 127-129], that can mediate several crucial steps in the viral replication cycle [130]. 
These structural elements include a trans-acting responsive (TAR) hairpin which binds 
the transcriptional trans-activator protein Tat to regulate viral transcription [131, 132]; a 
polyadenylation signal hairpin (poly(A)) which is inhibited by downstream splicing 
signals [133, 134]; a primer binding site (PBS) domain where the tRNALys3 anneals to the 
viral RNA as a primer to initiate reverse transcription [135, 136]; three stem-loops 
containing the dimerization initiation site (DIS or SL1) [137, 138], the splice donor site 
(SD or SL2) [139, 140] and the packaging signal (Ψ or SL3) domain [139, 141]; as well as 
the start codon of the Gag polyprotein.  
 
The NC domain or NCp7 can interact with many RNA motifs on the 5’-UTR region [53, 69, 
98]. But NC bears the highest specificity and affinity for the major packaging signal SL3 
[123, 142], which is considered as NC’s major RNA partner and primary recognition site 
on HIV-1 genome. SL3 is highly conserved in sequences among different strains of HIV-1 
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and well structured, which makes it of particular interest to many researchers [57, 61-66, 
141, 143]. Inhibition of NC-SL3 interaction can significantly reduce the release of virus 
particles from infected cells[144]. Deletion of the packaging signal causes loss of HIV-1 
specific RNA from the virus-like particles being released from infected cells [141]. 
Disruption of the stem-loop structure of SL3 significantly diminishes both viral RNA 
packaging and dimerization [145]. Further study of the interaction of NCp7 and SL3 
could provide useful information that can facilitate rational design of anti-HIV drugs. To 
investigate the interaction between NCp7 and SL3, De Guzman et al. (1998) constructed 
a 20-nucleotide RNA molecule containing the 14-nt core sequence of SL3 (as shown in 
Figure 1-5 inset) [57]. For consistency and convenience, in this study I used the same 20-
mer synthetic RNA molecule for affinity assays. 
 
1.5. Interactions within the NCp7-SL3 complex 
 
In 1998, the 3-D structure of the NCp7-SL3 complex (PDB 1A1T) was solved using 
heteronuclear magnetic resonance spectroscopy by the Summers lab at University of 
Maryland-Baltimore County, Baltimore, MD, with collaboration of the Borer lab at 
Syracuse University, Syracuse, NY [57]. This structure revealed many details of the 
interactions between NCp7 and SL3 RNA as summarized below, which served as a basis 
for designing the mutation sites in this study. 
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(1) Overall structure: The stem nucleotides of SL3 RNA form an A helix and the tetra 
loop bases project away from the stem and interact directly with NCp7. In NCp7, 
the N-terminal residues from Lys3 to Arg10 form a 310 helix that binds within the 
major groove of the RNA molecule. The two zinc fingers F1 and F2 are in close 
proximity and interact with the G320 and G318 bases on the RNA tetra loop, 
respectively, as shown in Figure 1-6. 
 
(2) Hydrophobic interactions play a significant role in maintaining the protein 
structure and contribute to the specific interactions between NC and SL3. 
Hydrophobic interactions among Phe6 of the 310 helix, Val
13 and Ile24 of F1 bring 
the 310 helix tightly against the F1 knuckle, whereas the hydrophobic interactions 
among Trp37of F2 and Phe16, Asn17, and Gly19 of F1 bring the two zinc fingers 
tightly together. G320 binds to a hydrophobic cleft formed by the side chains of 
Val13, Phe16, Ile24 and Ala25. G318 interacts with the F2 finger in a similar manner, 
by fitting into a hydrophobic cleft formed by Trp37, Gln45 and Met46 side chains. 
A319 makes hydrophobic contacts with the beta methyl or methylene groups of 
Ala25, Phe16 and Asn17. A zoomed-in view of the hydrophobic clefts on the 
surface model of the complex is shown in Figure 1-7. 
 
 
(3) Hydrogen bonding is another important factor in the intra- and intermolecular 
interactions within NCp7-SL3 complex. Phe16 forms a hydrogen bond with Trp37. 
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Extensive hydrogen bonding between the side chain atoms of Asn17 to Cys28, 
Pro31 and Lys33 stabilizes a single conformation of the linker region, which links 
the two zinc fingers in close proximity. G320 forms hydrogen bonds with the 
backbone atoms of Lys14, Phe16 and Ala25. G318 forms hydrogen bonds with the 
backbone atoms of Trp37, Met46 and Gly35. A319 forms a hydrogen bond with the 
side chain of Arg32. The side chain carbonyl of Asn5 forms a hydrogen bond with 
the RNA stem and its NH2 group interacts with atoms of G
320 and G321. 
 
(4) Electrostatic interactions also contribute to maintaining the structure of the 
NCp7-SL3 complex. Ten out of 15 basic residues are involved in intra- or 
intermolecular interactions in the NC-SL3 complex. Most notably, three salt 
bridges are formed between Lys14-Glu21, Lys33-Glu42 and Lys38-Glu51. The salt 
bridges involving Lys14-Glu21 and Lys38-Glu51 are believed to stabilize the folding 
of the F1 and F2 fingers, respectively. And the salt bridge between Lys33 and 
Glu42 is thought to stabilize F2-linker interactions. Lys26 and Lys47 are responsible 
for anchoring the zinc fingers to the RNA through electrostatic interactions. 
Other basic residues are involved in non-specific electrostatic contacts with the 
RNA. 
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1.6. Previous mutational studies 
 
The obvious significance and the unusual conservation of HIV-1 NC had invited extensive 
mutational analysis on the protein. Deletion and replacement analysis indicated that 
zinc finger F1 plays a more important role than F2 in NC’s functions [99, 102, 146, 147]. 
The intact CCHC motif of zinc finger F1 is required for the optimal target selectivity of 
NCp7 [93]. The four conserved C-C-H-C residues involved in the zinc fingers were shown 
to be critical for the functions of NC and infectivity of HIV-1 viral particles [76, 78, 95, 
101, 103, 110, 148]. Random single mutations in the zinc motifs of NC resulted in more 
relaxed RNA binding specificity of the protein [94]. Site-directed mutagenesis was 
carried out on each residue in zinc finger F1 [148]. Five mutants, including F16A and 
other four mutants on the C-C-H-C motif, showed no virus replication and significantly 
lower viral RNA content in mutant viral particles. Replacing zinc finger F1 with F2 also 
rendered similar adverse effects on virus replication and viral RNA content [148]. 
Binding assay using chemically synthesized mutants of NC protein showed that zinc 
finger F1 and its flanking basic amino acid residues are sufficient for specific RNA binding. 
Among those residues, F16 and T24 (a conserved variation of I24) and the arginine 
residues, as well as the C-C-H-C motif,  are essential for NC’s specific RNA binding [102]. 
Substitution of D-proline or leucine for Pro31 demonstrated reduced protein function 
and viral infectivity [108-110]. Mutational analysis on the linker region between the two 
zinc fingers indicated that the overall structure, rather than the basic nature, of the 
linker region is critical for virion structure and infectivity [108]. Mutational analysis of 
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basic residues in NCp7 suggested proportional relationship between the basicity of NC 
mutants and their binding affinity for RNA or infectivity of mutant viruses. Nonetheless, 
some basic amino acid residues, including R7, K14, R32 and K33, were proved to be 
more critical than others for NC’s activity or the structure and infectivity of mutant 
viruses [104, 149]. 
 
Some mutants reported in this dissertation, such as F16A and E21A, have been 
previously studied by various binding or functional assays [82, 102, 146, 148]. Most in 
vitro binding assays were carried out under different conditions than studied in this 
thesis, and some of the findings weren’t consistent with each other (studies at low ionic 
strength are largely irrelevant due to the dominance of non-sequence-specific 
interactions [124]). Our work addresses these conflicts via a systematic and thorough 
mutational and binding study on the effect of side chain contacts of NC residues on the 
interactions between NC and SL3.  
 
1.7. Specific Aims 
 
The goal of this project was to locate the key residues in the NCp7-SL3 interaction that 
are responsible for recognition and packaging of viral genomic RNA into nascent viral 
particles. Based on previous studies and current knowledge of HIV-1 biology, the 
following key hypotheses were proposed: 
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(1) The RNA-nucleocapsid interaction is nearly the same in the NC-domain of the 
Gag precursor as in the mature NCp7 protein. 
 
(2) The NC-SL3 interaction is mainly defined by direct side chain contacts between 
the protein and RNA. 
 
(3) Important RNA-protein contacts that stabilize the NCp7-SL3 complex can be 
probed by varying the protein sequence. 
 
These hypotheses lead to the following specific aims: 
 
A. Construct and express NCp7 variant proteins in which certain side chain contacts 
are altered. Site-directed mutagenesis was used to construct the mutants. The 
proteins were over-expressed in E. coli as recombinant proteins and used in in 
vitro affinity assays for SL3 RNA. 
 
B. Determine affinities of NCp7 variant proteins for SL3 RNA. Two types of affinity 
assays were used in this study. The primary assay is a fluorescence spectroscopy 
based assay, taking advantage of the natural fluorescence of Trp37. The 
secondary assay is a direct thermodynamic assay and is used to confirm and 
validate the data collected from the primary assay. 
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C. Map the binding surface on NCp7 for SL3 RNA by comparing the affinity of NCp7 
variants with wild type, so as to locate key residues in NCp7-SL3 interaction. 
 
The methods and results are described and discussed in the following chapters. 
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Figure 1-1. General features of HIV-1 replication cycle 
Viral proteins labeled in the graph are: Gag, group-specific antigen protein; matrix (MA, 
green), capsid (CA, red) and nucleocapsid (NC, blue); IN, integrase; Pol, polymerase; Rev, 
regulator of viral protein expression; RT, reverse transcriptase; Vpr, viral propagation. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, 
copyright 2005 (D’Souza and Summers [21]). 
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Figure 1-2. Schematic representation of the HIV-1 genome and virion 
(A) The location of the HIV-1 open reading frames is indicated. The RNA packaging signal, 
ψ, is shown near the 5’-end of the genome. The gag open reading frame is enlarged. 
(B) The HIV-1 virion, indicating the approximate location of Gag proteins, the Env 
glycoproteins and the pol-encoded enzymes IN, RT, and PR 
Reprinted from Virology, 251(1), Freed EO, pages 1-15, Copyright 1998, with permission 
from Elsevier [36]. 
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Figure 1-3. The amino acid sequence of HIV-1 NCp7 protein 
Residues carrying a charge at neutral pH are shown in solid letters (positive = blue 
capital letter, negative = red lower case); Zn2·NCp7 (1-55) carries a +9 charge at neutral 
pH. The green outlined letter W indicates that the residue Trp37 has natural fluorescence. 
 
 - 25 - 
 
 
 
Figure 1-4. Variation in 1700 NCp7 sequences 
Open bars: conservative amino acid substitutions, closed bars: non-conservative. 
Notation for RNA to protein side-chain interactions in the SL3-NCp7 complex: B = H-
bonds or salt-bridges, S = steric contacts. Side-chain protein to protein contacts are also 
noted: b = H-bonds or salt-bridges, s = steric contacts [57]. The consensus sequence is 
shown, with different residues in the pNL4-3 isolate used in this work noted in 
parentheses. CCHC in F1 and F2 are marked.  
Reprinted with permission from Lin and Borer, unpublished data [87]. 
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Figure 1-5. Secondary RNA structure model of HIV-1 5' un-translated region 
(5'-UTR) 
Schematic illustration of a consensus hypothetical model of the HIV-1 5'-UTR showing 
multiple stem-loop structures important for virus replication (from left to right): TAR 
element, the poly(A) hairpin, the PBS domain, Stem-Loop 1 (DIS), Stem-Loop 2 (splice 
donor, SD), Stem-Loop 3 (packaging signal, Ψ), and the Gag start codon, respectively. 
Inset shows a 20-mer synthetic RNA molecule, which contains the core sequence of SL3 
and is used in this study as a model for SL3. (Adapted from Russell et al. 2004 [127], 
Paillart et al. 2004 [128], De Guzman et al. 1998 [57] and Watts et al. 2009 [129]). 
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Figure 1-6. NMR structure of NCp7-SL3 complex 
White ribbon: SL3 RNA; Stick model: backbone and base of G318 and G320; Magenta 
ribbon: N-terminal 3-10 helix of NCp7; Yellow ribbon: N-terminal zinc finger (F1); Cyan 
ribbon: linker region; Red ribbon: C-terminal zinc finger (F2); White sphere: zinc. Drawn 
from PDB ID 1A1T using the UCSF Chimera package from the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported 
by NIH P41 RR001081) [150]. 
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Figure 1-7. Hydrophobic cleft on NCp7-SL3 complex 
White ribbon: SL3 RNA; Stick model: backbone and base of G318, A319 and G320; Surface 
model: NCp7 protein; Magenta: N-terminal 3-10 helix of NCp7; Yellow: N-terminal zinc 
finger (F1); Cyan: linker region; Red: C-terminal zinc finger (F2). Drawn from PDB ID 1A1T 
using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 
RR001081) [150].  
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Chapter 2. Construction, Expression, 
Purification and Characterization of 
Variants of NCp7 Protein 
 
2.1. Introduction 
 
2.1.1. Site-directed mutagenesis 
 
Site-directed mutagenesis is a widely used technique in molecular biology to introduce 
single point mutations or multiple mutations, insertions and deletions into a cloned DNA 
fragment by polymerase chain reaction (PCR) [151]. As shown in Figure 2-1 (Stratagene, 
2005 [152]), the desired mutation is designed and incorporated into a pair of mutagenic 
primers. The primers are annealed to the circular dsDNA template (plasmid) and 
extended by a high fidelity polymerase (PfuUltra). 
 
DNA methylation is not essential but nonetheless universal in E. coli [153]. Many 
laboratory strains of E. coli, including the XL1-blue and BL21(DE3)pLysS strains used in 
this study, encode three sequence-specific methylases:  the hsd  (host-specificity),  dam  
(DNA  adenine  methylation),  and  dcm (DNA cytosine methylation) [153]. Foreign 
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plasmids transformed into such E. coli strains will also become methylated if they 
contain sequences recognized by those methylases [154, 155]. The dam methylase 
specifically methylates the adenine residue in sequence GATC on both strands of the 
duplex DNA. The Dpn I restriction enzyme cleaves on the 3’ side of methylated adenine 
within the sequence GA*TC (* indicates methylation), which means all dam modified 
dsDNA molecules are susceptible to Dpn I digestion [155, 156]. 
 
After sufficient thermal cycles, the mutagenesis PCR reaction produces a large number 
of dsDNA molecules amplified by PfuUltra, which contain mutations introduced by the 
primers and do not have dam methylation. The amplified PCR mixture is then subjected 
to Dpn I digestion [152]. Because PCR synthesized products are not methylated, they 
can survive the Dpn I digestion and stay intact, while the parental plasmid templates 
containing dam methylation are degraded by Dpn I. Then the PCR synthesized DNA 
containing the desired mutation is transformed into E. coli cells for preservation and 
expression. Site-directed mutagenesis simplifies the process of gene manipulation and 
has become an important tool in protein engineering, functional genomics and 
structural biology. 
 
Alanine scanning mutagenesis is probably the most common practice of site-directed 
mutagenesis, in which the codon for one amino acid residue is substituted with a codon 
for alanine [157]. Alanine was chosen as the substitution because it’s the simplest chiral 
molecule of the 22 proteinogenic amino acids, with a chemically inert methyl group as 
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its side chain. By substituting alanine for other amino acid residues, the side chain 
contact on the mutated residue will be eliminated or greatly reduced whereas the 
protein backbone remains unaltered. Thus the role of the side chain contact of the 
mutated residue can be speculated from quantitative binding analysis of the alanine 
scanning mutants. 
 
2.1.2. Over-Expression and Purification of Recombinant NCp7 
 
Over-expression of recombinant proteins in E. coli has been a routine technique in 
modern biochemistry labs. Protocols for recombinant wild type NCp7 protein over-
expression and purification have been well established and documented [111, 158, 159]. 
Because of the unusually high content of basic residues in NCp7, few proteins in E. coli 
bear a higher charge than NCp7 does at neutral pH. Based on this fact, a two-part ion 
exchange purification procedure was successfully used for the separation and 
purification of NCp7. Because all mutants constructed in this study have the same or 
even higher charge than wild type NCp7 at neutral pH, similar purification protocols can 
be applied to the mutant proteins with only minimal modification. 
 
In previously established protocols for purification of NCp7 protein, reducing agents 
such as dithiothreitol (DTT) and beta-mercaptoethanol (BME) were used extensively in 
order to protect the thiol group on the cysteine residues of the recombinant protein 
from oxidation and forming disulfide bonds. DTT and BME are both widely used and 
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very effective reducing agents. But UV background interference tends to be a problem 
in accurate concentration determination of protein samples containing DTT or BME. The 
oxidized forms of both DTT and BME have high absorption around the UV280 region. 
Therefore they can interfere or even mask the UV absorption by a protein sample, 
especially when the protein concentration is low. Air oxidation of DTT and BME makes it 
difficult to avoid the interference by simply using a buffer blank. 
 
Tris(2-Carboxyethyl) phosphine Hydrochloride (TCEP·HCl) is an attractive alternative to 
DTT and BME [160]. It is a powerful reducing agent with a reducing potency comparable 
to that of DTT. It is also non-volatile, odorless and resistant to air oxidation. More 
importantly, it does not have absorption peak in the UV-Vis range so that it won’t 
interfere with the measurement of protein concentration by UV absorption. All these 
advantages make TCEP·HCl an ideal substitution for DTT and BME in the purification of 
recombinant NCp7 proteins in this study. The results in this study demonstrated 
satisfactory and reproducible purification of NCp7 with TCEP·HCl as the protective 
reducing agent. 
 
2.1.3. Protein characterization assays 
 
SDS-PAGE was routinely used in this study to check the expression level of recombinant 
NCp7 proteins and the purity of the purified proteins. Besides SDS-PAGE, two other 
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assays were used in this study to identify and characterize the proteins before they are 
subjected to affinity assays with SL3 RNA. 
 
Mass spectrometry has been a preferred technology in protein identification for many 
years [161]. Among different MS techniques, MALDI-TOF (Matrix-assisted laser 
desorption/ionization (MALDI) in combination with time-of-flight (TOF) mass analyzers) 
mass spectrometry is especially useful in protein and peptide analysis. MALDI-TOF mass 
spectrometry is applicable to a wide range of biomacromolecules and is more tolerant 
of common contaminants than other techniques. MALDI ionization preserves the 
structural integrity of ionized biomacromolecules and extends the molecular weight and 
polarity range of sample detection, allowing for easy sample preparation, large m/z 
range and enhanced sensitivity [162, 163]. MALDI-TOF mass spectrometry was mainly 
used in this study to determine the accurate molecular weight of the expressed and 
purified protein. It also further confirmed the purity of the protein sample which was 
checked on SDS-PAGE after purification. 
 
Analytical ultracentrifugation is often used as a “gold standard” for monitoring 
aggregation status of protein samples [164]. Protein oligomerization or aggregation can 
affect the stoichiometry and apparent affinity of the studied protein for its ligands. So it 
is important to determine the aggregation status of the protein of interest before 
subjecting it to affinity assays. Our previous fluorescence titration model had assumed 
that NCp7 is in monomer form and binds to SL3 RNA in a 1:1 ratio. The titration data 
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fitted the model well [165]. But this assumption had never been directly proved by 
experiment until now. 
 
2.2. Materials and Methods 
 
Unless otherwise noted, all chemicals and reagents were purchased from Sigma-Aldrich 
(St. Louis, MO), Thermo Fisher (Waltham, MA) or Thermo Pierce (Rockford, IL). All E. coli 
strains and site-directed mutagenesis kits were purchased from Stratagene (now Agilent 
Genomics, Santa Clara, CA). All buffers and media were prepared with analytical grade 
water produced from a Millipore Elix water purification system or ultrapure water 
produced from a Millipore Milli-Q Biocel ultrapure water system (Millipore, Billerica, 
MA). 
 
Strains, plasmids and media. XL1-Blue E. coli strain was used for plasmid cloning and 
preservation. BL21-(DE3)pLysS E. coli strain was used for the over-expression of NCp7 
wild type and mutant proteins. The pRD2 plasmid containing the coding sequence of the 
55-amino acid NCp7 from HIV-1 pNL4-3 strain[159] (a generous gift from Dr. Michael 
Summers at University of Maryland, Baltimore County, referred to as “wild type” in the 
following text. See plasmid map and sequence in appendix A) was used as template for 
site-directed mutagenesis to construct all the NCp7 mutants characterized in this study. 
The recombinant protein has methionine at position one of NCp7, coded by the AUG 
start codon, rather than isoleucine, which occurs in wild type NCp7 from HIV-1 pNL4-3 
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strain. Luria-Bertan (LB) medium was prepared according to Sambrook et al. [166] or 
using pre-packed LB medium capsules (MP Biomedicals, Solon, OH). XL1-Blue strains 
were grown in LB medium containing Ampicillin (Amp) (100μg/ml) as a selective 
antibiotic. BL21-(DE3)pLysS strains were grown in presence of Amp (100μg/ml) and 
Chloramphenicol (Cam) (34μg/ml). For protein over-expression, the LB-Amp-Cam media 
were also supplemented with glucose (4g/L), MgSO4 (1mM), ZnCl2 (100μM), and M9 
salts (NH4Cl (1g/L), Na2HPO4∙7H2O (3.2g/L) and KH2PO4 (3g/L) [111, 159, 167]. The sugar 
and salt solutions were prepared as 10X, 100X or 1000X stock solutions, sterilized 
separately and added to the media each time before starting culture. 
 
Plasmid preparation. A single XL1-Blue colony picked from a freshly grown LB-Amp plate 
was used to inoculate 5ml of LB-Amp media and grown at 37°C overnight, shaking at 
200-250rpm. The overnight culture was harvested by centrifugation in a refrigerated 
Eppendorf centrifuge Model 5804 (Eppendorf, Hauppauge, NY) for 5min at 3000rpm. 
The plasmid was prepared from the harvested XL1-Blue cells using a QIAprep Spin 
Miniprep kit (Qiagen, Valencia, CA) and eluted with 50µl of H2O or 1X TE (10mM Tris-
HCl, 1 mM EDTA, pH 8.0) [168] (also see appendix B-2). Plasmids are stored in 1X TE at -
80°C for long term storage. The purity of the plasmid miniprep was confirmed by 1% 
agarose gel electrophoresis and the concentration of the plasmid was determined using 
a Nanodrop ND-1000 UV-Vis spectrophotometer (Thermo Nanodrop, Wilmington, DE).  
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Site-directed mutagenesis. The Stratagene QuikChange® or QuikChange® II site-directed 
mutagenesis kit was used to introduce site-specific mutations at positions listed in 
Figure 2-2. Site-directed mutagenesis primers were designed using Stratagene 
QuikChange Primer Design Program (http://www.genomics.agilent.com) or PrimerX 
online tool (http://bioinformatics.org/primerx/) and synthesized by Integrated DNA 
Technologies, Inc. (Coralville, IA). The mutagenesis PCR reactions were set up according 
to the manufacturer’s instructions [152] (also see appendix B-3). After the PCR reactions 
were finished, 0.5 μl of Dpn I restriction enzyme (provided in the site-directed 
mutagenesis kit) was added into each reaction and incubated for 1 hr. The digested PCR 
products were run on a 1% Agarose gel to check product size and estimate DNA 
concentration. Then the digested PCR product was transformed into XL1-Blue E. coli 
competent cells according to the manufacturer’s instructions [152] (also see appendix B-
4). XL1-Blue strains transformed with plasmids can be preserved in 15% glycerol (final 
concentration) at -80°C for long term storage. Frozen stock of XL1-Blue strains should be 
renewed every six months by remaking frozen stock from fresh overnight culture (also 
see appendix B-6). Repeat the transformation if necessary. Plasmids containing the 
desired mutations were prepared and stored as described above. 
 
Sequencing. The prepared wild type and mutant plasmids were sequenced at the Core 
Facility for DNA Sequencing & Flow Cytometry at State University of New York Upstate 
Medical University, using a universal T7 promoter primer as sequencing primer. The 
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sequences of mutants and wild type were aligned using the ClustalW2 online tool [169], 
to confirm the position and sequence of the introduced mutation.  
 
Transformation of BL21-(DE3)pLysS competent cells. The mutated and confirmed 
plasmids were transformed into BL21-(DE3)pLysS E. coli competent cells according to 
the manufacturer’s instruction [170] (also see appendix B-5). BL21-(DE3)pLysS strains 
transformed with plasmids can be preserved in 15% glycerol (final concentration) at -
80°C for long term storage. Frozen stock of BL21-(DE3)pLysS strains should be renewed 
every six months by remaking frozen stock from fresh overnight culture (also see 
appendix B-6). Repeat the transformation if necessary. 
 
Over-expression of NCp7 Variants. The wild type and mutant NCp7 strains were grown in 
LB media and the proteins were over-expressed using a revised protocol based on that 
of Lee et al. [159] and Shubsda et al. [111] (also see appendix B-7). A Single BL21-
(DE3)pLysS colony was used to inoculate 5ml of supplemented LB-Amp-Cam media as 
starter culture and grown at 37°C overnight, shaking at 200-250rpm. The overnight 
starter culture was added to 1L of supplemented LB-Amp-Cam media and grown at 37°C, 
shaking at 200-250rpm. The culture was induced with 400µM IPTG (isopropyl-β-D-
thiogalactopyranoside) when its absorbance at 600nm reached 0.6-0.8. The induced 
cells were grown for 4 more hours and harvested by centrifugation on an Avanti® J-E 
centrifuge (Beckman Coulter, Brea, CA) using the JLA-10.5 rotor at 5000rpm for 15 
minutes. The cell pellets were kept frozen at -20°C before subjected to cell lysis. 
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Cell Lysis. Cell lysis was performed using a modified protocol based on that of Shubsda 
et al. [111] (see also appendix B-8) Cell pellets from 1L culture were re-suspended on ice 
in 30ml of lysis buffer (50mM Tris-HCl (pH 8.0), 10% (v/v) glycerol, 0.1M NaCl, 1µM ZnCl2, 
5mM TCEP·HCl (Tris(2-Carboxyethyl) phosphine Hydrochloride, 60µg/ml Lysozyme, 
53µM PMSF (phenylmethylsulfonyl fluoride), 1µg/ml Pepstatin A, 5mM sodium 
deoxycholate). The mixture was left on ice for 20minutes before 4ml of B-PER II Protein 
Extraction Reagent (Thermo Pierce) was added. The cells were then left on ice for 10 
minutes before subjected to 4x 25 seconds of sonication using a Microson XL2000 
Ultrasonic Liquid Processor (Misonix, now Qsonica, Newtown, CT) at an output power of 
20-25 watts. 2ml of 4% PEI (polyethyleneimine) was then added to the mixture and 
mixed thoroughly. The lysed cells were centrifuged at 17,000rpm for 30min at 4°C on an 
Avanti® J-E centrifuge using the JA-25.5 rotor and the supernatant (lysate) was collected 
for FPLC purification. 
 
FPLC purification of NCp7 proteins. FPLC purification was carried out on an AKTA FPLC 
system (Amersham, now GE Healthcare, Piscataway, NJ). Cell lysate was loaded onto a 
HiPrep Q FF and a HiPrep SP FF column (GE Healthcare) connected in series and 
previously equilibrated with  at least 200ml of buffer A (50mM Tris-HCl (pH 8.0), 10% 
(v/v) glycerol, 0.1M NaCl, 1µM ZnCl2, 1mM TCEP·HCl). After the A280 value returned to 
baseline, the Q-column was disconnected and NCp7 protein was eluted using a one-
hour linear gradient from 20% to 50% buffer B (50mM Tris-HCl (pH 8.0), 10% (v/v) 
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glycerol, 1.0M NaCl, 1µM ZnCl2, 1mM TCEP·HCl) (also see appendix B-9). Homogeneity 
of the eluted protein was determined by SDS-PAGE. The purified NCp7 protein fractions 
were then pooled and concentrated using a VIVASPIN 15ml Concentrator (5000 MWCO) 
(GE Healthcare). The NCp7 concentration was determined by UV280 absorbance using a 
molar extinction coefficient of ε280 = 6050 M
-1∙cm-1 [171, 172]. Sample purity and 
homogeneity was further confirmed by MALDI-TOF mass spectrometry and analytical 
ultracentrifugation. Purified NCp7 protein was stored at -80°C both in aliquots (typically 
in 100 µl aliquots at a concentration of 50 µM of protein in buffer A) and concentrate 
stocks (usually range from 0.5-2mM in buffer A). 
 
SDS-PAGE. Purity of the eluted protein was determined by SDS-PAGE [166]. Ten 
microliters of each fraction was loaded and run on a 15% acrylamide/SDS Tris-Tricine gel 
stacked with a 5% stacking gel. The gel was stained by Coomassie blue staining. The 
fractions of the correct size and at least 95% purity are pooled and concentrated. Some 
recent batches of over-expressed and purified protein were analyzed on precast 
gradient gels purchased from Invitrogen (Carlsbad, CA), Bio-Rad (Hercules, CA) or Lonza 
(Walkersville, MD) and stained using SimpleBlue™ SafeStain (Invitrogen).  
 
Mass Spectrometry. Purified and concentrated protein samples were dialyzed against 
MS buffer (5mM sodium phosphate, 0.2M NaCl, 1µM ZnCl2, 1mM TCEP·HCl, pH 7.0) 
overnight. The concentrations of the dialyzed samples were determined by UV using MS 
buffer as blank. The samples were then diluted to 20µM in 0.1% aqueous trifluoroacetic 
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acid (TFA) solution. The dilute samples were then mixed in 1:1 ratio with freshly 
prepared matrix solution (saturated Sinapinic Acid in Acetonitrile:0.1% aqueous TFA 1:2). 
1µl of each sample mixture was spotted onto a MALDI sample plate and was allowed to 
air dry. MALDI-TOF mass spectrometry was performed on an Autoflex III Smartbeam 
MALDI-TOF system (Bruker Daltonics, Billerica, MA) at State University of New York 
College of Environmental Science and Forestry, Syracuse, NY. The spectrometer was 
operated in reflectron mode. Triplicate measurements were taken for each protein 
sample. 
 
Analytical Ultracentrifugation. Protein samples were dialyzed against NCp7 MS buffer 
overnight. The concentrations of the dialyzed samples were determined by UV using MS 
buffer as blank. Samples were then diluted in MS buffer to an absorbance of 1-1.5 at 
280nm before being analyzed on a ProteomeLab™ XL-A Protein Characterization System 
(Beckman Coulter). 400µl of sample was loaded each time. Sedimentation velocity 
experiments were carried out at 50,000 rpm (200,000 x g) and 10°C overnight in 3-mm 
two-sector charcoal-filled Epon centerpieces with quartz windows. Sedimentation data 
were collected at 280nm and analyzed by the continuous sedimentation coefficient 
distribution method using the program SEDFIT [173] (Acknowledgement: the AUC 
sample run and data analysis were done by Dr. Anamika Patel (Laboratory of Prof. 
Michael S. Cosgrove, Biology department, Syracuse University)). 
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2.3. Results  
 
Starting from the wild type pRD2 plasmid, sixteen mutants of NCp7 protein were made 
as laid out in Figure 2-2. Thirteen out of the sixteen mutants are alanine scanning 
mutants in which one non-alanine residue in the wild type protein sequence was 
mutated into an alanine. These mutated residues were chosen because either they are 
predicted to be involved in direct side chain contact with SL3 RNA or other parts of the 
protein [57] (e.g. F16A) or they are structurally rigid (e.g. P31A) or flexible (e.g. G19A). 
The other three mutants contain double mutations, which resulted in position switching 
of the two residues involved in each of the three salt bridges in the wild type NCp7 
structure. The mutant proteins were then over-expressed in E. coli and purified by ion-
exchange chromatography on FPLC. 
 
Site-Directed Mutagenesis Primers. Designed mutagenesis primers are listed in table 2-1. 
The primers were designed to have a melting temperature (Tm) between 75-85°C, a GC 
content between 40-60% and a length between 30-55 bases [152]. The mutated codons 
were designed to have minimal change from the template codon sequences in the wild 
type and optimized for codon usage in E. coli [174, 175]. 
 
Sequence alignments. All 16 mutants and the wild type plasmids were sequenced and 
the coding sequence regions on each plasmid were aligned and shown in Figure 2-3. The 
sequencing results show that the desired mutations were introduced in the specific sites 
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successfully. As reference, the plasmid map of pET-3a (on which pRD2 was constructed 
[159]) was obtained from Novagen (now EMD4Biosciences, Gibbstown, NJ) [176] and 
shown in appendix A-1. The full sequence of pRD2 is listed in appendix A-2. 
 
FPLC chromatogram. A typical FPLC chromatogram is shown in Figure 2-4. Except for the 
mutant E21A, all other NCp7 mutant proteins and wild type NCp7 were eluted off SP FF 
column during the gradient from around 28% -42% Buffer B, with a peak at around 35% 
Buffer B (the conductivity of sample at peak is around 27 mS/cm). E21A was eluted later 
in the gradient because of its higher net charge than wild type.  
 
SDS-PAGE. An example of SDS-PAGE gel image is shown in Figure 2-5. The gel clearly 
shows that the recombinant NCp7 protein is expressed successfully and is a major 
protein component in the crude lysate of the induced cells. Most of the NCp7 fractions 
collected during the FPLC gradient elution are more than 95% pure. For the purpose of 
affinity assays, this level of purity is acceptable. Precast gels produce excellent 
resolution of NCp7 from other proteins. Representative gel images using precast gels 
from three different suppliers are shown in Figure 2-6, 2-7 and 2-8. Invitrogen precast 
gels have the best performance of the three. But in general all three kinds of precast 
gels produce satisfactory results with good reproducibility and great convenience. 
 
MALDI-TOF. An example of MALDI-TOF mass spectra of purified NCp7 protein is shown 
in Figure 2-9. The spectrum shows that the observed mass of the highest peak (M+) 
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agrees well with the calculated mass of the analyzed protein. The observed molecular 
weight and calculated molecular weight of purified NCp7 wild type and all mutant NCp7 
proteins are listed in table 2-2. 
 
Analytical Ultracentrifugation. Two sets of AUC experiments were performed by Dr. 
Anamika Patel using two different batches of NCp7 wild type protein samples. Results 
from both experiments had only one single peak in the sedimentation velocity profile 
with a calculated mass around 6.5 kDa, indicating that NCp7 is in the monomeric form in 
the buffer conditions used in this study and is stable enough to be used in overnight 
experiments. An example of the AUC profile of NCp7 wild type is shown in Figure 2-10. 
 
2.4. Discussion 
 
Protease inhibition. In cell lysis, the E. coli cells were homogenized by the concerted 
efforts of lysozyme digestion, detergent dissolution and ultrasonic disruption. The 
cellular proteins released after lysis were protected from endogenous proteases by 
addition of protease inhibitors PMSF and Pepstatin A. Nonetheless, the protection from 
protease inhibitors wears off soon due to their degradation in aqueous solution. For this 
reason, the FPLC purification needs to be carried out on the same day of cell lysis to 
avoid protein degradation. 
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DNA contamination. Genomic DNA is a common contamination in recombinant protein 
purification. NCp7 can bind DNA non-specifically because of its high basicity. So DNA 
contamination is especially a problem for NCp7 purification. Polyethyleneimine (PEI) is a 
basic cationic polymer which is positively charged at neutral pH. It can bind to negatively 
charged macromolecules like nucleic acid and acidic protein molecules and precipitates 
together with them. By addition of PEI and subsequent centrifugation, genomic DNA can 
be removed from the lysate [177]. 
 
FPLC purification.  The FPLC purification of NCp7 proteins involves two parts: removal of 
negatively charged impurities by the Q FF column and separation of positively charged 
NCp7 protein by the SP FF column. The purpose of flowing the cell lysate through the Q 
FF column before SP FF column is to reduce the burden on the SP FF column and 
increase the yield and purity of the separated NCp7 protein. SP FF column alone can be 
used to separate NCp7 protein from the crude cell lysate. But the existence of negatively 
charged cellular proteins can compete with the resin in the SP column for NCp7 protein, 
and therefore reduce the binding capacity of the SP column. Moreover, the negatively 
charged proteins might be co-eluted with NCp7 protein as a contaminant. So it is 
necessary to include the Q FF column in the FPLC purification procedure. 
 
Zinc concentration in media and buffers. The zinc concentration in the LB media used in 
NCp7 over-expression was 100µM. But in the following purification and analysis process, 
the zinc concentration used in all the buffers was reduced to 1µM. This was because of 
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the instability of TCEP·HCl observed in presence of high concentration of zinc ions (data 
not shown). The high concentration of zinc in the culture was to make sure that there 
was enough zinc to be incorporated into the protein for the zinc finger structure to 
correctly fold. Results from following affinity assays showed that NCp7 wild type protein 
has similar Kd for SL3 RNA compared to reported Kd values of NCp7 wild type for SL3 
RNA in the presence of higher zinc concentration (100 µM), which indicates that NCp7 
protein maintains its zinc finger structure in the presence of lower zinc concentration in 
the buffer (1µM). 
 
MALDI-TOF peaks. Before we had ready access to the MALDI-TOF mass spectrometer 
and worked out the optimal conditions for measuring NCp7 variants on MALDI, the most 
reliable method for protein identification available to us was Sanger sequencing of the 
plasmid being used for protein over-expression, which is indirect and often affected by 
sequencing noise. SDS-PAGE gels give a good indication of the purity of protein but 
don’t make accurate measurement of the molecular weight of protein and cannot 
distinguish mutant proteins that are similar in size. Therefore MALDI-TOF and other 
mass spectrometry techniques are powerful tools in protein chemistry. In fact, several 
mutants which had exhibited unexpected binding patterns in preliminary experiments 
were later found to contain unwanted mutations after being examined by MALDI-TOF. 
For example, the original F6A mutant showed very weak binding affinity for SL3 RNA and 
was later confirmed to be a double mutant, which contains both F6A and F16A 
mutations. An early stop codon was introduced in the original P31A mutant because of a 
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shift in the reading frame, which resulted in a shorter translated product (31aa, mw. 
3565). Those mutants were later re-constructed from scratch and confirmed to be the 
correct ones by MALDI-TOF. 
 
In the MALDI-TOF mass spectra of the NCp7 wild type and mutant proteins, the 
molecular ion peak (M+) is the most abundant peak. In some cases, small peaks with 
higher mass were observed. These peaks can be attributed to the zinc-bound protein 
molecules. The most frequently observed small peak has a mass around M+65, which 
can be attributed to the protein molecules coordinated with one zinc ion. Less 
frequently, a peak around M+130 can be observed, indicating the NCp7 molecules 
coordinated with two zinc ions. The low abundance of these peaks is probably because 
the ionization condition of MALDI is too harsh for the zinc-bound protein to keep the 
zinc ions upon the impact of laser. Using a milder ionization method such as 
electrospray ionization (ESI) might help improve the abundance of zinc bound protein 
peaks. 
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Table 2-1. Site-directed mutagenesis primers for construction of NCp7 mutants 
Primer Primer Sequence Length Tm 
N5A 
Fw 5'-GGAGATATACATATGCAGAAAGGCGCATTTAGGAACCAAAGAAAGACTGTT-3' 51 78.5°C 
Rv 5'-AACAGTCTTTCTTTGGTTCCTAAATGCGCCTTTCTGCATATGTATATCTCC-3' 51 78.5°C 
F6A 
Fw 5'-GAGATATACATATGCAGAAAGGCAATGCTAGGAACCAAAGAAAGACTGTTAA-3' 52 78.1°C 
Rv 5'-TTAACAGTCTTTCTTTGGTTCCTTGCATTGCCTTTCTGCATATGTATATCTC-3' 52 78.1°C 
V13A 
Fw 5'-TTTTAGGAACCAAAGAAAGACTGCTAAGTGTTTCAATTGTGGCAAAG-3' 47 79.0°C 
Rv 5'-CTTTGCCACAATTGAAACACTTAGCAGTCTTTCTTTGGTTCCTAAAA-3' 47 79.0°C 
F16A 
Fw 5'-CCAAAGAAAGACTGTTAAGTGTGCCAATTGTGGCAAAGAAGGGCAC-3' 46 79.4°C 
Rv 5'-GTGCCCTTCTTTGCCACAATTGGCACACTTAACAGTCTTTCTTTGG-3' 46 79.4°C 
N17A 
Fw 5'-CAAAGAAAGACTGTTAAGTGTTTCGCATGTGGCAAAGAAGGGCACATAG-3' 49 79.2°C 
Rv 5'-CTATGTGCCCTTCTTTGCCACATGCGAAACACTTAACAGTCTTTCTTTG-3' 49 79.2°C 
G19A 
Fw 5'-TGTTAAGTGTTTCAATTGTGCCAAAGAAGGGCACATAGC-3' 39 78.4°C 
Rv 5'-GCTATGTGCCCTTCTTTGGCACAATTGAAACACTTAACA-3' 39 78.4°C 
E21A 
Fw 5'-GTTTCAATTGTGGCAAAGCAGGGCACATAGCCAAA-3' 35 78.1°C 
Rv 5'-TTTGGCTATGTGCCCTGCTTTGCCACAATTGAAAC-3' 35 78.1°C 
G22A 
Fw 5'-TTCAATTGTGGCAAAGAAGCGCACATAGCCAAAAATTGC-3' 39 78.4°C 
Rv 5'-GCAATTTTTGGCTATGTGCGCTTCTTTGCCACAATTGAA-3' 39 78.4°C 
I24A 
Fw 5'-TGGCAAAGAAGGGCACGCAGCCAAAAATTGCAGGG-3' 35 78.8°C 
Rv 5'-CCCTGCAATTTTTGGCTGCGTGCCCTTCTTTGCCA-3' 35 78.8°C 
P31A 
Fw 5'-CAAAAATTGCAGGGCCGCTAGGAAAAAGGGCTGTT-3' 35 79.3°C 
Rv 5'-AACAGCCCTTTTTCCTAGCGGCCCTGCAATTTTTG-3' 35 79.3°C 
G40A 
Fw 5'-GGGCTGTTGGAAATGTGCAAAGGAAGGACACCAAA-3' 35 79.3°C 
Rv 5'-TTTGGTGTCCTTCCTTTGCACATTTCCAACAGCCC-3' 35 79.3°C 
Q45A 
Fw 5'-TGTGGAAAGGAAGGACACGCAATGAAAGATTGTACTGAGAG-3' 41 78.2°C 
Rv 5'-CTCTCAGTACAATCTTTCATTGCGTGTCCTTCCTTTCCACA-3' 41 78.2°C 
M46A 
Fw 5'-GTGGAAAGGAAGGACACCAAGCGAAAGATTGTACTGAGAGAC-3' 42 78.2°C 
Rv 5'-GTCTCTCAGTACAATCTTTCGCTTGGTGTCCTTCCTTTCCAC-3' 42 78.2°C 
K14E 
Fw 5'-CCAAAGAAAGACTGTTGAGTGTTTCAATTGTGGC-3' 34 75.6°C 
Rv 5'-GCCACAATTGAAACACTCAACAGTCTTTCTTTGG-3' 34 75.6°C 
K14E/
E21K 
Fw 5'-GTTTCAATTGTGGCAAAAAAGGGCACATAGCCAA-3' 34 75.6°C 
Rv 5'-TTGGCTATGTGCCCTTTTTTGCCACAATTGAAAC-3' 34 75.6°C 
K33E 
Fw 5'-TGCAGGGCCCCTAGGGAAAAGGGCTGTTGGAA-3' 32 81.6°C 
Rv 5'-TTCCAACAGCCCTTTTCCCTAGGGGCCCTGCA-3' 32 81.6°C 
K33E/
E42K 
Fw 5'-GCTGTTGGAAATGTGGAAAGAAAGGACACCAAATGAAAGA-3' 40 78.5°C 
Rv 5'-TCTTTCATTTGGTGTCCTTTCTTTCCACATTTCCAACAGC-3' 40 78.5°C 
K38E 
Fw 5'-GAAAAAGGGCTGTTGGGAATGTGGAAAGGAAG-3' 32 76.5°C 
Rv 5'-CTTCCTTTCCACATTCCCAACAGCCCTTTTTC-3' 32 76.5°C 
K38E/
E51K 
Fw 5'-CACCAAATGAAAGATTGTACTAAGAGACAGGCTAATTGAATTC-3' 43 77.8°C 
Rv 5'-GAATTCAATTAGCCTGTCTCTTAGTACAATCTTTCATTTGGTG-3' 43 77.8°C 
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Table 2-2. Observed and calculated molecular weight of purified NCp7 proteins 
 
# Name Observed Mr Calculated Mr 
Number of 
Measurements 
1 Wild Type 6369.7 ± 0.7 6369.4 11 
2 N5A 6327.1 ± 0.4 6326.4 7 
3 F6A 6293.0 ± 0.8 6293.3 6 
4 V13A 6340.5 ± 2.0 6341.3 8 
5 F16A 6293.2 ± 0.9 6293.3 9 
6 N17A 6327.2 ± 1.3 6326.4 9 
7 G19A 6383.4 ± 2.0 6383.4 8 
8 E21A 6311.0 ± 1.9 6311.3 8 
9 G22A 6385.0 ± 0.7 6383.4 6 
10 I24A 6328.4 ± 0.4 6327.3 7 
11 P31A 6344.3 ± 0.1 6343.3 6 
12 G40A 6384.6 ± 0.5 6383.4 7 
13 Q45A 6313.7 ± 0.6 6312.3 7 
14 M46A 6310.3 ± 0.5 6309.3 4 
15 K14E-E21K 6365.4 ± 0.2 6369.4 3 
16 K33E-E42K 6369.4 ± 1.2 6369.4 4 
17 K38E-E51K 6368.2 ± 0.1 6369.4 3 
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Figure 2-1. Schematic procedure of site-directed mutagenesis 
Circles indicate circular double stranded DNA templates and the nicked PCR amplified 
products. Arc arrows indicate the mutagenesis PCR primers. Crosses indicate the 
mutations being introduced via the primers. Dashed circles indicate the digested DNA 
templates. © Agilent Technologies, Inc. 2005 [152]. Reproduced with permission, 
courtesy of Agilent Technologies, Inc. 
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           1        10        20        30        40        50 
           |        |         |         |         |         | 
WT         MQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEGHQMKDCTERQAN 
N5A        ----A-------------------------------------------------- 
F6A        -----A------------------------------------------------- 
V13A       ------------A------------------------------------------ 
F16A       ---------------A--------------------------------------- 
N17A       ----------------A-------------------------------------- 
G19A       ------------------A------------------------------------ 
E21A       --------------------A---------------------------------- 
G22A       ---------------------A--------------------------------- 
I24A       -----------------------A------------------------------- 
P31A       ------------------------------A------------------------ 
G40A       ---------------------------------------A--------------- 
Q45A       --------------------------------------------A---------- 
M46A       ---------------------------------------------A--------- 
K14E-E21K  -------------E------K---------------------------------- 
K33E-E42K  --------------------------------E--------K------------- 
K38E-E51K  -------------------------------------E------------K---- 
 
Figure 2-2. HIV-1 NCp7 variants characterized in this study. 
The amino acid sequence of wild-type NCp7 (pNL4-3 strain) is given at the top with 
residue numbers labeled, followed by mutant sequences. The name of each mutant is 
listed on the left. Identical residues to that of wild-type are indicated by dashes. 
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                 M  Q  K  G  N  F  R  N  Q  R  K  T  V  K  C  F  N  C  G  K 
WT              ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
N5A             ATGCAGAAAGGCGCATTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
F6A             ATGCAGAAAGGCAATGCTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
V13A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGCTAAGTGTTTCAATTGTGGCAAA 60 
F16A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTGCCAATTGTGGCAAA 60 
N17A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCGCATGTGGCAAA 60 
G19A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGCCAAA 60 
E21A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
G22A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
I24A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
P31A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
G40A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
Q45A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
M46A            ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
K14E-E21K       ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTGAGTGTTTCAATTGTGGCAAA 60 
K33E-E42K       ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
K38E-E51K       ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA 60 
                ************     ******************** * *****  *   **** **** 
                 E  G  H  I  A  K  N  C  R  A  P  R  K  K  G  C  W  K  C  G 
WT              GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
N5A             GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
F6A             GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
V13A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
F16A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
N17A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
G19A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
E21A            GCAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
G22A            GAAGCGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
I24A            GAAGGGCACGCAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
P31A            GAAGGGCACATAGCCAAAAATTGCAGGGCCGCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
G40A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGCA 120 
Q45A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
M46A            GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
K14E-E21K       AAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA 120 
K33E-E42K       GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGGAAAAGGGCTGTTGGAAATGTGGA 120 
K38E-E51K       GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGGAATGTGGA 120 
                  ** ****  ******************* ***** ************** ****** * 
                 K  E  G  H  Q  M  K  D  C  T  E  R  Q  A  N  X 
WT              AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
N5A             AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
F6A             AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
V13A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
F16A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
N17A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
G19A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
E21A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
G22A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
I24A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
P31A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
G40A            AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
Q45A            AAGGAAGGACACGCAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
M46A            AAGGAAGGACACCAAGCGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
K14E-E21K       AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
K33E-E42K       AAGAAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168 
K38E-E51K       AAGGAAGGACACCAAATGAAAGATTGTACTAAGAGACAGGCTAATTAG 168 
                *** ********  *  ************* ***************** 
Figure 2-3. Sequence alignment of NCp7 wild type and mutants 
The name of each mutant is listed on the left. The amino acid sequence of the wild type 
is shown on top of the alignment. Mutated codons are indicated by underscored bold 
red font. X indicates the stop codon. 
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Figure 2-4. Typical FPLC chromatogram of NCp7 purification 
Blue curve: UV absorption at 280nm; Brown curve: conductivity of sample; Green curve: 
buffer gradient; Pink dashed line: Injection mark; Red tick marks: collected fractions. 
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Figure 2-5. SDS-PAGE gel image of NCp7 protein sample (Tris-Tricine) 
Lane 1: Protein mass ladder; lane 2: crude lysate of induced cells; lane 3-10: NCp7 
sample fractions collected during FPLC gradient elution. Stacking gel: 5%. Separating gel: 
15%. Gel thickness: 1.5mm. Running buffer: Tris-Tricine discontinuous buffer (see 
appendix B-1). Run condition: 160V, 45 minutes. 
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Figure 2-6. SDS-PAGE gel image of NCp7 protein sample (Invitrogen Precast Gel) 
Lane 1: blank; lane 2: protein mass ladder; lane 3: blank; lane 4, 6, 9, 11: crude lysate of 
un-induced cells; lane 5, 7, 10, 12: crude lysate of induced cells; lane 8 and 13-15: blank. 
Gel: Invitrogen NuPAGE® Novex® 4-12% Bis-Tris Precast Gel. Gel thickness: 1.0mm. 
Running buffer: 1X NuPAGE® MOPS SDS Running Buffer (Invitrogen). Run condition: 
200V, 50 minutes. 
 
  
1      2      3      4     5      6      7     8      9    10    11    12    13    14     15 
KDa 
 
260 – 
 
 
160 – 
 
110 – 
 
80 – 
 
60 – 
 
50 – 
 
40 – 
 
30 – 
 
20 – 
 
15 – 
10 – 
3.5 – 
 - 55 - 
 
 
 
 
Figure 2-7. SDS-PAGE gel image of NCp7 protein sample (Bio-Rad Precast Gel) 
Lane 1: blank; lane 2: protein mass ladder; lane 3: blank; lane 4 and 6: crude lysate of 
un-induced cells; lane 5 and 7: crude lysate of induced cells; lane 8: blank; lane 9-14: 
purified protein samples; lane 15: blank. Gel: Bio-Rad 4-20% Mini-Protean® TGX™ 
Precast Gel. Running buffer: 1X Tris-Glycine buffer (Bio-Rad). Run condition: 100V, 90 
minutes. 
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Figure 2-8. SDS-PAGE gel image of NCp7 protein sample (Lonza Precast Gel) 
Lane 1: protein mass ladder; lane 2: blank; lane 3: crude lysate of induced cells; lane 4: 
blank; lane 5-15: NCp7 sample fractions collected during FPLC gradient elution; lane 16: 
blank. Gel: Lonza PAGEr® 4-20%T-G Precast Gel. Running buffer: 1X Tris-Glycine buffer 
(Bio-Rad). Run condition: 125V, 6 minutes. 
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Figure 2-9. Sample MALDI-TOF spectrum of NCp7 protein variants 
Sample MALDI-TOF mass spectrum acquired on a Bruker Daltonics Autoflex III 
Smartbeam MALDI-TOF system. Analyzed protein sample shown in this spectrum is F16A. 
Spectrum was acquired in reflectron mode and recorded in the mass range between 
4000 and 22500 m/z.  
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Figure 2-10. Sedimentation velocity profile for NCp7 wild type 
Diffusion-free sedimentation coefficient distributions (c(s)) derived from sedimentation 
velocity data of NCp7 in MS buffer. Sedimentation data were collected at 280nm, 
centrifuging at 50,000rpm and 10°C overnight. Sedimentation velocity profile for NCp7 
wild type was fitted to a distribution of Lamm equation solutions using the SEDFIT 
software [173]. 
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Chapter 3. Quantitative Binding 
Analysis of NCp7 Variant Proteins with 
SL3 RNA 
 
3.1. Introduction 
After sufficient amounts (>1 mg) of pure NCp7 wild type and mutant proteins were 
acquired and identified, the proteins were subjected to quantitative binding analysis to 
determine their affinity for SL3 RNA. Two kinds of affinity assays, tryptophan 
fluorescence titration and isothermal titration calorimetry (ITC), were used in this study 
to measure the affinity of the proteins for HIV-1 SL3 RNA, as described below. 
 
3.1.1. Tryptophan fluorescence titration 
 
Tryptophan is the primary contributor of the intrinsic fluorescence of proteins [178]. The 
fluorescence emission of tryptophan is always dominant over that of other fluorescent 
residues such as tyrosine and phenylalanine. Fluorescence of phenylalanine is much 
weaker than that of tryptophan and tyrosine and can only be observed in the absence of 
those two stronger fluorescent residues. Tryptophan fluorescence is very sensitive to its 
microenvironment, which makes it especially useful as an intrinsic fluorescence probe in 
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gathering information about protein structures and conformational transitions. Changes 
of tryptophan fluorescence upon such transitions as protein unfolding, ligand binding or 
protein-protein association allow for acquisition of thermodynamic and kinetic 
information about these processes. 
 
As mentioned in Chapter 1, the NCp7 protein contains one and only one tryptophan 
residue (Trp37), two phenylalanine residues (Phe6 and Phe16) and no tyrosine residue. 
Therefore the W37 residue accounts for most of the intrinsic fluorescence of NCp7 
protein. The NMR structure of NCp7-SL3 complex revealed that the G318 base of SL3 RNA 
stacks tightly on the side chain of Trp37 upon binding [57]. This kind of stacking 
effectively quenches the fluorescence of tryptophan by nearly 100%, which is the 
underlying mechanism of the fluorescence titration assay used in this study. The assay 
can be conveniently conducted with 0.6 nmoles (~ 3.8 µg) of NCp7 protein and 2 nmoles 
(~ 13 µg) of SL3 RNA. 
 
In the tryptophan fluorescence titration assay, SL3 RNA was added in small aliquots into 
a protein solution under constant stirring in a quartz cuvette. After each addition, the 
solution is excited at 290nm and emission is recorded at 350nm. NMR structures 
showed that except for the zinc fingers, NCp7 is largely disordered in the absence of 
RNA [159], and the Trp37 residue is almost fully exposed to the solvent. Therefore an 
emission maximum at around 350nm is expected in the fluorescence emission spectrum 
of the NCp7 protein [179, 180]. By monitoring fluorescence emission at 350nm, the 
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highest sensitivity and signal-to-noise ratio can be achieved in the titration. Upon 
increasing concentration of SL3, the fluorescence emission was observed to drop 
following a quadratic curve with the 1:1 molar ratio trend line and the x axis as its 
tangent lines, and can be fitted using a simple 1:1 binding model of NCp7 and SL3 RNA 
[165].  
 
3.1.2. Isothermal titration calorimetry 
 
Isothermal titration calorimetry (ITC) is a thermodynamic technique for probing 
interactions between biomolecules. It directly measures the heat change upon binding 
of two or more species of molecules. This method is label-free and does not require the 
sample to have optical characteristics that change in response to a structural change, 
such as in fluorescence or UV spectrophotometry. ITC also doesn’t require sample 
immobilization as in surface plasma resonance (SPR) and doesn’t have a limitation on 
molecular weight. It can simultaneously determine multiple binding parameters such as 
the binding constant (K), enthalpy (ΔH), entropy (ΔS) and the binding stoichiometry (n). 
All of these make ITC a powerful and universal method to study biomolecular 
interactions [181]. A typical ITC assay requires 30 nmoles (~190 µg) of NCp7 protein and 
10 nmoles (~65 µg) of SL3 RNA. 
 
A schematic representation of isothermal titration calorimetry is shown in Figure 3-1 
(Freyer et al. 2008 [182]). In an ITC instrument (a calorimeter), a pair of identical coin 
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shaped cells made of highly efficient thermal conducting alloy are enclosed in an 
adiabatic shield. Both cells are filled with liquid during experiments. During a typical ITC 
experiment, the reference cell is filled with water and the sample cell is filled with one 
reactant (sample) in titration buffer. A spinning syringe is filled with the other reactant 
(titrant) in the same buffer and used for injecting and subsequent mixing of the two 
reactants. The reference cell is maintained at a user-defined constant temperature by 
applying a small constant power to it. The temperature difference between the sample 
and reference cells (ΔT) is kept at a constant value by increase or decrease of power 
being applied to the sample cell, as appropriate, using a feedback circuit. When 
precisely known aliquots of titrant are titrated into the sample cell through the syringe, 
heat gets released or absorbed, resulting in the increase or decrease of the sample cell’s 
temperature. This change activates the feedback circuit, causing the power being 
applied to the sample well to decrease or increase, in order to keep ΔT constant. This 
change in the power is recorded and used to calculate the thermodynamic parameters 
using preset or user-defined fitting models in Origin software [183]. 
 
ITC has its limitations, as well. It usually requires significantly higher amounts of sample 
than other binding assays do. The reason for that is to generate large enough heat 
change to be accurately measured by the calorimeter. The concentration of the sample 
is usually set between 1 and 1000 times of the estimated or expected Kd of the sample 
for the titrant [184]. The concentration of the titrant is set so that the final molar ratio 
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of titrant to sample is above 2 or higher, ensuring the sample to be saturated by titrant 
toward the end of titration.  
 
3.2. Materials and Methods 
 
SL3 RNA. Desalted SL3 RNA (rGrGrArCrUrArGrCrGrGrArGrGrCrUrArGrUrCrC) was 
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and used without 
further purification. SL3 RNA was reconstituted in NCp7 titration buffer (5mM sodium 
phosphate, 0.2M NaCl, 1µM ZnCl2, 1mM TCEP·HCl, 0.1% PEG 8000, pH 7.0). The 
concentration of SL3 RNA was determined by UV260 absorbance using a molar extinction 
coefficient of ε260 = 160,000 M
-1∙cm-1 as described previously [111]. Purity of SL3 RNA 
was examined by ion exchange HPLC using a DNAPac® PA200 4X250mm column (Dionex, 
Sunnyvale, CA) on an Agilent 1200 HPLC system. SL3 was heat denatured at 95°C and 
snap cooled on ice before being loaded onto HPLC. Ten microliters of ~30µM SL3 RNA 
was injected onto the PA200 column and eluted with a gradient from 0-65% B over 10 
minutes (solvent A=0.01M Tris-HClO4, 20% acetonitrile, pH 8.0; solvent B=0.01M Tris-
HClO4, 20% acetonitrile, 0.33M NaClO4, pH 8.0). 
 
Tryptophan Fluorescence Titration Assay. NCp7 wild type and mutant proteins were 
titrated with SL3 RNA using conditions similar to those described previously [111]. NCp7 
wild type protein was titrated every time as a positive control along with the mutant 
proteins. Fluorescence emission was measured at 350nm with a QuantaMaster QM-
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4/2005SE fluorometer (Photon Technology International, Birmingham, NJ) in the 
laboratory of Prof. Bruce Hudson at Chemistry Department, Syracuse University, 
Syracuse, NY, using a 290-nm excitation wavelength, a 4-nm excitation band-pass and a 
1.5-nm emission band pass. The fluorescence reading was acquired 2 minutes after each 
oligo aliquot using Felix 5.1 software. The titration curves were fitted to a model 
assuming 1:1 stoichiometry for the molar ratio of NCp7 to bound SL3 RNA as described 
by Paoletti et al. [165]. The titration curves were fitted to the following equation: 
        tdtdttdtt PKPKPRKPRIII 2/4/ 2/120    (3-1) 
where Rt and Pt are the total RNA and protein concentrations, respectively, I0 is the 
intensity at Rt =0, and I∞ is the limiting intensity at saturation. In this study I∞ was set to 
zero, leaving Kd as the only adjustable fitting parameter. The NCp7 concentration was 
fixed at 0.3 μM, and titrations were extended to Rt/Pt ≈3.0. Kd values were fitted using 
the above model in Origin 7.0 software (OriginLab, Northampton, MA).  
 
Isothermal Titration Calorimetry. Isothermal Titration Calorimetry (ITC) experiments 
were performed on a Microcal VP-ITC Micro Calorimeter (Microcal, now GE Healthcare) 
at State University of New York Upstate Medical University, Syracuse, NY, in the 
laboratory of Prof. Stephan Wilkens. Origin 7.0 software was used for data collection 
and analysis. The sample cell has a volume of 1.4 ml and the total available injection 
volume in the syringe is 300µl. The sample and titrant were degassed for 5 minutes 
before being loaded into the sample cell and syringe. Each time around 2ml of 5µM SL3 
RNA dissolved in NCp7 titration buffer was used to load the sample cell and the 
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overflow was removed by a syringe. About 500µl of NCp7 protein at a concentration 
around 60µM was needed for filling the syringe in each titration. Binding reactions were 
carried out at 30°C. Reference power was set to 5µcal/sec. The first injection volume 
was set to 2µL, 4sec, followed by 29 injections of 10µl, 20sec. The last injection volume 
was set to 8µL, 16sec. Interval between each injection was set to 240 sec. Syringe 
stirring speed was set at 295 rpm. The feedback gain was set at high and equilibrium set 
at fast, auto. The above-mentioned concentrations of sample and titrant were chosen so 
that the titration would reach saturation at least 5-10 data points before the last 
injection. A baseline was drawn by linear extrapolation using the data points collected 
under saturation conditions and subtracted from the whole data set to correct for the 
heat of dilution [185, 186]. Binding isotherms were then fitted to a one-binding-site 
model using the supplied manufacturer’s ITC add-on for Origin 7.0 software, with Kd and 
the binding stoichiometry, n, as adjustable parameters. 
 
3.3. Results 
 
SL3 RNA purity. The HPLC chromatogram of SL3 RNA is shown in Figure 3-2. The RNA 
sample shows no sign of degradation and the purity is higher than 90% as judged by 
integrals of the peaks in the HPLC chromatogram. This level of purity is acceptable for 
the purpose of the binding affinity assays used in this study. Therefore the SL3 RNA was 
used without further purification. 
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Tryptophan Fluorescence Titration Assay. Seven of the seventeen protein-SL3 titration 
curves are shown in Figure 3-3 covering the wide range of Kd values of the wild-type and 
mutant NCp7 proteins for SL3. All seventeen Kd values calculated from Trp titration data 
are compiled in Table 3-1 as well as in Appendix C-1, ranging from 9 nM to 720 nM. 
Pictorial summaries are displayed in Figures 3-4, 3-5 and 3-7. All individual Trp titration 
curves are shown in Appendix C-2. The Kd value for binding of the wild type NCp7 with 
SL3 was calculated to be 29 nM, which agreed with our previous experimental data 
[124, 165] and served as a good positive control for the mutant proteins. Dissociation 
constants were calculated by non-linear regression to get the best fit titration curves, 
assuming a 1:1 complex. No evidence for other stoichiometries was indicated by the 
data at 0.2 M NaCl [111, 124]. The binding isotherms for low-affinity complexes (e.g. 
F16A) were not extended to saturation because the nature of the complex may change 
in the presence of a large excess of RNA [165]. I∞ was set at zero because in the range of 
the Kd values for these titration curves, very little effect of the residual fluorescence was 
observed [165].  
 
Isothermal Titration Calorimetry. Due to limitations of material and time, only 8 mutant 
NCp7 proteins and NCp7 wild type protein and were examined using ITC assay. A set of 
ITC titration curves for all 9 proteins are shown in Figure 3-6. The Kd values and other 
binding parameters calculated from ITC experiments are compiled in table 3-2 as well as 
in Appendix C-1. All individual ITC titration curves are shown in Appendix C-3. The Kd 
values calculated from the ITC assays (termed KdITC) were compared with the ones 
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calculated from the tryptophan fluorescence titration assay (termed KdTrp) in Figure 3-5. 
Taking into account that ITC experiments were carried out at 30°C, the Kd values 
calculated from the ITC data were converted to equivalents at room temperature (22°C) 
using the van’t Hoff equation as shown in equations (3-2), assuming the ΔH0 is constant 
over the limited temperature range of eight degrees. The Kd values calculated and 
converted from ITC data were generally larger than their counterparts calculated from 
tryptophan fluorescence titration data. But the overall trend of the changes in KdITC 
values agrees well with the trend observed in KdTrp values, as demonstrated in Figure 3-
5. The average number of binding sites determined by ITC also suggested that NC-SL3 
binding follows a 1:1 binding model. These observations confirmed the validity of the 
tryptophan fluorescence titration as a good affinity assay for NCp7 proteins and SL3.  
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3.4. Discussion 
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For the convenience of discussion, the mutants are divided into groups based on their Kd 
values calculated from the tryptophan titration data. The factor (F) by which Kd change 
was calculated and is listed in Table 3-1 for each mutant protein by dividing its Kd value 
by the Kd value of wild type NCp7 (29nM). Mutants with a change factor less than 2 are 
considered as mutants with little or no change in affinity. Those with a change factor 
between 2 to 10 are considered to have moderate change in affinity. Those with an F 
value greater than 10 are considered as mutants with significant change in affinity. The 
observed changes from the fluorescence titrations are summarized in Figure 3-4 and 3-5 
and will be further discussed in the following section. A set of ITC data for the wild-type 
and eight mutants are displayed in Figure 3-6. 
 
3.4.1. Single mutants 
 
Mutants having little change in affinity. Most of the single mutants have a Kd value close 
to that of wild type NCp7. These mutants include N5A, F6A, V13A, N17A, G19A, E21A, 
G22A, P31A and G40A. 
 
In the case of F6A, this observation is not surprising because Phe6 does not participate in 
any RNA-protein or protein-protein side chain contacts and therefore may not 
contribute much in stabilizing the structure of the protein or protein-RNA complex. 
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Considering the position and structure of Gly19, Gly22 and Gly40 (each reside in similar 
positions in the two zinc finger motifs), we hypothesized that substitution of alanine for 
those residues might give rise to unwanted side chain contacts between NC and RNA or 
within the NC protein, or to a loss in flexibility in the zinc fingers, which would result in 
loss of affinity of NCp7 for SL3 RNA. The observations however indicated the opposite, 
that substitutions of alanine for glycine on these positions do not cause unfavorable 
effects. 
 
Pro31 itself does not have any RNA-protein or protein-protein side chain contact. But 
given its unique structural rigidity and high conservation, we expected that the P31A 
mutation might affect its affinity for SL3 RNA. In fact, it’s reported that Pro31 helps 
determine the spatial proximity of the two zinc fingers [109]. Substitution of Pro31 would 
result in significant impairment of viral RNA dimerization, virion formation and 
infectivity [108, 109]. So the observation that P31A only shows a slight change in affinity 
for SL3 RNA was surprising. This observation indicates that the affinity of NCp7 for SL3 
RNA doesn’t require specific spatial orientation of the zinc fingers. 
 
Val13 does participate in NCp7-SL3 interaction by forming a hydrophobic cleft, which 
interacts with G317 of SL3 RNA, with neighboring residues Phe16, Ile24 and Ala25.  When 
NCp7 is bound to SL3 RNA, Val13 also contributes to intra-protein hydrophobic 
interactions between the 310 helix and zinc finger 1 [57]. Molecular dynamics study 
suggests that Val13 resides within a hydrophobic core with Phe16, Ile24, Ala25, Trp37, Gln45 
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and Met46 [53, 89]. Substitution of Val13 with alanine shortened the side chain but still 
maintained similar polarity and hydrophobicity with those of valine. The observation 
that V13A mutation resulted in a smaller change in affinity than the other mutants in 
the same hydrophobic core suggests that Val13 contributes little to the RNA binding 
function of NCp7, except by maintaining the hydrophobic core. The fact that Val13 is 
among the residues with a higher frequency of natural variation with hydrophobic 
residues (see Figure 1-4) also suggests that the specific side chain of Val13 is less 
important to maintaining the hydrophobic core than some of the other residues. 
 
Asn5 and Asn17, especially Asn5, were thought to play a more significant role in NCp7’s 
RNA recognition. Asn5 is part of the 310 helix that binds the major groove of SL3 RNA and 
is also the only NC residue that forms specific hydrogen-bonds with the RNA stem. 
Moreover, Asn5 is one of the most conserved residues in NCp7. Asn17 is part of the F1 
knuckle and makes hydrophobic contacts with the SL3-tetraloop. It also stabilizes the 
protein structure through multiple hydrogen-bonding and hydrophobic interactions [57]. 
The observation that both N5A and N17A displayed no significant change in affinity for 
SL3 was unexpected. This may indicate that either these two residues are not essential 
in NCp7-SL3 binding or that conformational changes in the mutants could compensate 
for the loss of H-bonds that should be caused by these mutations. 
 
Another interesting mutant in this group is E21A. Glu21 forms a salt bridge with Lys14, 
which appears to stabilize the folding of the F1 knuckle [57]. Mutating Glu21 into Alanine 
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effectively destroys the above mentioned salt bridge. One would expect such a change 
might result in a noticeable loss in the mutant protein’s affinity for SL3 RNA. However, 
the affinity of E21A for SL3 RNA turned out to be even higher than that of wild-type 
NCp7. The Kd of E21A is calculated to be 9nM vs. 29nM for the NCp7 wild type. One 
explanation could be that although the mutation from Glu21 to alanine destroyed the 
salt bridge between Glu21 to Lys14, it also resulted in an increase of the mutated 
protein’s net charge from +9 to +10, which helps the protein to attract the negatively 
charged RNA. Also the zinc finger’s structure is stabilized by many forces including the 
salt bridge. While the loss of the salt bridge may destabilize the structure to some 
extent, other forces such as hydrophobic interaction could be enough to keep the 
structure of the zinc finger intact. Also the bound RNA might play a role to keep the 
protein correctly folded. Moreover, nucleic acid binding studies suggest that binding 
affinity of NC for RNA is strongly dependent on the net charge of the protein [104, 187, 
188]. 
 
Mutants with moderately change in affinity. I24A, Q45A and M46A show a moderately 
lower affinity with Kd values ranging from 2 to 10 times of that of wild-type NCp7. As 
shown in Figure 3-7, these residues occupy positions on the same side of the two fingers, 
with Ile24 and Gln45 in equivalent positions. 
 
Ile24, Gln45 and Met46 are members of the hydrophobic core described above. They all 
show certain steric interactions with the RNA molecule in the NMR structure [57]. The 
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loss of affinity caused by these mutations indicates that these interactions may 
contribute more to the stabilization of the complex than the residues in the first group. 
 
Mutant with significant change in affinity. F16A has a much larger Kd value than wild-
type NCp7 (approximately 25-fold). This observation also agrees with previously 
reported northwestern blot (meaning protein-RNA blotting) data and molecular 
dynamics analysis [148, 189]. Phe16 forms a hydrophobic cleft with several other amino 
acid residues and closely interacts with Trp37, for which fluorescence is monitored in the 
binding assay to determine the affinity of the binding. The mutation from Phe16 to 
alanine could result in relocation of Trp37 in the protein-RNA complex so that the 
binding of SL3 may no longer quench its fluorescence efficiently. 
 
3.4.2. Salt-bridge switching double mutants 
 
Two of the three double mutants, K33E-E42K and K38E-E51K, do not produce large 
changes in their affinity for SL3 RNA. But the other double mutant, K14E-E21K, which 
contains mutations within the F1 knuckle, showed a moderate change in its affinity for 
SL3. The Kd value of this double mutant for SL3 was calculated to be 140 nM. Compared 
to the other two double mutants, this observation indicated that structure of F1 knuckle 
is more susceptible to mutations and/or more crucial to NC’s affinity for SL3 RNA. The 
tryptophan titration curve of K14E-E21K doesn’t fit well with the model described by 
equation (3-1), as shown in Figure 3-8. One explanation could be that this mutant might 
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bind to SL3 RNA differently than the wild type NCp7 does. Its interaction with SL3 RNA 
might involve a tight binding phase and a weak binding phase, giving rise to the unique 
shape of the titration curve. 
 
The structure of NCp7-SL3 complex may offer a clearer explanation of the differences in 
the affinity of the three salt-bridge switching mutants for SL3. As shown in Figure 3-9, 
the salt bridge between Lys33 and Glu42 and the one between Lys38 and Glu51 are both 
directly exposed to solvent, while the one between Lys14 and Glu21 is partially buried 
inside the complex, especially residue Lys14. Salt bridges exposed to the solvent may not 
contribute to stabilizing protein structures because of the interference of solvent. But 
semi-buried salt bridges like the one between Lys14 and Glu21 can be a strong stabilizing 
force [190]. The moderate change of this double mutant’s affinity indicates that even 
though the switched residues are still in close proximity, their ability to form salt bridges 
might be modified. 
 
3.4.3. Comparison of Trp titration and ITC titration results 
 
The Kd values calculated from ITC titration data don’t match exactly with those 
calculated from Trp titration data for the same mutant. But overall they show the same 
trend. The same criterion (the change factor of Kd value, F) used to categorize the 
mutants based on their Trp titration data can be used on their ITC titration data and the 
mutants can be grouped exactly the same way (see Table 3-1, 3-2 and Figure 3-5). This 
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shows that ITC is a good alternative assay for measuring NCp7-SL3 RNA binding 
isotherms. 
 
Some of the differences in the Kd values calculated from the two methods may be 
attributed to the different nature of the assays. Tryptophan fluorescence titration relies 
on the direct interaction of Trp37 and the bases in the bound RNA, while ITC experiments 
directly measure the heat change upon binding, which is not dependent on the 
structure of protein or RNA. The ITC experiment can be more accurate than Trp titration, 
but this is only true at much higher concentrations than are practical for NC-SL3 
titrations. The ITC data, especially for the weakly bound complexes with F16A, I24A, 
K14E-E21K, are noisy or have unusual shape (See Figure 3-6). This causes more 
uncertainty in Kd. Trp titration has the advantage of being a convenient and 
straightforward assay with much higher sensitivity than ITC. The observation that ITC 
data follow the same trends for Trp titration data also endorses the validity of Trp 
titration assay for measuring the affinity of NCp7 for SL3 RNA. 
 
The order of titration in the two assays is also different in this work. In tryptophan 
fluorescence titrations, SL3 RNA is being titrated into NCp7 protein because it’s a well 
established and convenient way of titration and lots of titration data had already been 
collected before the ITC assay came into play. Our lab has recently worked out the 
conditions and fitting model for the AddPro approach of tryptophan fluorescence 
titration, in which NCp7 protein aliquots were added into a large excess of SL3 RNA 
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solution. Excellent agreement in Kd values was found at the nearly physiological salt 
concentrations used in the present work [124]. 
 
While in ITC titrations, NCp7 protein is loaded into syringe and titrated into SL3 RNA 
solution in the cell.  The amount of titrant (syringe sample) in ITC experiments needs to 
be at least two to three times of that of sample (cell sample). Considering the cost 
efficiency, it was reasonable to use SL3 RNA as the cell sample which requires smaller 
amount of the two binding partners, because SL3 RNA is the most expensive material 
needed in this assay. 
 
3.4.4. ITC data analysis 
 
Origin software defines the "ligand" as the species with only one site and calls the 
species with n greater than 1.0 the "macromolecule", irrespective of their molecular 
weights [191]. In theory, when two binding partners follow a 1:1 binding stoichiometry 
and have only one binding site, as in the case of NCp7 and SL3, it shouldn’t matter which 
one is defined as “ligand” and which one is loaded into syringe, because the system 
would be symmetrical. But in reality, systematic errors and other factors would prevent 
one from acquiring perfect data that produces an exact n=1 stoichiometry. So it’s 
important to be consistent in the ITC experiment setup and data analysis for the same 
set of samples. In this study, the SL3 RNA was defined as “ligand” and was loaded into 
the cell in all the experiments. 
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One should note that the order of titration in ITC experiments, i.e. whether the “ligand” 
is in the syringe or in the cell, needs to be specified under the “ITC” menu in the Origin 
software before data analysis. The default option in the software is the “ligand-in-
syringe” mode. The second option is the “ligand-in-cell” mode. It has been observed 
that the same set of data can produce similar shape of fitted curve but very different 
binding parameters. The binding stoichiometry n calculated in one mode is normally the 
reciprocal of the n value calculated from the same set of data in the other mode. But the 
Kd and ΔH values are less straightforward, thus much more difficult, to convert between 
the two modes. So it’s necessary to choose the appropriate mode for the data being 
analyzed. All the ITC data in this study were fitted in the “ligand-in-cell” mode because 
SL3 was the loaded in the cell in all experiments. 
 
Before fitting the ITC titration data, it’s necessary to subtract from the data set the 
baseline or background heat signal, which is largely due to the heat change generated 
from dilution of the injected titrant. There are two approaches to establish the baseline 
for ITC data analysis [186]. One is to run a separate background titration by injecting the 
same titrant into buffer only. The other is to include extra data points at the end of 
titration when the sample in the cell has already been saturated by the titrant. The heat 
change in this phase is mainly because of dilution of the titrant. I have tried both 
approaches of background correction and found that overall the two approaches 
demonstrated good agreement with each other. When there is discrepancy in data 
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analyzed with different approaches, the ones corrected with terminal injection data 
generate a better fit (see Appendix C-3).  
 
3.5. Conclusion 
 
Overall, most of the mutations did not result in significant loss of affinity for SL3 RNA in 
the mutant NC proteins. This indicates that the side chain contacts of those involved 
residues in wild type NCp7 either contribute little to its stability or can be compensated 
by new contacts in the mutants. On the other hand, conservation of many of these 
residues could arise from NC’s interactions with other proteins or in other aspects of its 
many roles in HIV infection. 
 
The F16A mutant exhibits a profound loss of affinity for SL3 RNA and is confirmed by 
both fluorescence titration and ITC assay. This observation agrees with previously 
reported NMR structure and molecular dynamics analysis [57, 189]. All of these indicate 
that Phe16 is a key site in the NCp7-SL3 interaction and warrant further structural and 
functional study focusing on Phe16. Other interesting mutants include I24A and K14E-
E21K. 
 
Tolerance to alanine mutagenesis mutation in some structurally important sites, such as 
Asn5, Gly19, Pro31 and Gly40, indicates the key interactions between NCp7 and SL3 might 
be confined in a small locale on protein surface and is not sensitive to the overall 
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protein structure. Yet the high conservation of those residues suggests that they have 
important roles in other functions of NCp7, if not in the NCp7-SL3 interactions. 
 
Fluorescence titration and ITC are complementary methods, both of which have their 
own flaws and advantages. Both assays make reliable and reproducible measurements 
of the Kd value. Both methods have good agreement with each other’s data and have 
confirmed an n=1 stoichiometry for NCp7-SL3 binding, which is shown in the complexes 
used in previous NMR study [57]. 
 
The Trp titration assay is robust, sensitive and straightforward. It also doesn’t require 
large amount of sample. But the Trp titration assay requires that the protein has 
intrinsic fluorescence and the fluorescent residue has to be directly involved in the 
binding site, which limit the application of this assay for other proteins and one NCp7 
mutant of great interest, W37A. Also because Trp titration measures the fluorescence 
signal of protein, it can distinguish complexes with R1P1 (complexes consist of one 
molecule of RNA and one molecule of protein) from R1P2 (complexes consist of one 
molecule of RNA and two molecule of protein), R1P3, etc., but not R1P1 from R2P1, R3P1, 
etc. (See Athavale et al., 2010 [124]). 
 
ITC can distinguish those different stoichiometries of complexes, because it measures 
the heat change of the binding reaction, which is independent from species and optical 
characteristics. The nature of ITC assay makes it a universal and direct method for 
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measuring parameters in a binding reaction. But ITC experiments require a much larger 
amount of sample and much longer time to finish than Trp titrations. And ITC 
experiments are more susceptible to background noises, thus more difficult to be 
optimized with the experimental conditions. The data analysis of ITC is also trickier than 
Trp titration. Different titration mode can affect fitted data as mentioned earlier. There 
are also more variables that cannot be fixed when fitting ITC data, such as the binding 
stoichiometry n. This can produce more accurate fit of data but on the other hand also 
makes the fitted data more difficult to interpret. 
 
3.6. Suggestions for future work 
 
The discoveries in this study shed light on some promising projects for future work. 
Since ITC has been confirmed as a good alternative assay for measuring Kd value of 
NCp7-SL3 interactions, the mutant W37A, which was not able to be measured by the 
Trp titration assay, can now be subjected to ITC assay. One would expect to see Kd 
changes in W37A similar to the level of F16A, if not greater, given its key position in the 
binding site and direct involvement in the binding as demonstrated in the Trp titration 
assays. 
 
There are other interesting mutants that can be constructed and subjected to either Trp 
titration or ITC assay. These include G43A, for its similar position in F2 finger as Gly22 in 
F1 finger; K14A, K33A, K38A, E42A, E51A and combinations of these mutations, to 
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further investigate the stabilizing effect of salt bridges for the zinc finger structures; 
F16W, W37F and F16W-W37F, to investigate the involvement of Phe16 and Trp37 in the 
interaction between NCp7 and SL3. 
 
Some interesting mutants such as N5A and F16A should also be studied with NMR. 
Solving the structures of these mutant proteins in complex with SL3 RNA can lead to 
better understanding of the mechanism underlying the NCp7-SL3 recognition and 
interactions and further decipher the roles of NCp7 in HIV-1 biology. 
 
Mutants with moderate to significant Kd changes, such as F16A, I24A and K14E-E21K, 
should be further studied by functional assays such as viral infectivity assay in human 
cell lines to determine the relationship of the affinity for SL3 RNA and the viability of 
mutant viruses.  
 
The findings of this project will also benefit drug screening for anti-HIV drugs or 
aptamers. Prior work done by Dr. Chris DeCiantis has identified about 20 drug leads 
from over 2000 compounds in the NCI diversity set [192]. Because the similarity of F16A 
and NCp7 WT in sequence and basicity, we can use F16A to eliminate the non-specific 
hits from those drug leads or from an aptamer library.  
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Table 3-1. Trp titration results of NCp7 wild type and mutant proteins 
# 
Mutant 
Name 
Kd
Trp (nM) 
m b 
Avg. SD SD% F a 
1 WT 29 ± 4.5 ± 15% 1.0 8 
2 N5A 29 ± 5.6 ± 19% 1.0 5 
3 F6A 33 ± 3.3 ± 10% 1.1 3 
4 V13A 31 ± 6.9 ± 22% 1.1 3 
5 F16A 720 ± 26 ± 4% 25 3 
6 N17A 32 ± 1.4 ± 4% 1.1 3 
7 G19A 45 ± 2.6 ± 6% 1.5 3 
8 E21A 8.6 ± 2.3 ± 26% 0.3 3 
9 G22A 45 ± 6.7 ± 15% 1.6 3 
10 I24A 170 ± 29 ± 17% 5.8 5 
11 P31A 23 ± 5.8 ± 25% 0.8 3 
12 G40A 33 ± 6.5 ± 20% 1.1 3 
13 Q45A 73 ± 14 ± 20% 2.5 4 
14 M46A 62 ± 10 ± 16% 2.1 3 
15 K14E-E21K 140 ± 5.1 ± 4% 4.8 7 
16 K33E-E42K 40 ± 11 ± 27% 1.4 3 
17 K38E-E51K 33 ± 5.1 ± 15% 1.1 3 
a. F is the change factor for the Kd of a mutant NC compared with that of wild type 
NC. F = (Kd of mutant)/(Kd of WT). 
b. m is the number of measurements. 
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Table 3-2. ITC titration results of NCp7 wild type and mutant proteins 
# 
Mutant 
Name 
Kd
ITC 
(nM) N b ΔH (kcal/mol) 
m c 
30°C RT a SD SD% F Avg. SD Avg. SD 
1 WT 69 42 ± 5.0 ± 12% 1.0 1.1 ± 0.034 -11E+03 ± 600 4 
2 N5A 124 80 ± 26 ± 33% 1.9 1.1 ± 0.082 -9.8E+03 ± 1500 4 
3 F6A 97 58 ± 23 ± 40% 1.4 0.87 ± 0.041 -12E+03 ± 690 3 
4 F16A 1790 1200 ± 540 ± 45% 28 1.4 ± 0.13 -9.0E+03 ± 2500 3 
5 I24A 483 310 ± 130 ± 42% 7.3 1.4 ± 0.18 -9.0E+03 ± 910 4 
6 P31A 81 46 ± 5.6 ± 12% 1.1 1.1 ± 0.044 -13E+03 ± 320 3 
7 Q45A 177 120 ± 12 ± 10% 2.8 1.2 ± 0.087 -8.2E+03 ± 360 3 
8 K14E-E21K 195 150 ± 14 ± 9% 3.5 0.79 ± 0.021 -6.3E+03 ± 430 3 
9 K33E-E42K 75 43 ± 4.1 ± 9% 1.0 1.1 ± 0.049 -12E+03 ± 1100 3 
a. Kd values measured at 30°C were converted to equivalents at room temperature 
(22°C) using van‘t Hoff equation. The Kd values at 22°C are rounded to two 
significant digits.  
b. N is the average number of binding sites determined by ITC. 
c. m is the number of measurements. 
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Figure 3-1. Schematic representation of isothermal titration calorimetry (ITC) 
Major features of ITC instrument such as the reference and sample cells, sample 
injection syringe and the adiabatic shield are noted in the figure. This schematic diagram 
shows how the power applied by the instrument to maintain constant temperature 
between the reference and sample cells is measured resulting in the instrument signal.  
Reprinted from Methods in Cell Biology, vol. 84, Freyer MW & Lewis EA, Pages 79-113, 
Copyright 2008 [182], with permission from Elsevier. 
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Figure 3-2. HPLC chromatogram of SL3 RNA 
SL3 RNA sample purchased from IDT was run on an ion-exchange column on Agilent 
1200 HPLC system. UV absorption signal was monitored and recorded at 260nm. 
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Figure 3-3. Tryptophan fluorescence titration curves of NCp7 wild type and mutant 
proteins with SL3 RNA 
Compilation of tryptophan fluorescence titration curves of NCp7 wild type and mutant 
proteins with SL3 RNA. Only 7 sample curves are shown for clear presentation. Molar 
ratio of total RNA to total protein, Rt/Pt, increases from left to right. Colored curves are 
fitted curves using the data points of the same color coding. Data point sets are as 
following: green square, NCp7 wild type; pink circle, N5A; red triangle, F16A; blue 
triangle, E21A; brown diamond, I24A; orange triangle, Q45A; teal circle, K14E-E21K. The 
black line is the trend line for a 1:1 complex with an infinite binding constant (Kd
-1). See 
all calculated Kd values in table 3-1. 
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Figure 3-4. The effect of site-directed mutagenesis on the Kd values of NCp7 mutant 
proteins for SL3 RNA 
Kd values of NCp7 mutants for SL3 RNA calculated from the tryptophan titration data 
were taken from table 3-1 and shown in the above bar chart as change relative to the Kd 
value of wild type NCp7. Y axis is the change factor F. F = (Kd of mutant)/(Kd of WT). The 
three mutants with highest Kd values are: F16A, I24A and K14E-E21K.  
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Figure 3-5. Comparison of the Trp Titration and ITC Data 
Kd values of NCp7 mutants for SL3 RNA calculated from the tryptophan titration data 
(orange bar) and ITC data (blue bar) were taken from table 3-1 and 3-2 and shown in the 
above bar chart as change relative to the Kd value of wild type NCp7. Y axis is the change 
factor F. F = (Kd of mutant)/(Kd of WT).  
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Figure 3-6. Representative ITC titration curves of NCp7 WT and mutant proteins 
Note that the vertical axis scales are not constant. 
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Figure 3-7. Comparison of the changes in NCp7 protein’s affinity for SL3 RNA by 
alanine mutations on different residues 
The highly conserved residues are shown in larger fonts and the residues in smaller 
fonts are more tolerant to variations. The red solid letters indicate residues with RNA-
Protein steric contact. Black solid letters indicate residues with protein to protein steric 
contact.  The red hollow letters are the residues with both protein-to-protein and RNA-
to-protein steric contacts. The black hollow letters are the ones with no steric contacts 
at all. The green boxes mark the salt bridge switch mutants. The blue ovals indicate 
alanine scanning mutants. Yellow background is used to highlight the mutants with 
moderate to significant change in affinity, with the Kd change factor (F) shown next to 
the residue(s) (See Table 3-1). 
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Figure 3-8. Tryptophan fluorescence titration curve of K14E-E21K for SL3 RNA 
K14E-E21K titrated with SL3 RNA. The fitted titration curve does not provide a good fit 
for the data points, indicating a different binding model might play a role in K14E-E21K’s 
binding with SL3 RNA. 
  
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0
20
40
60
80
100
I/
I
0
 (
%
)
R
t
/P
t
 - 91 - 
 
 
 
Figure 3-9. Positions of the three salt bridges in NC-SL3 complex 
 
White ribbon: SL3 RNA; Colored ribbon: NCp7 protein; Stick model: side chain atoms of 
Lys14, Glu21, Lys33, Lys38, Glu42 and Glu51; Surface model: NCp7 protein; Magenta: N-
terminal 3-10 helix of NCp7; Yellow: N-terminal zinc finger (F1); Cyan: linker region; Red: 
C-terminal zinc finger (F2). Surface is shown in 60% transparency. Drawn from PDB ID 
1A1T using the UCSF Chimera package from the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported 
by NIH P41 RR001081) [150].
  
 
 
 
 
 
 
 
 
Part II.   Methods Development for 
Aptamer Discovery 
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Chapter 4. Introduction 
 
For decades after the elucidation of the genetic code [193] and the articulation of the 
central dogma of molecular biology [194], nucleic acids had been envisioned mainly as 
carriers of genetic information through their sequences. Nonetheless, extensive studies 
on the relationship between the structure and function of nucleic acids had indicated 
that the structure of nucleic acids is equally, if not more, important than their sequence. 
The stem-loop structure has been shown to be critical for the recognition of HIV-1 
packaging signal by NCp7 [145]. Single stranded nucleic acids can carry out various 
biological functions such as enzymatic activities and specific target binding [195-198]. 
The secondary and tertiary structure of a DNA or RNA molecule can be affected by the 
sequence of the molecule, by the ionic strength of the buffer or by the ligand bound to 
it. Because of the vast diversity in the secondary and tertiary structure of nucleic acids, 
researchers have begun to explore a new application of nucleic acids as, other than the 
genetic material, affinity ligands. 
 
4.1. Aptamers 
Aptamers (termed from the Latin aptus, meaning “to fit” [199]) are synthetic RNA or 
ssDNA molecules with stable three-dimensional structures and high affinity and 
specificity for certain target molecules. Since first described in 1990 [199, 200], 
aptamers have been developed over the past two decades to be a powerful tool for 
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drug discovery, biosensors, diagnosis and therapy [201-219]. They are now widely used 
in place of antibodies, especially in diagnostic applications [220]. 
 
Aptamers can be composed of naturally occurring nucleotide bases or chemically 
synthesized or modified derivatives. By incorporation of unnatural nucleotides or post-
selection modifications, aptamer molecules can withstand hydrolysis or enzymatic 
degradation. The length of aptamers ranges from 15 nt to about 100 nt long. After 
modification, the size of aptamer molecules can range from 6kDa to 40kDa, most 
commonly be seen around 10kDa [220]. Because of the small size of aptamers, they 
usually penetrate or diffuse in biological tissues better than antibodies do. There also 
has been no evidence of aptamers’ immunogenicity [221]. 
 
Aptamers usually have well-defined three-dimensional structures, especially when 
complexed with target molecules. Their structures result from a combination of Watson-
Crick and non-canonical interactions. Common structural motifs seen in aptamers 
include G-quartets [222], non-canonical base pairs, in particular, purine-purine base 
pairs like G-G base pairs [223], and the GNRA tetra-loop (N is any nucleotide and R is a 
purine) [224, 225]. RNA aptamers usually can adopt a greater variety of complex tertiary 
structures than DNA aptamers can. This is because RNA molecules are more lenient in 
allowing non-Watson-Crick base pairs and have great rotational freedom in the 
backbone of their non-base-paired regions[226]. In addition, the 2’-hydroxyl groups on 
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the riboses of RNA molecules are potential hydrogen bond donors in intermolecular 
interactions [227]. 
 
The affinity of aptamers for their targets can vary a lot from target to target. They 
usually have affinities for small molecules in the micro-molar range, nano-molar level 
affinities for nucleic acid binding molecules and affinities in the nano-molar to subnano-
molar range for proteins. Targets that have high affinity aptamers also tend to have 
measurable non-specific affinity for nucleic acids [220]. 
 
Nonetheless, aptamers can show significant specificity for their target molecules. 
Aptamers can distinguish different enzymes with similar activity, enantiomers of small 
molecules or minor sequence variants of macromolecules with several orders of 
magnitude difference in Kd values between the two similar species of molecules being 
distinguished by the aptamers. The targets of aptamers can be as small as metal ions or 
as big as large glycoproteins. The targets of aptamers are also chemically diverse, 
including organic dyes, neutral disaccharides, aminoglycoside antibiotics, dopamine, etc. 
[220]. 
 
To sum it up, aptamers are interesting because they are: 
 
1) Synthetic molecules. The manufacturing cost of aptamers therefore is 
considerably lower than that of antibodies, which requires much longer time and 
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much more expensive animals to produce the desired antibodies. They are also 
easy to make, modify and label. 
2) Structurally diverse and stable. The diverse structure allows for selection of 
aptamers for a large variety of target molecules, making aptamers good 
candidates in a wide range of applications. Assisted with unnatural nucleotides 
and chemical modifications, aptamers can have a much longer shelf life than 
antibodies. 
3) Ligands with high affinity and specificity for their targets. Comparable affinities 
and specificities as antibodies make aptamers good substitutes for antibodies. 
Low immunogenicity and smaller size also make them attractive as therapeutic 
agents. 
 
4.2. SELEX 
 
Aptamers are usually selected from a large pool of random DNA or RNA sequences by an 
iterative in vitro process termed SELEX (systematic evolution of ligands by exponential 
enrichment) [200]. The name “SELEX” was coined two decades ago, but the history of in 
vitro selection for RNA ligands goes back much further. 
 
In 1974, Sol Spiegelman and his colleagues reported an in vitro evolutionary method to 
select an RNA ligand that has specificity for Qβ phage RNA polymerase [228]. This 
experiment and other work by Spiegelman and his co-workers are considered as 
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pioneering work to SELEX and aptamer science[197]. These experiments and SELEX 
share the same rationale. These methods consisted of rounds of replication and 
selection procedures and enabled selection of specific RNA ligands from a random pool 
of RNA sequences, which is in essence an in vitro Darwinian evolutionary process. 
 
A schematic representation of SELEX procedure is shown in Figure 4-1 [229]. SELEX is a 
cyclic combinatorial procedure. Each round of SELEX involves three major steps: 
 
1. Binding. Target molecules are added to and incubated with a pool of DNA/RNA 
sequences which have a completely random sequence region with flanking 
defined primer binding sites required in the following PCR amplification. The 
starting DNA/RNA pool usually contains 1013 - 1015 molecules and each one is a 
unique sequence. By mixing this DNA/RNA library with target molecules, 
potential aptamer molecules will bind tightly to the target molecules, while most 
sequences will remain unbound or loosely bound to the target molecules. 
2. Partitioning. In this step, the bound and unbound species of DNA/RNA sequences 
are partitioned to remove the sequences with no or low affinities for the target. 
This is a critical step in the SELEX procedure. Partitioning can be achieved by 
affinity chromatography, magnetic beads, electrophoresis or microfluidics. After 
partitioning, most unbound or loosely bound DNA/RNA sequences will be 
washed off the target molecules and removed from the library. 
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3. Regeneration by amplification. The bound DNA/RNA molecules are eluted off the 
target molecules and used as PCR template to amplify and regenerate a new 
library which contains only the surviving members of the original library. But 
each sequence remaining in the new library now has multiple copies. This newly 
generated library is then used as starting library for the next round of SELEX. 
 
A single round of selection is not sufficient to recover a tight binding aptamer sequence 
from a large random pool. Usually it takes multiple (10 to 15) rounds of SELEX runs 
before a successful aptamer sequence is enriched to the extent that it accounts for a 
significant portion of the final DNA/RNA library. At that point, a small number (1-100) of 
survivors will be cloned and sequenced to identify the potential aptamer sequence. 
 
SELEX has its advantages. It is an in vitro process, which makes it easy for optimization 
and manipulation. The complexity of the starting pool is much greater than other 
combinatorial methods. And the selection does not require any prior knowledge about 
the structure of the target or the library. 
 
However, SELEX also has its limitations. The multiple cycles of amplification and 
partitioning could make SELEX time consuming, labor intensive and require substantial 
amounts of purified target. A typical SELEX process may take several weeks before an 
aptamer sequence is identified. Repetitive PCR amplifications tend to produce a higher 
background in identifying the final aptamer sequences, making it difficult to tell a tight 
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binding aptamer from sequences with moderate affinities. More importantly, PCR 
amplifications might produce cycling artifacts, in which case some sequences are 
favored because they are easier to amplify, not because they have higher affinity for the 
target molecules. 
 
4.3. Acyclic identification of aptamers 
 
Many of the limitations of SELEX are intrinsic to repetitive cycling. To overcome these 
limitations, our lab proposed and validated a method for acyclic identification of 
aptamers (AIA) [230]. A schematic comparison between SELEX and AIA is shown in 
Figure 4-2 (McPike, M.P., 2011 [231]). This method eliminates the need for cycling by 
utilizing guided library design and the large sequencing capacity of next generation 
sequencing (NGS) technology. The overall screening time for AIA is shortened to less 
than a week compared with several weeks for SELEX. One successful AIA run can turn 
out millions of sequences while SELEX usually produces less than 100 sequences each 
time. 
 
A typical AIA procedure includes the following steps: 
 
1. Binding. Similar to SELEX, a random library of 1014 molecules is used to incubate 
with the target molecules in this step. The key difference is the design of the 
library. Even though an AIA library can contain a number of molecules similar to 
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SELEX libraries, the variable region of the AIA library is usually shorter (22nt or 
less) than that of SELEX libraries (often 40nt or more). This design ensures that 
the complexity of AIA library is lower than that of SELEX library so that each 
unique sequence in the AIA library is represented multiple times in the library. 
This kind of over-representation is essential for the acyclic selection to be able to 
obtain a meaningful signal-to-noise ratio in the final sequencing results. 
2. Partitioning. This step is basically the same as the partitioning step in SELEX, 
where unbound and loosely bound sequences are separated from the tight 
binding sequences and removed from the library by stringent washing. 
3. Sequencing and counting. After elution from the target, the tightly bound 
molecules are directly subjected to sequencing without going through iterative 
steps of amplification and partitioning. The partitioned library is linked to two 
universal adapters and sequenced on a next generation sequencer such as an 
Illumina GAII sequencer. The final sequences are analyzed using a Perl script and 
the good reads (sequences with intact flanking sequences) are counted. The 
count number of each sequence should be proportional to its affinity for the 
target molecules. So the sequence with highest count number is also in theory 
the sequence with highest affinity for the target. 
 
As described so far, AIA overcomes the main bottleneck in SELEX by eliminating cyclic 
enrichment. But it has its own limitation of low complexity in the library. However, for 
libraries with high complexity and low representation, a pre-selection step can be added 
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before the AIA procedure to increase the sample representation level to a suitable level 
for AIA experiments [232]. Twenty years of research on SELEX can also be used to guide 
the design of AIA libraries to focus on regions of sequence and fold-space that are 
especially productive for aptamer discovery. AIA can be used to further refine the 
structure and sequence of aptamers selected using SELEX.  
 
AIA also has great multiplexing potential. Multiplexing is limited with SELEX because an 
especially high affinity aptamer for one target can take over the evolving pool. While in 
AIA, multiple targets can be screened in parallel and aptamers with different level of 
affinities can be selected at the same time because the aptamers with lower affinity are 
not suppressed by evolutional selection. 
 
4.4. Next-generation sequencing (NGS) technologies 
 
The success of AIA relies in large part on the commercial realization of next generation 
sequencing (NGS) technologies. Ever since next-generation sequencing instruments 
became commercially available in 2004, these fast-paced technologies have already 
made a significant impact in many fields of biological sciences, such as genome-wide 
association studies, transcriptome analysis, synthetic biology and systems biology. 
 
Next-generation sequencing technologies generate fragment libraries by ligating 
platform-specific linkers to DNA fragments, amplify single strands of this library and 
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perform sequencing reactions on amplified strands. Next-generation sequencing 
technologies are highly streamlined, high throughput and high yield. Each NGS run can 
generate from several hundred thousand to tens of millions of reads [233]. 
 
Most imaging equipment used in modern sequencing systems cannot detect single 
fluorescent events, therefore in many cases templates need to be amplified before they 
can be sequenced. Based on the strategies used for template preparation, current 
commercially available NGS technologies can be divided into two major categories, 
which I’ll briefly describe below [234]: 
 
4.4.1. Bridge amplification based NGS technology (Illumina)  
 
Illumina (San Diego, CA) is currently the market leader and the most widely used 
platform in the NGS industry. The Illumina technology generates DNA clusters by bridge 
amplification as shown in figure 4-3-a (adapted from Metzker, M.L. 2010) [234]. Each 
cluster contains thousands of copies of one single DNA fragment, ensuring sufficient 
signal intensity for detection during sequencing. There are 8 lanes on an Illumina sample 
slide. Each lane can produce 10-40 million sample reads. The clusters are sequenced 
using the sequence-by-synthesis approach. 
 
4.4.2. Emulsion PCR based NGS technology (454/SOLiD/Polonator) 
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Emulsion PCR is commonly used for preparing sequencing templates in several types of 
NGS technologies (Roche/454, Life/APG (SOLiD) and Polonator). Emulsion PCR was 
originally designed to analyze rare gene mutations in a large pool of gene templates 
[235, 236]. In emulsion PCR, each emulsion droplet contains only one template, as 
shown in figure 4-3-b (adapted from Metzker, M.L. 2010) [234]. After amplification, 
each droplet contains thousands of copies of the single starting template sequence. 
Thus high signal to noise ratio can be achieved. Millions of droplets can be formed in 
one emulsion and make high throughput screening possible. The homogeneity and 
multiplexing nature of emulsion PCR makes it an ideal method for aptamer screening. 
The amplified sequences on the emulsion beads are sequenced using either the 
sequence-by-ligation or pyrosequencing approach, depending on the platform of choice. 
 
4.5. Potential of NGS in aptamer discovery 
 
A typical sequencing run on an Illumina GAII sequencer can generate over 100 million 
sample reads per slide and similar output can be expected from an ABI SOLiD sequencer. 
We prefer to get 5-15 million reads from each partitioned AIA library sample. This huge 
difference between the sequencing capability and the multitude of sample necessitates 
multiplexing of samples. 
 
Besides multiplexing of samples, there’s another way that we can utilize the full capacity 
of next generation sequencing technology. I call it the sequence-and-screen approach. 
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Compared to this approach, the traditional SELEX and AIA method can both be 
attributed as screen-and-sequence approaches. In screen-and-sequence approaches, 
the initial library is partitioned by incubating with target molecules, the partitioned 
library is subjected to sequencing and the resulting sequences are aligned and counted 
to generate the final aptamer candidate sequences. Whereas in sequence-and-screen 
approaches, the initial library is directly subjected to next generation sequencing to get 
the full coverage of every possible sequence in the library. The sequenced library should 
have formed small clusters of single sequences on the slide that was used in earlier 
sequencing. We propose that these clusters can be detected and screened by ds-DNA 
binding fluorescent dyes, fluorescently labeled complementary DNA probes or 
fluorescently labeled targets to generate hits in the clusters. The sequence of those hit 
clusters would then be tracked and pulled out of the sequence file and tested for 
affinities and specificities for the probes used. 
 
The advantages of sequence-and-screen approach are as below: 
 
1. There is no partitioning step, which could save time and resources.  
2. Target molecules are not immobilized on the slide except by binding to 
aptamers, which are attached to the surface. This might be beneficial for the 
target to retain its natural structure or activity. 
3. Multiplexing of target molecules is easy and convenient, parallel or subsequent 
screening is possible. 
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4. The library will get full coverage after screening. Effect of PCR artifacts would be 
minimal. 
 
 
4.6. Specific aims 
 
When the idea of the sequence-and-screen approach was first brought up by Dr. Mark 
McPike and I around 2007, next-generation sequencing technologies and instruments 
were much more expensive than they are as of today. Without easy access to a high 
capacity next-generation sequencer, we decided to create our own prototype sequence-
and-screen platform based on known principles of commercialized next generation 
sequencers at that time. What we were trying to accomplish are listed as below: 
 
A. Establish prototype sample preparation platforms similar in principle as 
commercialized next-generation sequencers. 
B. Develop sensitive and efficient detection and screening methods on the 
established prototype platforms. 
C. Develop multiplexed screening protocols using the above-mentioned platforms 
and methods. 
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Figure 4-1. Schematic SELEX (Systematic Evolution of Ligands by Exponential 
Enrichment) procedure 
Adapted from http://www.molgen.mpg.de/~nabt/background.html [229]. See 
description in text. 
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Figure 4-2. Comparison of SELEX and AIA 
Reproduced from McPike, M.P. 2011 [231] with permission. See description in text. 
 
AIA 
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Figure 4-3. Template preparation strategies in NGS 
Adapted by permission from Macmillan Publishers Ltd: Nature Review Genetics [234], copyright 2010. See description in text.   
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Chapter 5. Experimental Design and 
Preliminary Data 
 
5.1. Experimental design 
 
At the time these preliminary experiments began, our lab was planning to purchase a 
high-throughput DNA sequencer. Under consideration were the Illumina/Solexa GAIIx 
(using bridge amplification) and the Life Technologies (formerly Applied Biosystems) 
SOLiD or Dover Systems Polonator(both the SOLiD and Polonator use emulsion PCR for 
amplification). We decided to investigate strategies to utilize both bridge amplification 
and emulsion PCR for aptamer discovery. 
 
In 1992, Bock et al. reported a 15-nt long DNA sequence (5′-GGTTGGTGTGGTTGG-3′) for 
human alpha thrombin, which was later named thrombin binding aptamer (TBA) [201]. 
Thrombin has high affinity for TBA (Kd ≈ 100 nM) but not for a similar sequence (5′-
GGTGGTTGTTGTGGT-3′) (TBA scrambled, or TBA-S) (Kd > 1 µM) [237]. Because of this 
distinction, TBA and TBA scrambled sequences have often been used with thrombin as a 
model system in aptamer application development experiments to examine the validity 
and efficiency of the applications being developed [238-240]. In this project, I also chose 
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to use TBA and TBA scrambled sequences with thrombin in a set of proof-of-concept 
experiments for the proved robustness and convenience of this model system. 
 
5.1.1. Bridge amplification 
 
In this proof-of-concept experiment, I tried to create DNA clusters consisting of either 
positive control sequence (TBA sequence) or negative control sequence (TBA scrambled 
sequence) by bridge amplification on a glass slide, as depicted in figure 5-1.  A lawn of a 
universal primer is attached onto a glass slide by tight binding between the streptavidin 
coating on the slide and the dual biotin label on the 5’-end of the primer. Also attached 
onto the slide is a template sequence with a stem-loop structure. The stem region of the 
template contains an identical sequence to the universal primer and its complementary 
sequence. The loop region contains the target sequence, in this case, either TBA or TBA 
scrambled sequence. Sequences and secondary structures of the two templates are 
shown in figures 5-2 and 5-3. The template sequences are attached to the slide in a 
small ratio to the primer sequences. Then bridge amplification reaction is carried out on 
the surface of the slide. If the amplification is successful, clusters containing the target 
sequence and its complimentary sequence should be formed on a background of the 
primer lawn, which would look like bacteria colonies on a LB-plate. These colonies could 
be detected by different probes such as DNA stain, labeled complementary DNA probe 
or labeled protein affinity ligand, as represented in figure 5-4. 
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5.1.2. Emulsion PCR 
 
At the beginning of emulsion PCR, each emulsion bead is in an isolated compartment 
containing no more than one copy of the starting template sequence. Therefore each 
amplified bead should be equivalent to a DNA cluster containing a single DNA sequence 
and its complementary sequence. These beads are magnetic and can be harvested using 
a magnetic separator. The harvested beads are attached onto a glass slide and then 
subjected to detection and screening. 
 
To successfully attach the emulsion PCR beads onto the glass slide, a capping oligo and a 
bridging oligo sequence are adopted according to the Polonator chemistry which is also 
based on emulsion PCR [241]. The capping oligo has 5’-phosphate and 3’-amine 
modification. The bridging oligo is partly complementary to the 3’-end of amplified 
sequence and partly complementary to the capping oligo. The capping oligo is ligated by 
T4 DNA ligase onto the 3’-end of the amplified sequences on emulsion PCR beads via 
splinted ligation guided by the bridging oligo [242]. Two set of capping oligos and 
bridging oligos were used to attach both control beads and sample beads onto the slide. 
The processed beads are then covalently attached onto a glass slide pretreated with 
aminosilane. A schematic setup for emulsion PCR process is shown in figure 5-5. 
Uniformly dispersed beads containing the successfully amplified sequences can then be 
detected and screened in a similar manner as shown in figure 5-4. 
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5.2. Methods and Materials 
 
Primers and templates. The primers and templates used in this study are listed in table 
5-1. All oligos were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) in 
desalted form and used without further purification.  
 
5.2.1. Methods for bridge amplification based detection 
 
Sample coating. Dissolve biotinylated primer and template oligos in Micro Spotting 
Solution Plus (ArrayIt, Sunnyvale, CA) at designed final concentration. Mix the primer 
and template oligos in designed ratio. Attach a 25-µl frame-seal incubation chamber 
(Bio-Rad) onto a SuperStreptavidin Substrates slide (ArrayIt, Sunnyvale, CA). Spot mixed 
DNA samples inside the chamber using a micropipette. Hybridize the sample at room 
temperature for 30 minutes. 
 
Slide Blocking. Block the slide with 25 µl SuperStreptavidin blocking buffer (ArrayIt, 
Sunnyvale, CA). Incubate the slide at room temperature for 1 hour. Wash the slide twice 
in 1x PBST (NaCl 8g/L, KCl 0.2g/L, Na2HPO4 1.44g/L, KH2PO4 0.24g/L, Tween-20 0.05%, 
MgCl2 5mM, pH 7.4) for 5 minutes each. Spin dry the slide.  
 
Bridge Amplification. Prepare PCR mix 25ul: Turbo Pfu 2ul (2.5U/µl), dNTP 0.25mM 
each, 1x Pfu buffer. Fill the chamber with the PCR mix. Seal the chamber with a plastic 
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cover slip. Run PCR in DNA Engine Dyad Thermocycler or Thermo PX2 Thermocycler. PCR 
cycles were set up as the following: 92°C, 1 minute; (92°C, 30 seconds; 55°C, 30 seconds; 
72°C, 30 seconds) x 40 cycles; 72°C, 1 minute; 4°C hold. 
 
Sample staining. After amplification, remove the cover slip and rinse the slide twice with 
1X PBST for 5 minutes each time. Stain the slide with 20 µl of Sybr555 DNA stain 
(Invitrogen) in 27ml of 1X PBST at room temperature for 5 minutes. Wash the slide twice 
with 1X PBST for 5 minutes each time. Spin dry the slide (optional). 
 
Imaging. Stained slides were scanned in a GenePix 4400A microarray scanner (Axon™ 
Instruments, Union City, CA, USA). Images were taken using GENEPIX PRO 5.0 software 
(Axon).  
 
5.2.2. Methods for emulsion PCR based detection 
 
Bead loading. Re-suspend Dynabeads MyOne streptavidin C1 beads (10mg/ml) in stock 
vial by vortexing. Take 100 µl of suspended beads and transfer into a 1.5 ml eppendorf 
microcentrifuge tube. Add 100 µl of Bind and Wash buffer (5mM Tris-HCl, 0.5mM EDTA, 
1.0M NaCl, pH 7.5). Mix by vortexing and remove all liquid on a magnetic particle 
concentrator (Dynal MPC-S magnet). Wash 2 more times in 200 µl Bind and Wash 
buffer, and re-suspend in 198 µl Bind and Wash buffer. Add 2 µl of 1mM forward primer 
with 5’ dual-biotin label. Mix well by pipetting and incubate the mixture at room 
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temperature on a Dynabeads rotary mixer for 20 minutes. Remove all liquid, and wash 
twice in 200 µl of Bind and Wash buffer, then once in 200 µl of 1X TE (10mM Tris-HCl, 1 
mM EDTA, pH 8.0). Remove all liquid and re-suspend beads in 200 µl of 1X TE. These 
beads should now be around 5x10^9 beads/ml. 
 
Emulsion PCR. Prepare the aqueous and oil phase according to the protocols established 
by Church lab at Harvard [241, 243] (also described in Appendix D-3), scale up or down 
when necessary. Mix oil and aqueous phase, vortex well for 5 minutes, distribute into 
PCR tubes or 96-well plate for approximately 50 µl per tube/well. PCR amplify for 120 
cycles. 
 
Breaking emulsion. Add 100 µl isopropanol to each tube or well containing the amplified 
PCR mixture, mix well by pipetting. Pool the mixture into a 15 ml polypropylene falcon 
tube, vortex for 1 minute. Spin down the beads for 30 seconds at 4000 rpm. Remove 
supernatant by decanting. Add 2 ml isopropanol and re-suspend the pellet by pipetting. 
Add 1 ml of isopropanol, vortex for 30 seconds. Spin down the beads for 30 seconds at 
4000 rpm. Remove supernatant as much as possible. Re-suspend the pellet in 3 ml of 
NXS (10mM Tris pH 7.5, 1mM EDTA pH 8.0, 100mM NaCl, 1% (v/v) Triton X-100, 1% 
(w/v) SDS) and mix well by vortexing. Split the suspension into two 1.5ml siliconized 
microcentrifuge tubes, spin down the beads for 30 seconds at 3000 rpm. Remove the 
supernatant on a magnet. Wash the pellet in 1 ml of NXS once and then in 1 ml of 1X TE 
twice. Re-suspend the beads in 500 µL 0.1 M NaOH. Incubate the suspension at room 
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temperature on a Dynabeads rotary mixer for 5 minutes. Wash the beads once with 500 
µl of 0.1 M NaOH, then twice with 500 µl of 1X TE. Re-suspend and combine the beads 
in 30 µl of 1X TE. 
 
Bead capping. Prepare the hybridization mixture by adding 1.8 µl 1mM bridging oligo 1 
and 1.8 µl 1mM bridging oligo 2 into 90 µl 6X SSPE with 0.01% Triton X-100. Re-suspend 
amplified emulsion PCR beads in this solution and mix well by vortexing. Incubate the 
mixture at 56°C for 10 minutes. Mix well again and then incubate the mixture at room 
temperature on a Dynabeads rotary mixer for 10 more minutes. Wash the beads twice 
with 200 µl of 1X TE. Prepare ligation mix by mixing the following: 84 µl dH2O; 10 µl 10x 
T4 Ligase Buffer; 2 µl 1mM Capping oligo 1; 2 µl 1mM Capping oligo 2; 2 µl T4 DNA ligase 
(3U/µl). Remove all liquid from beads and re-suspend them in the ligation mix solution. 
Incubate the mixture at room temperature on a Dynabeads rotary mixer for 1 hour. 
Remove ligation mixture solution on a magnet. Wash beads once with 200 µl of 1X TE, 
once with 200 µl of NX (10mM Tris pH 7.5, 1mM EDTA pH 8.0, 100mM NaCl, 1% (v/v) 
Triton X-100), then twice with 200 µl of 1X TE. Transfer the beads to a new tube, wash 
once with 200 µl of 1X TE, then re-suspend the beads in 30 µl of 1X TE. 
 
Aminosilane treatment of glass slide. Load slides (Erie Scientific, Portsmouth, New 
Hampshire) into a glass rack. Wash the slides by immersing the loaded rack in solution 
of 0.5% Triton X-100 in dH2O and manually agitating the rack for ~1 minute. Drain all the 
liquid and wash slides thoroughly under running water to remove all detergent, then 
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rinse slides with dH2O. Drain all the liquid and rinse the slides in 100% EtOH, then let air 
dry. Use glass pipettes to prepare 2% aminopropyl triethoxysilane (Pierce) solution in 
dry acetone in a glass beaker. Immerse the rack with completely dry (and ethanol-free) 
slides in the silane solution for 30 seconds. Manually agitate the rack. Remove and 
immediately immerse in fresh dry acetone, rinse for 1 minute. Remove rack and blow-
dry partially with compressed air (to remove the bulk of the acetone). Let the slides 
completely air dry and store them under vacuum at room temperature. 
 
Bead attachment. Wash beads three times in 50 µl 1x PBS (NaCl 8g/L, KCl 0.2g/L, 
Na2HPO4 1.44g/L, KH2PO4 0.24g/L, pH 7.4). Quickly re-suspend beads in 35 µl fresh BS3 
(Bis(Sulfosuccinimidyl) suberate) solution in 1x PBS (2.86 mg BS3 in 1 ml 1x PBS). Add 
the beads onto the aminosilane treated center circle on a Teflon coated glass slide, 
apply the cover slip. Incubate the slide at room temperature for 1 hour. Wash the slide 
twice with 1x TE for 5 minutes each time to remove any unattached beads. 
 
Staining the beads. Add 35 µl of 6x SSPE (0.9M NaCl, 60mM NaH2PO4, 60mM EDTA, pH 
7.4) with 0.01% Triton X-100 to each circle, cover with a cover slip. Incubate at 56°C for 
10 minutes. Wash immediately with 1x TE twice for 2 minutes on labquake. Add 35 µl of 
6.7 µM 6-FAM labeled probe dissolved in 6x SSPE w/ 0.01% Triton X-100 to each slide, 
cover with a cover slip. Incubate at 56°C for 2 minutes, then 40°C for 10 minutes and 
25°C for 10 minutes. Wash twice with 1x TE for 5minutes each time on a labquake. Spin 
dry the slide. Add 25ul 1x self seal reagent (Bio-Rad) in 1X TE, cover with a cover slip. In 
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the case of thrombin staining, stain the slide overnight at room temperature using Cy3 
or Cy5 labeled thrombin in 1X PBST (thrombin concentration 500nM). Keep the slide 
covered throughout the staining procedure. Wash the stained slide with 1X PBST twice 
and twice with 1X PBS for 10 minutes each time. Add 25 µl of 1x self-seal reagent in 1X 
PBS, cover with a cover slip. 
 
Visualization. Stained slides were visualized using epifluorescence microscopy on a 
Nikon TE2000 microscope (Nikon, Tokyo, Japan) equipped with a CCD camera, a 100X, 
1.4 numerical aperture objective and standard FITC-Texas Red dichroic filter sets. Snap 
images were taken by the CCD camera using SPOT software (Diagnostic Instruments, 
Sterling Heights, MI), in both bright field mode and fluorescence mode. Bright field 
images and the fluorescent images were superimposed using Adobe Photoshop 
software.  
 
5.3. Preliminary Results 
 
5.3.1. Bridge amplification 
 
Figure 5-6 shows the preliminary result from bridge amplification approach. 0.5 µM 
template (TBA 55mer) was spotted on the slide as a positive control. The initial sample 
spotting solution contained 0.5 µM primer (BA primer) and 0.01 pM template (TBA 
55mer). The negative control spotting solution contained 0.5 µM primer (BA primer) and 
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1 pM template (TBA 55mer) but no polymerase was added in the PCR mix for negative 
control. The slides were subjected to bridge amplification and subsequent staining with 
Sybr555 DNA stain. 
 
Both positive control and sample spots were stained by Sybr555. Negative control spots 
weren’t visible. Sample spots were much brighter than the positive control spots. This 
could be considered as a sign of successful amplification. But the bridge amplification 
slides suffered from uneven staining and high background problems. The staining results 
were not consistent and at times the staining results for controls and samples were not 
distinguishable. I also tried staining with Cy5-labeled thrombin. The staining results 
weren’t satisfactory with very high background issues (data not shown). 
 
I also used an open loop template design (TBA and TBA-S 63mer as templates and BA 
fwd and rev primers in table 5-1)  as shown in figure 5-7 and tried to repeat in situ 
polony PCR in gel pads as Mitra et al. reported in 1999 [244]. The open loop template 
design was to make the template more accessible to primers and thus make the 
amplification more efficient. The polony PCR protocol was adopted also to increase PCR 
efficiency. The gel pad was supposed to hold the PCR mixture within and create a 
solution-like environment for the reaction while holding the amplified DNA clusters in 
place. However, both approaches did not help solve the high background problem. In 
fact, the background was worse in the gel pads (data not shown). The possible reason 
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might be that the gel monomers and/or APS and TEMED inhibited the enzyme activity 
and the probes were difficult to diffuse into or to be washed out of the gel pad. 
 
5.3.2. Emulsion PCR 
 
One set of the initial emulsion PCR experiment results is shown in Figure 5-8. In this 
experiment, the results show that the control beads (no template added) and sample 
beads (using TBA 89mer as template) were both attached to the silane-treated glass 
slide. But only the sample slide was stained by 6-FAM labeled TBA probe. Successful 
amplification on the sample beads was indicated by the staining result. Logically, the 
next step was to see whether the sample beads could be stained by fluorophore-labeled 
thrombin. 
 
As can be seen in Figure 5-9, the emulsion PCR beads were stained with Cy3-labeled 
thrombin. But to our disappointment, both control slide and sample slide were stained 
by Cy3-thrombin. And there weren’t distinct differences between the fluorescence 
signal intensity of the two slides, which suggested non-specific binding between 
thrombin and the control beads. 
 
To reduce this kind of non-specific binding, 10mg/ml casein was added into the block 
solution and 2mg/ml casein was added into the staining solution. And one more set of 
negative control (where no forward primers were loaded onto the beads) was 
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examined. But the staining result still show signs of non-specific binding of thrombin to 
the control beads, as shown in figure 5-10. It suggested that casein did not provide 
sufficient blocking in this experimental setup. 
 
To determine the source of the non-specific binding, another set of control experiments 
was carried out. Beads loaded with forward primers but not stained were used as 
negative control 1. Unloaded beads were used as negative control 2. Positive control 
beads are loaded with a 5′-dual biotin labeled DNA 35mer consisting 20 T’s on the 5′-
end and the 15mer TBA sequence on the 3′-end (T20TBA). Both negative control 2 and 
the positive control beads were stained with Cy5-labeled thrombin in eppendorf tubes 
for overnight instead of 30 minutes on slide. The staining results showed clear 
distinction between the negative and positive control beads, as shown in Figure 5-11. 
This suggests that the non-specific binding was not between thrombin and the bead 
surface. Also the beads or the primers did not have background fluorescence. The 
positive control had very satisfactory staining result. The contributing factors might be 
the overnight staining in tubes and the TBA sequence being at the far end of the 
attached oligos. 
 
To examine the effect of staining conditions, a set of experiments similar to that shown 
in Figure 5-9, except that the beads were stained overnight in tubes instead of 30 
minutes on slide. The results showed that the fluorescence signal on sample beads did 
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improve compared with the control beads, as shown in Figure 5-12. But the improved 
signals were not as bright as the positive sample in Figure 5-11. 
 
To test the hypothesis that the TBA sequence binds thrombin better on the free end of 
the sequence than in the middle, a new emulsion PCR template (Temp-AloI) was 
designed as shown in Table 5-1 and Figure 5-13. A restriction enzyme recognition site 
was designed into the template to the 5′-end of the TBA region. After amplification, the 
beads were digested with the restriction enzyme AloI to expose the TBA sequences so as 
to allow easy access for thrombin binding. The control (no template) and sample beads 
were digested and stained with 6-FAM labeled TBA probe (Figure 5-14) or Cy5-labeled 
thrombin (Figure 5-15) in parallel. The results showed that AloI digestion increased the 
Cy5 signal but decreases the 6-FAM signal. And non-specific binding between thrombin 
and the control beads are still noticeable. 
 
5.4. Discussion 
 
Amplification efficiency. It has been reported that PCR amplifications on a solid surface 
has much lower efficiency than solution-phase PCR reactions [245, 246], which might 
explain the considerably greater difficulties in establishing a prototype bridge 
amplification platform than an emulsion PCR platform. The close proximity of the 
clustered complementary DNA strands makes them not able to freely move inside the 
reaction chamber and results in low efficiency of bridge amplification. The low 
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amplification efficiency made it difficult to distinguish between samples and controls, 
therefore the high background issues. The amplicon length also has a negative 
correlation with the efficiency of the emulsion PCR [247]. The in-gel polony PCR 
approach was supposed to improve the amplification efficiency and help with polony 
formation [244]. But the less-than-satisfactory results called for more optimization 
before an ideal condition for bridge amplification could be worked out. 
 
Staining efficiency. Staining of the amplicons also works better in solution phase than on 
a solid surface, as demonstrated in Figure 5-11 and previously stained images. This is 
probably because the probes, especially the protein probes, have less steric hindrance 
staining the amplicons floating in solution than staining the ones being attached onto a 
planar solid surface. Also, the on-slide staining for emulsion PCR beads was performed 
in a small chamber, which usually has smaller volume than tubes and is less efficient for 
the staining solution and/or the PCR mix to reach the beads. When comparing different 
probes, the performance can be listed from the best to the worst as: thrombin (Cy5) > 
thrombin (Cy3) > TBA probe (6-FAM) > Sybr555. The sybr555 DNA dye is a non-specific 
DNA dye and prefers double stranded DNA over single stranded DNA. The clusters 
formed by bridge amplification have only partial double stranded stem region near the 
surface of the slide, so the staining efficiency was not good in the case of Sybr555. The 
TBA probe and thrombin are both specific probes. The fact that thrombin stained better 
than the TBA probe indicated that the TBA sequence might have higher affinity for 
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thrombin than for the complementary TBA probe sequence. The structural stability of a 
G-quadruplex makes it easier to bind thrombin than the TBA probe sequence.  
 
Background issue. In the whole slide staining and washing steps, the slides were stained 
in a plastic tube filled with appropriate solutions and incubated on a lab rocker. It’s 
observed that slides stained and washed in this manner tend to have weaker signals on 
both ends of the slides and a streaky pattern in background can often be seen. Using a 
larger tray and enough solutions to cover the slide throughout the time of incubation on 
the lab rocker might improve this issue of uneven staining. The catch is that more 
probes would be needed as the volume would be larger in this staining setup. But that 
should be a small price to pay. Other factors contribute to high or uneven backgrounds 
include insufficient blocking, air bubbles in the staining chamber, and slides drying out 
before wash. Non-specific binding could result from residual components from the PCR 
mixture, which contribute to the high background as well as false positive signal. It was 
also observed that Cy3- or Cy5-labeled thrombin has reduced affinity for TBA sequence, 
which indicates possible structure change or denaturation of thrombin due to the 
fluorophore labeling [248]. This fact might also contribute to the staining/background 
issues. 
 
 
5.5. Conclusions and suggestions for future work 
 
 - 124 - 
 
5.5.1. Bridge amplification 
 
The bridge amplification platform did not work as planned, mostly because of the low 
amplification efficiency and staining issues. Initial data did show signs of successful 
amplification but the results weren’t consistent. 
 
With the recent acquirement of an Illumina GAII sequencer in our lab, the need to 
create a prototype bridge amplification platform is not as significant as before. We are 
planning to work on screening protocols using actual Illumina sample slides, which could 
be an extension of this project. 
 
5.5.2. Emulsion PCR 
 
The emulsion PCR platform can be considered as partly accomplished. There was clear 
sign that template sequences were successfully amplified on magnetic beads using 
emulsion PCR. The results were reproducible and the detection methods worked well. 
 
But there are still issues with non-specific binding and detection sensitivity. One should 
be able to improve or solve these issues given more time and resources. But without 
access to an NGS sequencer based on emulsion PCR, this project currently remains at 
the prototype stage. 
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Table 5-1. Template and primer sequences used in aptamer discovery method development 
Name Length modification Sequence (5'->3') 
TBA 15 - GGTTGGTGTGGTTGG 
TBA Scrambled 15 - GGTGGTTGTTGTGGT 
B
ri
d
ge
 A
m
p
 
TBA 55mer 55 5'-dual biotin CGGTTGCGTTTACTGCCGTCGGTTGGTGTGGTTGGGACGGCAGTAAACGCAACCG 
TBA-S 55mer 55 5'-dual biotin CGGTTGCGTTTACTGCCGTCGGTGGTTGTTGTGGTGACGGCAGTAAACGCAACCG 
BA Primer 20 5'-dual biotin CGGTTGCGTTTACTGCCGTC 
TBA 63mer 63 5'-dual biotin AGAAGGAGAAGGAAAGGGAAAGGGGGTTGGTGTGGTTGGGGTTTGGGTTGGTTTGGGTTGGTG 
TBA-S 63mer 63 5'-dual biotin AGAAGGAGAAGGAAAGGGAAAGGGGGTGGTTGTTGTGGTGGTTTGGGTTGGTTTGGGTTGGTG 
BA Fwd Primer 24 5'-dual biotin AGAAGGAGAAGGAAAGGGAAAGGG 
BA Rev Primer 24 5'-dual biotin CACCAACCCAAACCAACCCAAACC 
Em
u
ls
io
n
 P
C
R
 
TBA 89mer 89 - 
AACTGCCCCGGGTTCCTCATTCTCTACGCCAACCACACCAACCCGTATCACCGACTGCCCATA
GAGAGGAAAGCGGAGGCGTAGTGGTT 
Fwd primer 29 5'-dual biotin CCACTACGCCTCCGCTTTCCTCTCTATGG 
Rev primer 21 - CTGCCCCGGGTTCCTCATTCT 
Bridging oligo 1 24 - GTGAGCTTCGTCTGCCCCGGGTTC 
Bridging oligo 2 28 - GTGAGCTTCGTCCATAGAGAGGAAAGCG 
Capping oligo 1 10 
5'-phosphate, 
3'-amine 
CGAAGCTCAC 
Capping oligo 2 11 
5'-phosphate, 
3'-amine 
ACGAAGCTCAC 
TBA Probe 12 5'-6-FAM CCAACCACACCA 
T20TBA 35 5'- dual biotin TTTTTTTTTTTTTTTTTTTTGGTTGGTGTGGTTGG 
Temp-AloI 77 - 
AAGTCAGCTATGCCGCTACGGACCCGGGGTTCTCAGATCCCAACCACACCAACCTCCAAACAC
CTCCGCATCACCTT 
Rev primer AloI 21 - GTCAGCTATGCCGCTACGGAC 
Fwd primer AloI 21 5'-biotin GGTGATGCGGAGGTGTTTGGA 
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Figure 5-1. Formation of DNA clusters by bridge amplification 
Red: universal primer; green: complementary region to the universal primer; Black: TBA 
sequence; gray: complementary sequence of TBA; blue: TBA scrambled sequence; light 
blue: complementary sequence of TBA scrambled; dotted arrow indicates the bridge 
amplification reaction and its extension direction. 
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Figure 5-2. TBA 55mer 
Drawn with mfold web server online tool at http://mfold.rna.albany.edu/?q=mfold 
[249].  
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Figure 5-3. TBA scrambled 55mer 
Drawn with mfold web server online tool at http://mfold.rna.albany.edu/?q=mfold 
[249]. 
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Figure 5-4. Detection of DNA clusters after bridge amplification 
Black: TBA cluster; blue: TBA scrambled cluster; gold: DNA clusters stained with Sybr555 
DNA stain; green: DNA clusters stained with labeled thrombin; red: DNA clusters stained 
with labeled TBA scrambled probe. 
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Figure 5-5. Schematic setup of emulsion PCR 
Grey circle: magnetic emulsion beads; green bar: forward primer; purple bar: reverse 
primer; the three-part bar: template; light green bar: capping oligo; the two-part bar: 
bridging oligo; arrows: extension direction.  
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Figure 5-6. TBA clusters formed by bridge amplification 
Positive control: 0.5 µM template (TBA 55mer); Negative control: 0.5 µM primer (BA 
primer) + 1 pM template (TBA 55mer), no polymerase; Sample: 0.5 µM primer (BA 
primer) + 0.01 pM template (TBA 55mer). Controls and sample were stained with 
Sybr555 DNA stain for 5 minutes. All chambers went through the same thermo cycling 
and staining procedure.  
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Figure 5-7. Open loop template design 
Two set of non-complementary primers are attached on the solid surface. The 5′-region 
and 3′-region of the template match the two primers, respectively. The template does 
not have stable secondary structure by design.  
 - 133 - 
 
 
 
 
 
 
Figure 5-8. Detection of emulsion PCR beads by TBA probe (6-FAM) 
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain 
template in the PCR mixture. Both control beads and sample beads went through the 
same thermo cycling and were stained with 6-FAM labeled TBA probe.  
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Figure 5-9. Detection of emulsion PCR beads by Thrombin (Cy3) 
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain 
template in the PCR mixture. Both control beads and sample beads went through the 
same thermo cycling and were stained by thrombin labeled with Cy3.  
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Figure 5-10. Detection of emulsion PCR beads by Thrombin (Cy5) 
Panel A: bright field images. Panel B: fluorescent images. Control 1: no template; control 
2: no forward primers. Both control beads and sample beads were blocked in the 
presence of 10mg/ml casein for 1 hour and went through the same thermo cycling. All 
beads were stained with Cy5-labeled thrombin in the presence of 2mg/ml casein in the 
staining solution.   
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Figure 5-11. Detection of control beads by Thrombin (Cy5) 
Panel A: bright field images. Panel B: fluorescent images. Negative control 1: beads 
loaded with forward primers but not stained; negative control 2: unloaded beads; 
positive control: beads loaded with T20TBA. Both negative control 2 and positive control 
were stained with Cy5-labeled thrombin overnight in eppendorf tubes.  
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Figure 5-12. Detection of emulsion PCR beads by Thrombin (Cy3) 
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain 
template in the PCR mixture. Both control beads and sample beads went through the 
same thermo cycling and were stained by thrombin labeled with Cy3 overnight in 
eppendorf tubes.  
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Figure 5-13. New emulsion PCR template design 
Gray circle: magnetic emulsion beads; scissor: restriction enzyme (AloI); green bar: 
forward primer; purple bar: reverse primer; the three-part bar: template; arrows: 
extension direction.  
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Figure 5-14. Detection of emulsion PCR beads by TBA probe (6-FAM) 
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Figure 5-15. Detection of emulsion PCR beads by Thrombin (Cy5) 
 
  
- 141 - 
 
 
 
 
 
 
 
 
 
 
Appendices  
 - 142 - 
 
Appendix A. NCp7 Site-Mutagenesis 
Sequence information 
A-1. Map of pET-3a plasmid 
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A-2. Full sequence of the pRD2 construct (from HIV-1 pNL4-3 strain) 
 
> pRD2 
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAAT 
AATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTG 
TTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAAT 
GCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTAT 
TCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT 
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG 
CGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAA 
AGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCG 
CCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCT 
TACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACAC 
TGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA 
CAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCAT 
ACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACT 
ATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGC 
GGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGA 
TAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGG 
TAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACG 
AAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCA 
AGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTA 
GGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCA 
CTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG 
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGA 
TCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAA 
TACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCC 
TACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTG 
TCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAAC 
GGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCT 
ACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC 
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG 
GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATG 
CTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCT 
GGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGA 
TAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCG 
CAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCA 
TCTGTGCGGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCC 
GCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCC 
GACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTT 
ACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCAC 
CGAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGA 
TGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGC 
TTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCG 
TGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCA 
CGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAAC 
TGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCG 
TTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGA 
ACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGA 
AGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTC 
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GCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGG 
TCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGA 
TGCGCCGCGTGCGGCTGCTGGAGATGGCGGACGCGATGGATATGTTCTGCCAAGGGTTGG 
TTTGCGCATTCACAGTTCTCCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATC 
CGTTAGCGAGGTGCCGCCGGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCG 
ACGCAACGCGGGGAGGCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTT 
CCATGTGCTCGCCGAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAGTGATCGAAGT 
TAGGCTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCATCTACCTG 
CCTGGACAGCATGGCCTGCAACGCGGGCATCCCGATGCCGCCGGAAGCGAGAAGAATCAT 
AATGGGGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTC 
GGCCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGT 
GACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCAT 
CGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTG 
TCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCG 
CGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGACGCTCTCC 
CTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGC 
CGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCC 
TGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTC 
CCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCC 
GGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTC 
ACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGA 
        NdeI   
GATATACATATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAAT 
TGTGGCAAAGAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGG 
AAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAGTTA 
     BamHI 
GGGAGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG 
AGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGA 
AAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCG 
ATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT 
GCTCCGAGAACGGGTGCGCATAGAAATTGCATCAACGCATATAGCGCTAGCAGCACGCCA 
TAGTGACTGGCGATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGCAGTACCGGC 
ATAACCAAGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCA 
TTGTTAGATTTCATACACGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCG 
CATTAAAGCTTATCGATGATAAGCTGTCAAACATGAGAA 
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Appendix B. Recipes and Protocols 
Used in NCp7 Mutagenesis 
 
B-1. Recipes for medium, buffers and solutions 
 
LB Medium 
Per liter: 
Tryptone   10g 
Yeast extract   5g 
NaCl   10g 
Or use the premixed capsules (MP Biomedicals, Solon, OH), 4 capsules per liter 
Sterilize by autoclaving 
Store media at room temperature (RT) 
 
Antibiotics 
Chloramphenicol: 34mg/ml in ethanol, filtered, store at -20°C. 
Ampicillin: 100mg/ml in ddH2O, filtered, store at -20°C. 
 
 
1X TE 
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Tris-HCl 10mM 
EDTA  1 mM 
pH 8.0 
 
10x M9 Salts 
Per liter: 
NH4Cl               10g 
KH2PO4  30g 
Na2HPO4∙7H2O 32g 
Filtered sterile, store at RT 
 
ZnCl2 (200mM) 
Weigh 1.363g of ZnCl2, dissolve in 50ml ddH2O, filtered, store at 4°C 
 
MgSO4 (1M) 
Weigh 6.02g of MgSO4, dissolve in 50ml ddH2O, filtered, store at 4°C 
 
40% Glucose (w/v) 
Weigh 80g of Glucose, dissolve in 200ml ddH2O, filtered, store at 4°C 
 
10mg/ml Lysozyme 
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Weigh 10mg Lysozyme, dissolve in 1ml filtered ddH2O. Prepare fresh solution 
each time immediately before use. 
 
1mg/ml Pepstatin A 
Pepstatin A comes in 5mg/bottle package (Sigma P4265). Dissolve the content in 
5ml of methanol. Store at 4°C 
 
10mM PMSF(Phenylmethylsulfonyl Fluoride) 
Weigh 87.1mg PMSF, dissolve in 50ml of ethanol, filtered, store at 4°C 
 
1% Deoxycholate 
Weigh 0.5g of sodium deoxycholate monohydrate, dissolve in 50ml ddH2O, 
filtered, store at 4°C 
 
1M TCEP·HCl (Tris(2-Carboxyethyl) phosphine Hydrochloride) 
Weigh 5.733g of TCEP·HCl, dissolve in 20ml ddH2O, filtered, make 1ml aliquots, 
store at -20°C 
 
4% PEI (polyethyleneimine) 
Take 4ml of 50 % (w/v in water) Poly(ethyleneimine) solution (Sigma P3143), add 
ddH2O to a total volume of 50ml, filtered, store at 4°C 
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2M NaCl 
Weigh 116.88g of NaCl, dissolve in 1 L of ddH2O, filtered, store at 4°C 
 
1M NaOH 
Weigh 40g of NaOH, dissolve in 1 L of ddH2O, filtered, store at 4°C 
 
NCp7 FPLC Buffers 
Buffer A (1 Liter) 
Tris-Base  6.06g  (final 50mM) 
Glycerol  100ml  (final 10%)  
NaCl   5.8g  (final 100mM) 
200mM ZnCl2  500μl  (final 100μM) 
1M TCEP·HCl  1ml  (final 1mM) 
Adjust to pH8.0 with HCl 
Filtered sterile, store at 4°C 
Buffer B (1 Liter) 
Tris-Base  6.06g  (final 50mM) 
Glycerol  100ml  (final 10%)  
NaCl   58.4g  (final 1M) 
200mM ZnCl2  500μl  (final 100μM) 
1M TCEP·HCl  1ml  (final 1mM) 
Adjust to pH8.0 with HCl 
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Filtered sterile, store at 4°C 
Note: The FPLC buffers were made and stored without TCEP·HCl. TCEP·HCl was 
only added immediately prior to use. 
 
10X TBE 
 
Per liter: 
Tris-Base  108g  (final 890mM) 
Boric Acid  55g  (final 890mM) 
0.5M EDTA pH8.0 40ml  (final 20mM) 
Add ddH2O to 1 liter, filter and store at RT. 
Note: Do not adjust pH. pH of the stock solution should be around 8.3. Filtering is 
optional and can delay precipitation. 
 
SDS PAGE Gel 
15% Separating Gel (10ml) 
H2O     3.55ml 
40% Gel concentrate   3.75ml 
1.5M Tris (pH 8.8)   2.5ml 
10% SDS    0.1ml 
10% Ammonium Persulfate  0.1ml 
TEMED    4µl 
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5% Stacking Gel (4ml) 
H2O     2.92ml 
40% Gel concentrate   0.5ml 
1.5M Tris (pH 8.8)   0.5ml 
10% SDS    0.04ml 
10% Ammonium Persulfate  0.04ml 
TEMED    4µl 
Note: This recipe is enough for making one 7mm x 8mm x 1.5mm gel or two 7mm 
x 8mm x 0.75mm gel (regular gel size for Bio-Rad mini-protean tetra cell 
system). Scale up or down if necessary. 
 
SDS PAGE Running Buffer 
Anode Buffer (10X): 2.0M Tris HCl (pH8.9) 
Dissolve 121.1 g of Tris base in 400ml ddH2O, adjust pH to 8.9 with HCl, 
and add ddH2O to final volume of 500ml. Store at RT. 
Cathode Buffer (10X): 1.0M Tris HCl, 1.0M Tricine, SDS (pH8.25) 
Dissolve 60.55 g of Tris base, 89.58g of Tricine and 5g of SDS in 400ml 
ddH2O, adjust pH to 8.25 with HCl, and add ddH2O to final volume of 
500ml. Store at RT. 
Note: Cathode Buffer goes to upper chamber; Anode Buffer goes to the bottom 
chamber. 
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SDS 2X Loading Buffer 
1M Tris-HCl pH 6.8 1 ml 
10% SDS  4 ml 
Glycerol  2 ml 
Bromophenol blue 0.02 g 
1M DTT  2 ml 
Adjust volume to 10 ml, divide into 1 ml aliquots, and store at -20°C 
 
Gel Staining and Destaining Solution 
Coomassie Brilliant Blue staining solution  
PhastGel Blue R 1 tablet 
Methanol   450ml 
ddH2O   450ml 
Glacial acetic acid 100ml 
Filter and store at RT 
 
Destaining solution  
Methanol  450ml 
ddH2O   450ml  
Glacial acetic acid 100ml 
Store at RT 
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10X NCp7 MS Buffer* 
Per liter: 
NaH2PO4  6g  (final 50mM) 
NaCl   116.8g  (final 2M) 
200mM ZnCl2  50µl  (final 10µM) 
Adjust pH to 7.0 with HCl. Filter and store at RT. 
*Dilute with ddH2O to 1X and add TCEP·HCl to 1mM final concentration before 
use. 
 
10X NCp7 Titration Buffer* 
Per liter: 
NaH2PO4  6g  (final 50mM) 
NaCl   116.8g  (final 2M) 
200mM ZnCl2  50µl  (final 10µM) 
PEG 8000  10g  (final 1%) 
Adjust pH to 7.0 with HCl. Filter and store at RT. 
*Dilute with ddH2O to 1X and add TCEP·HCl to 1mM final concentration before 
use.  
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B-2. Protocol for plasmid preparation 
 
Materials: 
 
 XL1-Blue strain or other endA- strain containing the needed plasmid 
 LB-Amp medium 
 QIAprep Spin Miniprep kit 
 
Procedure: 
 
1. Streak the frozen culture of XL1-Blue cells onto a LB agar plate containing 
100μg/ml Ampicillin. Incubate the streaked plate at 37°C overnight. 
2. Pick a single colony from the overnight grown plate to inoculate 5ml of LB-Amp 
medium. Incubate the liquid culture at 37°C overnight, shaking at 200~250rpm. 
3. Harvest the overnight culture by spinning the cells for 5 minutes at 3000rpm in a 
tabletop centrifuge. Remove all the supernatant. 
4. Re-suspend pelleted bacterial cells in 250 µl of Buffer P1 and transfer the 
suspension to a microcentrifuge tube. 
5. Add 250 µl of Buffer P2 and mix thoroughly by inverting the tube 4–6 times. 
6. Add 350 µl of Buffer N3 and mix immediately and thoroughly by inverting the 
tube 4–6 times. 
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7. Centrifuge for 10 minutes at 13,000 rpm (~17,900 x g) in a table-top 
microcentrifuge. 
8. Apply the supernatant (from step 7) to the QIAprep spin column by decanting or 
pipetting. 
9. Centrifuge for 1 minute. Discard the flow-through. 
10. Wash QIAprep spin column by adding 0.75 ml of Buffer PE and centrifuging for 1 
minute. 
11. Discard the flow-through, and centrifuge for an additional 1 minute to remove 
residual wash buffer. 
12. To elute DNA, place the QIAprep column in a clean 1.5 ml microcentrifuge tube. 
Add 50 µl of nuclease-free water to the center of each QIAprep spin column, let 
stand for 1 minute, and centrifuge for 1 minute. 
13. Check the purity and integrity of the miniprep by agarose gel electrophoresis. 
Measure the concentration of the prepared plasmid DNA by UV absorption at 
260nm.  
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B-3. Protocol for site-directed mutagenesis 
 
Materials:  
 
 Stratagene® QuikChange® II Site-Directed Mutagenesis Kit (Stored at -20°C) 
 Plasmid DNA template: dilute to 10ng/μl 
 Primers: dilute to 10μM (100~150ng/μl) 
 
Procedure: 
 
1. Prepare PCR mix as below: 
 
10× reaction buffer   2.5 μl 
dsDNA template (10ng/μl)*  0.5 μl 
Forward primer (10 μM)  0.5 μl 
Reverse primer (10 μM)  0.5 μl 
dNTP mix (10mM)   0.5 μl 
PfuUltra polymerase (2.5 U/μl) 0.5 μl 
Nuclease free H2O   20 μl  
Final volume:    25  μl 
* Nuclease free H2O was added instead of DNA template as a negative control. 
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2. Set up and run mutagenesis PCR reactions as below: 
 
1) 95°C 30 seconds 
2) 95°C 30 seconds 
3) 55°C 1 minute 
4) 68°C 6 minutes 
5) go to step 2) for a total of 16 cycles 
6) hold at 4°C 
 
3. Add 0.5µl of DpnI restriction enzyme into each PCR reaction. Mix well and 
incubate the mixture at 37°C for 1 hour. 
4. Check product size and integrity on agarose gel. Load 5 µl of each digested PCR 
reaction per well on a 1% agarose gel. Use 1X TBE as running buffer. Run the gel 
at 160V for 40 minutes. Stain with ethidium bromide and take gel image on a 
Kodak Gel Imager equipped with UV transilluminator. 
5. Transform mutated DNA product into XL1-Blue competent cells (See appendix B-
4 for detailed protocol). 
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B-4. Protocol for transformation into XL1-Blue competent cells 
 
Materials:  
 
 XL-1 Blue competent cells(Stratagene), stored at -80°C 
 Digested PCR mix 
 LB+0.4% glucose 
 LB/AMP plates 
 
Procedure: 
 
1. Estimate concentration of PCR product based on the agarose gel. (UV absorption 
at this time is not reliable because of interference by dNTPs and free primers.)  
2. Use ~5ng of DNA (DNA volume should not exceed 10% of reaction volume, in this 
case, 2μl) for each transformation. Add the DNA into a 200μl PCR tube, let it chill 
on ice. Use 1 μl of pUC18 control DNA (0.1ng/μl, included in the kit) as positive 
control. Use 1 μl of nuclease free H2O as negative control. 
3. Thaw a tube of XL-1 Blue competent cells on ice. Add 20 μl of competent cells 
into each tube. 
4. Incubate the mixture on ice for 30 minutes. In the mean time, warm up a tube of 
LB+0.4% glucose at 42°C. 
 - 158 - 
 
5. Heat-shock the cell mixture at 42°C for 45 seconds on a pre-warmed thermal 
cycler. 
6. Immediately put tubes back on ice, incubate for 2 minutes. 
7. Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix. 
8. Pool the tubes in a 15ml falcon tube, shake at 250rpm in a 37°C incubator for 1 
hour. Warm up a few LB/AMP plates during this time. 
9. Spread 50 μl of the recovered cells onto each LB/AMP plate. Grow plates at 37°C 
overnight. 
10. Pick single colony from plate, inoculate a 5-ml LB/AMP liquid culture, grow at 
37°C overnight, shaking at 220~250rpm. 
11. Make permanent glycerol storage culture (see appendix B-6). Store the frozen 
stocks at -80°C. 
12. Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50 μl of 
nuclease free H2O. 
13. Measure plasmid concentration by UV absorption. Use 200-800ng of each 
plasmid as Sanger sequencing template. Store the rest of plasmid at -80°C. 
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B-5. Protocol for transformation into BL21 competent cells 
 
Materials:  
 
 BL21-(DE3)pLysS competent cells (Stratagene), stored at -80°C 
 Mutant plasmid DNA, dilute to 10ng/μl 
 LB+0.4% glucose 
 LB/AMP/Chl plates 
 
Procedure: 
 
1. Add 1 μl of plasmid (10 ng) to a 200 μl PCR tube, let it chill on ice. Use 1 μl of 
pUC18 control DNA (0.1 ng/μl) as positive control. Use 1 μl of nuclease free H2O 
as negative control. 
2. Thaw a tube of BL21 competent cells on ice. Add 20ul of BL21 competent cells to 
each tube. 
3. Incubate the mixture on ice for 30 minutes. In the mean time, warm up a tube of 
LB+0.4% glucose at 42°C. 
4. Heat-shock the cell mixture at 42°C for 20 seconds on a pre-warmed thermal 
cycler. 
5. Immediately put tubes back on ice, incubate for 2 minutes. 
6. Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix. 
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7. Pool the tubes in a 15ml falcon tube, shake at 250rpm in a 37°C incubator for 1 
hour. Warm up a few LB/AMP/Chl plates during this time. 
8. Spread 50 μl of the recovered cells onto each LB/AMP/Chl plate. Grow plates at 
37°C overnight. 
9. Pick single colony from plate, inoculate a 5-ml LB/AMP/Chl liquid culture 
supplemented with Zinc, M9 salts and glucose (see recipe for starter culture in 
appendix B-5), grow at 37°C overnight, shaking at 220~250rpm. 
10. Make permanent glycerol storage culture (see appendix B-6). Store the frozen 
culture at -80°C. 
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B-6. Protocol for making or renewing frozen stock of E. coli strains 
 
Materials:  
 
 Fresh LB plates with healthy colonies of E. coli cells (plated with freshly 
transformed cells or streaked from previous frozen stock) 
 LB medium 
 Antibiotics of choice/Glucose/M9 salts 
 50% glycerol (sterilized by autoclave) 
 Dry ice 
 
Procedure: 
 
1. Prepare 5 ml of fresh LB media, add appropriate antibiotic(s) and nutrients at 
desired concentration. 
2. Pick a single colony from the LB plate, inoculate the above 5-ml LB media with 
this colony, mix well and grow cells overnight. 
3. Aliquot 150 µl of 50% glycerol to microcentrifuge tubes or cryo-vials. 
4. Add 350 µl of fresh overnight culture to each tube containing glycerol, mix well. 
5. Immediately put tubes on dry ice. Transfer tubes into -80°C freezer after the 
mixture is completely frozen. 
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B-7. Protocol for NCp7 protein over-expression 
 
Materials: 
 
 BL21-(DE3)pLysS cells containing the needed plasmid 
 LB-Amp-Chl medium 
 Supplements: 10X M9 salts, 200mM ZnCl2, 1M MgSO4, 40% Glucose 
 1M IPTG 
 
Procedure: 
 
1. Streak the frozen culture of BL21-(DE3)pLysS cells onto a LB-Amp-Chl plate. 
Incubate the streaked plate at 37°C overnight. 
2. Pick a single colony from the overnight grown plate to inoculate 5ml of starter 
culture as described below: 
Starter culture media 
LB media     4.45ml 
10X M9 salts*   500μl  (final conc. 1X) 
34mg/ml Chloramphenicol 5μl  (final conc. 34μg/ml) 
100mg/ml Ampicillin  5μl  (final conc. 100μg/ml) 
200mM ZnCl2   2.5μl  (final conc. 100μM) 
1M MgSO4    5μl  (final conc. 1mM) 
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40% Glucose   50μl  (final conc. 0.4%) 
Final Volume:   5ml 
*See appendix B-1 for recipe. 
3. Grow the inoculated starter culture overnight at 37°C, shaking at 200-250rpm. 
4. Transfer the overnight starter culture to 1 liter of fresh media as described below: 
NCp7 expression media (1 Liter) 
LB media     890ml 
10X M9 salts*   100ml  (final conc. 1X) 
34mg/ml Chloramphenicol 1ml  (final conc. 34μg/ml) 
100mg/ml Ampicillin  1ml  (final conc. 100μg/ml) 
200mM ZnCl2   0.5ml  (final conc. 100μM) 
1M MgSO4    1ml  (final conc. 1mM) 
40% Glucose   10ml  (final conc. 0.4%) 
Final Volume:   1L 
*See appendix B-1 for recipe. 
5. Incubate the 1L culture at 37°C, shaking at 200-250rpm. Monitor cell density by 
measuring the culture’s absorbance at 600nm every half hour until OD600 
reaches 0.6-0.8, which usually takes 4-5 hours after inoculation. 
6. Induce the culture with 400μl of 1M IPTG (final conc. 400μM) when the culture’s 
OD600 is between 0.6-0.8. Incubate the culture at 37°C, shaking at 200-250rpm, 
for 4 more hours after induction. 
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7. Harvest cells by centrifuging the culture on an Avanti® J-E centrifuge (Beckman 
Coulter) using the JLA-10.5 rotor, spinning at 5000rpm for 15 minutes. Dump the 
clear supernatant and keep the cell pellet. 
8. Use the cell pellet for cell lysis or freeze the cell pellet at -20°C. 
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B-8. Protocol for cell lysis 
 
Materials: 
 
 Cell pellets from over-expression (see appendix B-6) 
 Lysis buffer (see procedure below for recipe) 
 B-PER II Protein Extraction Reagent (Thermo Pierce) 
 4% PEI (polyethyleneimine) 
 
Procedure: 
 
1. Re-suspend fresh or frozen cell pellet in ~30ml of ice-cold lysis buffer as 
described here: 
NCp7 Lysis Buffer (for pellets from 1L culture) 
NCp7 FPLC Buffer A w/o TCEP* 30ml 
10mg/ml freshly made Lysozyme  200μl  (final 60μg/ml)  
1mg/ml Pepstatin A   30μl   (final 0.9μg/ml) 
10mM PMSF    172μl   (final 53μM) 
1% Deoxycholate    2.1ml   (final 5mM) 
1M TCEP     150μl   (final 5mM) 
*See appendix B-1 for recipe. 
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2. Transfer the re-suspended cells into a pre-chilled 50ml conical tube and left on 
ice for 20 minutes. 
3. Add 4ml of B-PER Protein Extraction Reagents (Thermo Pierce), mix well and 
leave the lysate on ice for additional 10 minutes. 
4. Further disrupt the cells using a Microson XL2000 Ultrasonic Liquid Processor 
(Misonix, now Qsonica) for 4 times, 25 seconds each time, at an output power 
setting of 20-25 watts, with 1-minute intervals in between pulses. 
5. Add 2ml of 4% PEI (Sigma-Aldrich), mix well and transfer the lysate into a pre-
chilled 50ml Oakridge tube. 
6. Spin down the lysed cells on an Avanti® J-E centrifuge (Beckman Coulter) using 
the JA-25.5 rotor, spinning at 17,000rpm for 30 minutes at 4°C. 
7. Transfer supernatant into a clean conical tube, filter with 0.45μm syringe filter 
when necessary. Load the collected lysate onto FPLC immediately for purification. 
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B-9. Protocol for FPLC purification of NCp7 
 
Materials: 
 
 Fresh cell lysate (see appendix B-7) 
 NCp7 FPLC buffer A and B (see appendix B-1) 
 SP FF and Q FF FPLC columns 
 
Procedure: 
 
1. Wash and equilibrate a 20ml HiPrep Q FF column (GE Healthcare) and a 20ml 
HiPrep SP FF column (GE Healthcare) connected in series with at least 200ml of 
NCp7 FPLC Buffer A, at a flow rate of 3ml/min.  
2. Set flow rate to 2ml/min and load cell lysate onto the Q FF column (a strong 
anion exchange column). 
3. After loading, set the flow rate back to 3ml/min. When the flow through peak is 
washed off and the UV absorbance decreases to ~15mAU, quickly take the Q FF 
column off the system and keep washing the SP FF column until the UV 
absorbance reaches a stable base line. 
4. Start a 5-min linear gradient from 0% to 20% NCp7 FPLC Buffer B. Wash SP FF 
column with 20% NCp7 FPLC Buffer B until the UV absorbance reaches a stable 
base line again. 
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5. Start a one-hour linear gradient from 20% to 50% NCp7 FPLC Buffer B. Collect 
peak fractions for further analysis. 
6. Start a 5-min linear gradient from 50% to 100% NCp7 FPLC Buffer B. Wash the 
column with 100% NCp7 FPLC Buffer B until the UV absorbance reaches a stable 
baseline. 
7. Start a 5-min linear gradient from 100% to 0% NCp7 FPLC Buffer B. Wash the 
column with 100% NCp7 FPLC Buffer A until the UV absorbance reaches a stable 
baseline. 
8. Clean the columns separately with 2M NaCl solution and ddH2O before the next 
FPLC run. Clean and store the columns appropriately following the 
manufacturer’s protocol (also see appendix B-10). 
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B-10. Protocols for cleaning and storing FPLC columns 
 
Materials: 
 
 FPLC columns 
 ddH2O 
 2M NaCl 
 1M NaOH 
 70% Ethanol 
 20% Ethanol or 20% Ethanol with 0.2 M sodium acetate 
 
Procedure: 
 
Regular cleaning 
 
1. Wash the column with 2 column volumes of 2M NaCl at a flow rate of 5 ml/min 
after each run to elute material still bound to the column, followed by 2 column 
volumes of ddH2O. 
2. Re-equilibrate the column before use with at least 5 column volumes of start 
buffer or until the UV base-line and pH/conductivity values are stable. 
 
More rigorous cleaning 
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1. Reverse the flow direction and run at a flow rate of 5 ml/min at room 
temperature the following sequence of solutions. 
1) 4 column volumes of a 2 M NaCl solution (removes ionically bound 
proteins from the column) followed by 3 column volumes of ddH2O. 
2) 4 column volumes of a 1 M NaOH solution (removes precipitated proteins, 
hydrophobically bound proteins and lipoproteins from the column) 
followed by 3 column volumes of ddH2O. 
3) 4 column volumes of 70% ethanol (removes proteins, lipoproteins and 
lipids that are strongly hydrophobically bound to the column) followed by 
3 column volumes of ddH2O. 
2. Re-equilibrate the column before use with at least 5 column volumes of start 
buffer in the normal flow direction. 
 
Storage 
 
If the column is to be stored for more than two days after use, clean the column 
according to the procedure described above. Then equilibrate with at least 5 
column volumes of 20% ethanol (for Q FF column) or 20% ethanol with 0.2 M 
sodium acetate (for SP FF column) at a flow rate of 5 ml/min. Cap the outlet 
tubings and store the columns at 4°C. 
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B-11. Protocol for FPLC column packing 
 
Materials: 
 
 SP FF resin or Q FF resin, 25ml/bottle 
 20% Ethanol 
 XK 16 column 
 ddH2O 
 FPLC buffer 
 
Procedure: 
 
1. Disassemble the column following the column’s manual, use the right tools. 
Remember to loosen the adjusting knob before pulling out the plungers. 
2. Clean the parts thoroughly. Autoclave the chromatographic glass tube without 
the thermostat jacket and tubings. 
3. Re-assemble the column. Put an end piece to the bottom. 
4. Add 20% ethanol into column, use a syringe to pull ethanol through the tubing to 
get rid of air bubbles. Let the ethanol dripping into a clean beaker. 
5. Shake the resin well, pour down the column, let it settle, add more till 
appropriate height. 
6. Draw ethanol through the top end piece to get rid of air bubbles. 
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7. Insert top end piece at an angle to avoid trapping air bubbles. Assemble the 
column. 
8. Let the resin settle overnight. 
9. Adjust adaptor until it touches the surface of resin. Tighten the O-ring to lock the 
adaptor in position. 
10. Connect the column to FPLC, wash column with 3 column volumes of ddH2O 
then 3 column volumes of buffer A at regular flow rate. Re-adjust adaptor 
position if necessary. 
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Appendix C. NC-SL3 Titration Data 
C-1. Compilation of NCp7-SL3 Trp titration data 
 
# Mutant Titration Date Kd(nM) R
2
 Endpoint ITC Date Kd(nM) 
Fitting 
Error 
N Memo ΔH0 
1 WT 
10/29/2010 23.72 0.999 4.54% 10/18/2010 63.69 11% 1.09 
 
-1.162E+04 
11/7/2010 21.81 0.999 3.21% 10/20/2010 65.79 15% 1.14 
 
-1.081E+04 
11/17/2010 32.98 0.999 5.47% 10/28/2010 65.36 21% 1.17 
 
-1.030E+04 
11/18/2010 34.06 0.999 5.56% 11/17/2010 80.97 13% 1.15 
 
-1.041E+04 
11/19/2010 31.13 0.998 5.88% 
   
11/22/2010 32.39 0.999 5.09% 
11/23/2010 27.32 0.999 3.96% 
11/29/2010 29.34 0.999 5.82% 
 Avg. Kd= 29 M= 8 Avg. Kd= 69 Avg. N = 1.1 Avg. ΔH
0= -1.079E+04 
SD= 4.5 F= 1.0 SD= 8.1 SD= 0.034 SD= 598.2474404 
SD%= 15% 
  
SD%= 12% SD%= 3% SD%= 6% 
  
  
     Kd
RT= 42 
  
ln(K1/K2)= 0.4857564 
SD= 5.0 
  
M= 4 
SD%= 12% 
  
F= 1.0 
  
Analyzed w/ separate blank titration 
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10/18/2010 79.37 14% 0.928 
 
-1.325E+04 
10/20/2010 71.94 14% 0.886 
 
-1.279E+04 
10/28/2010 33.67 48% 0.835 
 
-1.094E+04 
11/17/2010 90.09 11% 0.879 
 
-1.246E+04 
  
Avg. Kd= 69 Avg. N = 0.88 Avg. ΔH
0= -1.236E+04 
SD= 25 SD= 0.038 SD= 1000.566506 
SD%= 36% SD%= 4% SD%= 8% 
  
Kd
RT= 39 
  
ln(K1/K2)= 0.5566944 
SD= 14 
  
M= 4 
SD%= 36% 
  
F= 1.0 
  
2 N5A 
10/20/2010 33.01 0.999 4.75% 10/28/2010 72.99 16% 0.993 
 
-1.077E+04 
10/29/2010 23.66 0.997 5.86% 11/11/2010 169.78 31% 1.18 
 
-7.615E+03 
11/9/2010 22.75 0.993 6.81% 11/15/2010 138.12 14% 1.04 
 
-1.042E+04 
11/15/2010 33.45 0.995 6.84% 11/17/2010 116.55 13% 1.03 
 
-1.034E+04 
11/18/2010 33.86 0.994 7.57% 
   
 Avg. Kd= 29 M= 5 Avg. Kd= 124 Avg. N = 1.1 Avg. ΔH
0= -9.786E+03 
SD= 5.6 F= 1.0 SD= 41 SD= 0.082 SD= 1459.494062 
SD%= 19% 
  
SD%= 33% SD%= 8% SD%= 15% 
  
  
Kd
RT= 80 
  
ln(K1/K2)= 0.4407727 
SD= 26 
  
M= 4 
SD%= 33% 
  
F= 1.9 
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3 F6A 
7/26/2010 29.63 0.999 5.81% 10/22/2010 70.92 20% 0.884 
 
-1.097E+04 
10/12/2010 32.73 0.987 10.60% 10/28/2010 78.74 18% 0.824 
 
-1.125E+04 
11/15/2010 36.17 0.988 10.26% 11/15/2010 142.25 21% 0.902 
 
-1.228E+04 
 
   
Avg. Kd= 33 M= 3 Avg. Kd= 97 Avg. N = 0.87 Avg. ΔH
0= -1.150E+04 
SD= 3.3 F= 1.1 SD= 39 SD= 0.041 SD= 689.8550572 
SD%= 10% 
  
SD%= 40% SD%= 5% SD%= 6% 
   
  
Kd
RT= 58 
  
ln(K1/K2)= 0.51796 
SD= 23 
  
M= 3 
SD%= 40% 
  
F= 1.4 
   
4 V13A 
11/7/2010 38.79 0.992 9.60% 
 
6/8/2011 25.32 0.969 8.95% 
6/9/2011 29.13 0.976 8.65% 
 Avg. Kd= 31 M= 3 
SD= 6.9 F= 1.1 
SD%= 22% 
    
5 F16A 
10/12/2010 686.35 0.986 50.00% 9/29/2010 1701 7% 1.26 12 uM -1.051E+04 
11/19/2010 732.30 0.994 50.51% 10/4/2010 2639 7% 1.33 19 uM -1.036E+04 
11/23/2010 730.75 0.987 50.22% 11/19/2010 1031 27% 1.51 5uM -6.121E+03 
 
  
Avg. Kd= 720 M= 3 Avg. Kd= 1790 Avg. N = 1.4 Avg. ΔH
0= -8.997E+03 
SD= 26 F= 25 SD= 808 SD= 0.13 SD= 2491.818011 
SD%= 4% 
  
SD%= 45% SD%= 9% SD%= 28% 
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Kd
RT= 1200 
  
ln(K1/K2)= 0.40522488 
SD= 540 
  
M= 3 
SD%= 45% 
  
F= 28 
  
Analyzed w/ separate blank titration 
  
9/29/2010 667 33% 0.77 12 uM -8.673E+03 
10/4/2010 592 65% 0.71 19 uM -1.026E+04 
11/19/2010 2262 21% 0.68 5uM -1.517E+04 
  
Avg. Kd= 1174 Avg. N = 0.72 Avg. ΔH
0= -1.137E+04 
SD= 943 SD= 0.046 SD= 3387.173797 
SD%= 80% SD%= 6% SD%= 30% 
  
Kd
RT= 703 
  
ln(K1/K2)= 0.511999707 
SD= 565 
  
M= 3 
SD%= 80% 
  
F= 17.8 
    
6 N17A 
11/7/2010 30.39 0.992 7.73% 
   
6/8/2011 32.55 0.990 9.96% 
6/9/2011 32.98 0.984 9.38% 
 Avg. Kd= 32 M= 3 
SD= 1.4 F= 1.1 
SD%= 4% 
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7 G19A 
11/3/2010 41.78 0.999 7.32% 
  
   
  
  
  
  
  
11/23/2010 44.87 0.999 7.67% 
6/8/2011 46.96 0.997 9.55% 
 Avg. Kd= 45 M= 3 
SD= 2.6 F= 1.5 
SD%= 6% 
    
8 E21A 
11/23/2010 10.25 0.984 5.90% 
  
  
  
  
6/8/2011 6.04 0.968 5.16% 
6/9/2011 9.55 0.980 5.92% 
 Avg. Kd= 8.6 M= 3 
SD= 2.3 F= 0.3 
SD%= 26% 
     
9 G22A 
11/23/2010 48.84 0.988 11.37% 
  
  
  
  
  
  
6/8/2011 37.68 0.969 9.89% 
6/9/2011 49.72 0.952 14.42% 
 Avg. Kd= 45 M= 3 
SD= 6.7 F= 1.6 
SD%= 15% 
     
10 I24A 
10/30/2010 141.42 0.997 16.89% 10/30/2010 359.7 20% 1.19 
 
-1.000E+04 
11/4/2010 140.32 0.999 16.71% 11/4/2010 366.3 22% 1.13 
 
-8.347E+03 
11/9/2010 168.53 0.996 21.32% 11/11/2010 787.4 23% 1.49 
 
-1.037E+04 
11/12/2010 161.24 0.998 21.50% 11/15/2010 416.7 23% 1.32 
 
-9.117E+03 
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11/15/2010 211.09 0.999 23.29% 
  
 Avg. Kd= 170 M= 5 Avg. Kd= 483 Avg. N = 1.3 Avg. ΔH
0= -9.459E+03 
SD= 29 F= 5.8 SD= 205 SD= 0.16 SD= 908.4985782 
SD%= 17% 
  
SD%= 42% SD%= 12% SD%= 10% 
   
  
Kd
RT= 310 
  
ln(K1/K2)= 0.42601084 
SD= 130 
  
M= 4 
SD%= 42% 
  
F= 7.3 
    
11 P31A 
10/18/2010 17.02 0.999 3.31% 10/18/2010 69.93 9% 1.06 
 
-1.304E+04 
10/30/2010 28.69 1.000 4.82% 10/18/2010 87.72 9% 1.13 
 
-1.240E+04 
6/9/2011 22.97 0.998 6.02% 10/30/2010 86.21 10% 1.14 
 
-1.279E+04 
 
  
Avg. Kd= 23 M= 3 Avg. Kd= 81 Avg. N = 1.1 Avg. ΔH
0= -1.274E+04 
SD= 5.8 F= 0.8 SD= 10 SD= 0.044 SD= 322.5419869 
SD%= 25% 
  
SD%= 12% SD%= 4% SD%= 3% 
  
  
Kd
RT= 46 
  
ln(K1/K2)= 0.573959733 
SD= 5.6 
  
M= 3 
SD%= 12% 
  
F= 1.1 
  
Analyzed w/ separate blank titration 
  
10/18/2010 74.63 8% 0.95 
 
-1.399E+04 
10/18/2010 93.46 9% 0.89 
 
-1.446E+04 
10/30/2010 84.03 10% 0.88 
 
-1.486E+04 
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Avg. Kd= 84 Avg. N = 0.9 Avg. ΔH
0= -1.444E+04 
SD= 9 SD= 0.038 SD= 435.4690957 
SD%= 11% SD%= 4% SD%= 3% 
  
Kd
RT= 44 
  
ln(K1/K2)= 0.650227467 
SD= 4.9 
  
M= 3 
SD%= 11% 
  
F= 1.1 
   
12 G40A 
11/3/2010 30.03 0.996 5.57% 
  
  
  
  
  
  
  
  
11/23/2010 39.97 0.998 6.70% 
6/9/2011 27.74 0.995 7.06% 
 Avg. Kd= 33 M= 3 
SD= 6.5 F= 1.1 
SD%= 20% 
    
13 Q45A 
10/13/2010 69.80 1.000 10.17% 11/1/2010 163.93 29% 1.18 
 
-8.250E+03 
11/1/2010 58.18 0.995 10.25% 11/4/2010 169.78 21% 1.16 
 
-8.463E+03 
11/4/2010 71.02 0.999 10.59% 11/22/2010 198.02 11% 1.32 
 
-7.753E+03 
11/22/2010 92.65 0.999 12.54% 
   
 Avg. Kd= 73 M= 4 Avg. Kd= 177 Avg. N = 1.2 Avg. ΔH
0= -8.155E+03 
SD= 14 F= 2.5 SD= 18 SD= 0.087 SD= 364.3437022 
SD%= 20% 
  
SD%= 10% SD%= 7% SD%= 4% 
  
  
  
Kd
RT= 120 
  
ln(K1/K2)= 0.367316213 
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SD= 12 
  
M= 3 
SD%= 10% 
  
F= 2.8 
   
14 M46A 
11/23/2010 72.46 0.991 13.54%   
  
  
  
  
  
   
  
  
6/8/2011 52.28 0.994 7.43% 
6/9/2011 61.16 0.995 11.32% 
 Avg. Kd= 62 M= 3 
SD= 10 F= 2.1 
SD%= 16% 
    
15 
K14E-
E21K 
10/12/2010 146.74 0.967 23.83% 11/1/2010 184.2 38% 0.774 
 
-6.162E+03 
11/1/2010 131.91 0.972 21.92% 11/4/2010 184.5 43% 0.814 
 
-6.804E+03 
11/4/2010 142.90 0.944 25.32% 11/22/2010 215.5 38% 0.784 
 
-6.000E+03 
11/22/2010 137.51 0.971 22.71% 
  
   
11/29/2010 138.46 0.939 17.11% 
11/29/2010 144.02 0.960 16.72% 
11/29/2010 136.74 0.936 16.72% 
 Avg. Kd= 140 M= 7 Avg. Kd= 195 Avg. N = 0.79 Avg. ΔH
0= -6.322E+03 
SD= 5.1 F= 4.8 SD= 18 SD= 0.021 SD= 425.2105361 
SD%= 4% 
  
SD%= 9% SD%= 3% SD%= 7% 
  
   
  
Kd
RT= 150 
  
ln(K1/K2)= 0.28474288 
SD= 14 
  
M= 3 
SD%= 9% 
  
F= 3.5 
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16 
K33E-
E42K 
11/1/2010 30.17 0.999 6.40% 11/1/2010 68.49 10% 1.04 
 
-1.356E+04 
11/18/2010 51.36 0.999 8.49% 11/17/2010 75.19 10% 1.12 
 
-1.158E+04 
11/22/2010 38.84 0.998 8.47% 11/22/2010 82.64 12% 1.13 
 
-1.192E+04 
 
  
Avg. Kd= 40 M= 3 Avg. Kd= 75 Avg. N. = 1.1 Avg. ΔH
0= -1.235E+04 
SD= 11 F= 1.4 SD= 7.1 SD= 0.049 SD= 1058.741391 
SD%= 27% 
  
SD%= 9% SD%= 4% SD%= 9% 
  
   
  
Kd
RT= 43 
  
ln(K1/K2)= 0.556394133 
SD= 4.1 
  
M= 3 
SD%= 9% 
  
F= 1.0 
   
17 
K38E-
E51K 
11/7/2010 27.80 0.950 10.80% 
  
  
   
11/23/2010 37.96 0.963 11.34% 
6/9/2011 33.72 0.938 12.17% 
 Avg. Kd= 33 M= 3 
SD= 5.1 F= 1.1 
SD%= 15% 
     
*M = number of measurements 
F = Change factor of Kd
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C-2. Individual NCp7-SL3 Trp Titration Curves 
 
 
Individual curves start from the next page. 
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10/29/2010  WT 
 
11/7/2010  WT 
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11/17/2010  WT 
 
11/18/2010  WT 
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11/19/2010  WT 
 
11/22/2010  WT 
 
  
 - 186 - 
 
11/23/2010  WT 
 
11/29/2010  WT 
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11/29/2010  WT (SL3+10%) 
 
11/29/2010  WT (SL3-10%) 
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10/20/2010 N5A 
 
10/29/2010 N5A
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11/9/2010 N5A
 
11/15/2010 N5A
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11/18/2010 N5A 
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7/26/2010 F6A 
 
10/12/2010 F6A 
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11/15/2010 F6A 
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11/7/2010 V13A 
 
6/8/2011 V13A 
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6/9/2011 V13A 
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10/12/2010 F16A 
 
11/19/2010 F16A 
 
  
 - 196 - 
 
11/23/2010 F16A 
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11/7/2010  N17A 
 
6/8/2011 N17A 
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6/9/2011 N17A 
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11/3/2010  G19A 
 
11/23/2010  G19A 
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6/8/2011 G19A 
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11/23/2010  E21A 
 
6/8/2011 E21A 
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6/9/2011 E21A 
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11/23/2010 G22A 
 
6/8/2011 G22A 
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6/9/2011 G22A 
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10/30/2010 I24A 
 
11/4/2010 I24A 
 
  
 - 206 - 
 
11/9/2010 I24A 
 
11/12/2010 I24A 
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11/15/2010 I24A 
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10/18/2010  P31A 
 
10/30/2010  P31A 
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6/9/2011 P31A 
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11/3/2010  G40A 
 
11/23/2010  G40A 
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6/9/2011 G40A 
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10/13/2010 Q45A 
 
11/1/2010 Q45A 
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11/4/2010 Q45A 
 
11/22/2010 Q45A 
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11/23/2010  M46A 
 
6/8/2011 M46A 
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6/9/2011 M46A 
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10/12/2010 K14E-E21K 
 
11/1/2010 K14E-E21K 
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11/4/2010 K14E-E21K 
 
11/22/2010 K14E-E21K 
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11/29/2010 K14E-E21K-1 
 
11/29/2010 K14E-E21K-2 
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11/29/2010 K14E-E21K-3 
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11/1/2010  K33E-E42K 
 
11/18/2010  K33E-E42K 
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11/22/2010  K33E-E42K 
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11/7/2010  K38E-E51K 
 
11/23/2010  K38E-E51K 
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6/9/2011 K38E-E51K 
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C-3. Individual NCp7-SL3 ITC Curves 
6/9/2011 WT blank titration 
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6/9/2011 F16A blank titration 
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6/12/2011 P31A blank titration 
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10/18/2010 WT (Use endpoints data as baseline) 
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10/18/2010 WT (Use blank titration data as baseline) 
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10/20/2010 WT (Use endpoints data as baseline) 
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10/20/2010 WT (Use blank titration data as baseline) 
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10/28/2010 WT (Use endpoints data as baseline) 
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10/28/2010 WT (Use blank titration data as baseline) 
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11/17/2010 WT (Use endpoints data as baseline) 
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11/17/2010 WT (Use blank titration data as baseline) 
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10/28/2010 N5A  
 
  
 - 236 - 
 
11/11/2010 N5A  
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11/15/2010 N5A  
 
  
 - 238 - 
 
11/17/2010 N5A  
 
  
 - 239 - 
 
10/22/2010 F6A  
 
  
 - 240 - 
 
10/28/2010 F6A  
 
  
 - 241 - 
 
11/15/2010 F6A  
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9/29/2010 F16A (Use endpoints data as baseline) 
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9/29/2010 F16A (Use blank titration data as baseline) 
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10/4/2010 F16A (Use endpoints data as baseline) 
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10/4/2010 F16A (Use blank titration data as baseline) 
 
  
 - 246 - 
 
11/19/2010 F16A (Use endpoints data as baseline) 
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11/19/2010 F16A (Use blank titration data as baseline) 
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10/30/2010 I24A 
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11/4/2010 I24A 
 
  
 - 250 - 
 
11/11/2010 I24A 
 
  
 - 251 - 
 
11/15/2010 I24A 
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10/18/2010 P31A-1 (Use endpoints data as baseline) 
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10/18/2010 P31A-1 (Use blank titration data as baseline) 
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10/18/2010 P31A-2 (Use endpoints data as baseline) 
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10/18/2010 P31A-2 (Use blank titration data as baseline) 
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10/30/2010 P31A (Use endpoints data as baseline) 
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10/30/2010 P31A (Use blank titration data as baseline) 
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11/1/2010 Q45A 
 
  
 - 259 - 
 
11/4/2010 Q45A 
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11/22/2010 Q45A 
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11/1/2010 K14E-E21K 
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11/4/2010 K14E-E21K 
 
  
 - 263 - 
 
11/22/2010 K14E-E21K 
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11/1/2010 K33E-E42K 
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11/17/2010 K33E-E42K 
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11/22/2010 K33E-E42K 
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Appendix D. Recipes and Protocols 
Used in the Development of Methods 
for Aptamer Discovery 
D-1. Recipes for buffers and solutions 
 
5X PBS 
Per liter: 
NaCl  40g 
KCl  1g 
Na2HPO4 7.2g 
KH2PO4 1.2g 
Adjust pH to 7.4 with HCl. Filter and store at RT. 
 
1X PBST 
PBS  1X 
Tween-20 0.05% 
MgCl2  5mM 
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Bind and Wash buffer (for MyOne beads) 
Tris-HCl 5mM 
EDTA  0.5mM 
NaCl  1.0M 
pH 7.5 
 
1X TE 
Tris-HCl 10mM 
EDTA  1 mM 
pH 8.0 
 
NXS 
Tris-HCl  10mM, pH 7.5 
EDTA   1mM, pH 8.0 
NaCl   100mM 
Triton X-100  1% (v/v) 
SDS   1% (w/v) 
 
NX 
Tris-HCl  10mM, pH 7.5 
EDTA   1mM, pH 8.0 
NaCl   100mM 
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Triton X-100  1% (v/v) 
 
0.1 M NaOH 
Per liter: 
NaOH  4g 
  Filtered sterilize and store air tight at room temperature. 
 
20x SSPE 
 Per liter: 
NaCl   175.3g 
NaH2PO4∙H2O  27.6g 
EDTA   7.4g 
Dissolve in 800ml of H2O, adjust pH to 7.4 with NaOH, adjust volume to 1 liter. 
Filtered sterilize. Store at RT. 
 
6X SSPE w. Triton X-100 
Adjust 20X SSPE stock solution to 6X with dH2O. 
Add Triton X-100 to 0.01% 
 
10X Sodium Borate Buffer (0.5M) 
 Per liter: 
  Boric Acid  30.92g 
 - 270 - 
 
  Dissolved in 800ml of ddH2O, adjust pH to 8.5 using NaOH 
  Filtered sterilize and store at room temperature. 
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D-2. Protocol for bridge amplification and detection 
 
Materials: 
 
 SuperStreptavidin substrates slide (ArrayIt) 
 Micro Spotting Solution Plus (ArrayIt) 
 SuperStreptavidin blocking buffer (ArrayIt) 
 25ul Frame-seal incubation chambers (Bio-Rad) 
 1X PBST 
 Templates and primers (biotinylated) 
 dNTP, TurboPfu, 10X Pfu buffer 
 Sybr555 DNA stain (Invitrogen) 
 
Procedure: 
 
1. Dissolve biotinylated primer and template oligos in Micro Spotting Solution Plus 
at desired final concentration. Mix the primer and template oligos in designed 
ratio. 
2. Attach a 25-µl frame-seal incubation chamber (Bio-Rad) onto a SuperStreptavidin 
Substrates slide (ArrayIt, Sunnyvale, CA). 
3. Spot DNA samples inside the incubation chamber by pipetting. Let the sample 
hybridize with the substrates for 30 minutes at room temperature. 
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4. Block with 25 µl SuperStreptavidin blocking buffer for 1 hour at room 
temperature. 
5. Wash twice with 1x PBST for 5 minutes each time. Spin dry the slide. 
6. Prepare PCR mix as below:  
Turbo Pfu, 2.5 U/µL  2 µL 
10mM dNTP   2.5 µL 
10X Pfu Buffer   2.5 µL 
Nuclease free H2O  18 µL 
Final Volume:   25 µL 
7. Fill the chamber with the PCR mix. Seal the chamber with a plastic cover slip. 
8. Run PCR thermal cycles as below: 
1) 92°C 1 minute 
2) 92°C 30 seconds 
3) 55°C 30 seconds 
4) 72°C 30 seconds 
5) Go back to 2) for a total of 40 cycles 
6) 72°C 1 minute 
7) Hold at 4°C 
9. After amplification, remove the cover slip rinse the slide twice with 1X PBST for 5 
minutes each time. 
10. Stain the slide with 20 µl of Sybr555 DNA stain (Invitrogen) in 27ml of 1X PBST at 
room temperature for 5 minutes. 
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11. Wash the slide twice with 1X PBST for 5 minutes each time. 
12. Spin dry the slide (optional). 
13. Scan the stained slides in a GenePix 4400A microarray scanner (Axon™ 
Instruments, Union City, CA, USA). Record images using GENEPIX PRO 5.0 
software (Axon). 
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D-3. Protocol for emulsion PCR and detection 
 
Materials: 
 
 Dynal MyOne streptavidin C1 beads 
 Bind and Wash buffer 
 Dynal MPC-S magnet 
 1X TE, NXS, NX, 0.1 M NaOH, 1X PBS, 1X PBST, 6x SSPE w/ 0.01% Triton X-100 
 Templates and primers, capping and bridging oligos 
 dNTP, 10X Taq buffer without MgCl2, 50mM MgCl2 (Invitrogen) 
 hot-start Taq (5U/µl, Denville) 
 Tegosoft DEC (Degussa) 
 light mineral oil (Sigma #5904-500ml) 
 ABIL WE09 (Degussa) 
 Bis(Sulfosuccinimidyl) suberate (BS3) 
 Teflon coated glass slide (Erie Scientific) (pre-treated with aminosilane) 
 2X Self-seal reagent (Bio-Rad) 
 SuperStreptavidin blocking buffer (ArrayIt) 
 
Procedure: 
 
1. Bead-loading 
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1) Take 100 µl of Dynal MyOne paramagnetic streptavidin beads (10mg/ml) 
from stock vial, transfer into a 1.5ml eppendorf tube. 
2) Add 100ul Bind and Wash buffer into the beads. Mix and remove all liquid on 
a magnetic particle concentrator (Dynal MPC-S magnet). 
3) Wash twice in 200 µl of Bind and Wash buffer, and re-suspend in 198 µl of 
Bind and Wash buffer. 
4) Add 2ul 1mM 5’-dual-biotin labeled forward primer. Mix well by pipetting 
and incubate the mixture at room temperature for 20 minutes on a 
Dynabeads rotary mixer, or periodically mix by pipetting or flicking. 
5) Remove all liquid, and wash twice in 200 µl of Bind and Wash buffer, then 
once in 200ul of 1X TE. 
6) Remove all liquid and re-suspend beads in 200 µl of 1X TE. These beads 
should now be around 5x10^9 beads/ml. 
 
2. Emulsion PCR 
1) Prepare the aqueous and oil phase as below: 
 
Aqueous phase a: 
10X Taq buffer without MgCl2 (Invitrogen)   12 µl 
50 mM MgCl2       45 µl 
10 mM dNTP mix      17 µl 
2 mM reverse primer      1 µl 
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Pre-loaded MyOne beads in 1X TE    7.5 µl 
Hot-start Taq (5U/µl, Denville)    7 µl 
Template DNA at appropriate concentration  1 µl 
Nuclease free H2O      22.5 µl 
Total volume:       120 µl 
 
Oil phase b: 
Tegosoft DEC (Degussa)   500 µl 
light mineral oil (Sigma #5904-500ml) 138 µl 
ABIL WE09 (Degussa)    48 µl 
Total volume:     686 µl 
a. For aqueous phase, add all components except Taq polymerase, mix well 
by vortexing. Then add Taq and mix well again. 
b. For oil phase, add all components to a 15 ml polypropylene falcon tube and 
vortex well to mix. 
 
2) Add aqueous phase to oil phase, vortex well for 5 min. Distribute mix into 
PCR tubes at approximately 50 µl per tube. 
3) Run thermal cycle as below: 
 
(1) 94°C  10 minutes 
(2) 94°C  15 seconds 
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(3) 57°C  30 seconds 
(4) 70°C  75 seconds 
(5) Go back to (2) for a total of 120 cycles 
(6) 70°C  2 minutes 
(7) 4°C   hold 
 
3. Breaking emulsion 
1) Add 100 µl of isopropanol to each tube or well containing the amplified PCR 
mixture. Mix well by pipetting. 
2) Pool the isopropanol/PCR mixes into a 15 ml polypropylene falcon tube. 
Vortex for 1 minute. 
3) Spin down the beads for 30 seconds at 4000 rpm in a table-top 
microcentrifuge. Remove supernatant by decanting 
4) Add 2 ml of isopropanol and re-suspend the pellet by pipetting. Make sure 
no visible clumps in the suspension. Add 1 ml of isopropanol. Vortex for 30 
seconds. 
5) Spin for 30 seconds at 4000 rpm in a table-top microcentrifuge. 
6) Remove supernatant as much as possible. Re-suspend the pellet in 3 ml of 
NXS and mix well by vortexing. Make sure that the pellet is VERY well re-
suspended. 
7) Spin down the beads for 30 seconds at 3000 rpm in table-top centrifuge 
8) Remove supernatant using a magnetic particle separator 
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9) Wash the pellet once in 1 ml of NXS and then twice in 1 ml of 1X TE. 
10) Re-suspend in 500 µl of 0.1 M NaOH. Incubate the suspension at room 
temperature on a rotary mixer for 5 minutes. 
11) Wash once with 500 µl of 0.1 M NaOH, then twice with 500 µl of 1X TE. 
12) Re-suspend and combine beads in 30 µl of 1X TE. 
 
4. Bead Capping 
1) Prepare the hybridization mixture as below: 
6x SSPE with 0.01% Triton X-100  180 µl 
1mM Bridging oligo 1    1.8 µl 
1mM Bridging oligo 2    1.8 µl 
2) Re-suspend beads in the hybridization mixture solution, mix well and 
incubate for 10 minutes at 56°C. 
3) Mix again, and then incubate the mixture on a rotary mixer for 10 more 
minutes at room temperature. 
4) Wash the beads twice with 200 µl of TE. Prepare ligation mix as below: 
10x T4 Ligase Buffer  10 µl 
1mM Capping oligo 1  2 µl 
1mM Capping oligo 2  2 µl 
T4 DNA ligase (3U/µl)  2 µl 
Nuclease free dH2O  84 µl 
Total volume:   100 µl 
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5) Remove all liquid from beads and re-suspend them in the ligation mix 
solution. Incubate the mixture on a rotary mixer for 1 hour at room 
temperature. 
6) Remove liquid and wash beads once with 200 µl of 1X TE, once with 200 µl of 
NX, then twice with 200 µl of 1X TE. 
7) Transfer beads to a new tube, wash once with 200 µl of 1X TE, then re-
suspend the beads in 30 µl of 1X TE. 
 
5. Bead attachment 
1) Wash beads three times in 50 µl of 1X PBS. 
2) Prepare fresh BS3 solution (2.86 mg of Bis(Sulfosuccinimidyl) suberate in 1 ml 
of 1X PBS). 
3) Remove all liquid from beads, quickly re-suspend the beads in 35 µl of fresh 
BS3 solution 
4) Apply the beads onto the glass surface of the center circle on a Teflon coated 
glass slide (Erie Scientific) that has been pre-treated with aminosilane. Cover 
the circle with a cover slip. 
5) Incubate the slide with beads at room temperature for 1 hour without 
disturbing. 
6) Wash the slide twice with 1X TE for 5 minutes each time to remove any 
unattached beads. 
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6. Staining the beads with TBA probe (on slide) 
1) Add 35 µl of 6x SSPE w/ 0.01% Triton X-100 to each circle, cover with cover 
slip. 
2) Incubate the slide at 56°C for 10 minutes. 
3) Wash immediately with 1x TE twice for 2 minutes on labquake. Add 35 µl of 
the following staining solution: 
 
6x SSPE w/ 0.01% Triton X-100  149 µl 
1mM 5’-6-FAM-TBA comp oligo  1 µl 
Total volume:     150 µl 
 
4) Cover with a cover slip. Incubate the slide on a thermal cycler using a heat 
cycle setting as below: 
56°C  2 minutes 
40°C  10 minutes 
25°C  10 minutes 
5) Wash twice with 1x TE for 5 minutes each time on a labquake. 
6) Spin dry the slide. Add 25 µl of 1x self-seal reagent in TE, cover with a cover 
slip. 
 
7. Staining the beads with TBA probe (unattached, in tube) 
1) Wash beads wash twice with 200 µl of 6X SSPE.  
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2) Prepare the staining solution as below: 
6X SSPE     149 µl 
1mM 5’-6-FAM-TBA comp oligo  1 µl 
Total volume:     150 µl 
3) Re-suspend beads in 150 µl of the staining solution. Incubate in a thermal 
cycler using the same heating cycles as described above. 
4) Wash the stained beads twice with 200 µl of 1XTE. 
5) Re-suspend the beads in 25 µl of 1X self-seal reagent in 1X TE, apply the 
suspension onto a glass slide, and cover with a cover slip. 
 
8. Staining the beads with thrombin (on slide) 
1) Block the slide with SuperStreptavidin blocking buffer for 1 hour at room 
temperature. 
2) Prepare staining solution as below: 
1X PBST     150 µl 
Thrombin (Cy3 or Cy5 labeled)  500 nM (final concentration) 
Total volume:     150 µl 
3) Apply 25 µl of the staining solution onto each circle and cover with a cover 
slip. Incubate the slide overnight at room temperature. 
4) Wash the stained slide twice with 1X PBST and twice with 1X PBS for 10 
minutes each time. 
5) Add 25 µl of 1x self-seal reagent in TE, cover with a cover slip. 
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9. Staining the beads with thrombin (unattached, in tube) 
1) Wash the beads twice with 200 µl of 1X PBST.  
2) Prepare the staining solution as below: 
1X PBST     150 µl 
Thrombin (Cy3 or Cy5 labeled)  500 nM (final concentration) 
Total volume:     150 µl 
3) Re-suspend beads in 150 µl of the staining solution. Incubate overnight at 
room temperature. 
4) Wash the stained beads twice with 200 µl of 1X PBST and twice with 200 µl of 
1X PBS for 5 minutes each time. 
5) Re-suspend the beads in 25 µl of 1x self-seal reagent in 1X PBS, apply the 
suspension onto a glass slide, cover with a cover slip. 
 
10. Visualization using Nikon TE2000 microscope 
1) Turn on Nikon TE2000 microscope in the following order: 
a. X-Cite mercury bulb 
b. Nikon Scope 
c. Spot Camera 
2) Light path of different ports are: 
Port 1: eye; 
Port 5: camera; 
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Port 3: both eye and camera. 
3) Emulsion beads are only visible under a 100X objective. Use oil specific for 
Nikon microscopes. 
4) Lower the platform before load the sample slide. Slowly raise the platform 
using the adjusting screw. When the objective hits the oil drop, a sudden 
flash of light can be seen. Start micro-tuning at that point. 
5) Take one bright field image and one fluorescence image of the same 
microscopic field. 
6) Use ImageJ to view and measure the photos. 
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D-4. Protocol for aminosilane treatment of glass slides 
 
Materials: 
 
 Teflon coated glass slide (Erie Scientific) 
 Glass rack for microslides 
 0.5% Triton X-100 in dH2O 
 100% ethanol, dry acetone 
 aminopropyl triethoxysilane (Thermo Pierce) 
 
Procedure: 
 
1. Load glass slides onto a glass rack with handle. 
2. Immerse glass slides in solution of 0.5% Triton X-100 in dH2O. Wash by manually 
agitating the rack for 1 minute. 
3. Pour all liquid off and wash thoroughly under running water to remove all 
detergent. Rinse with dH2O. 
4. Pour off all liquid and dry by immersion in 100% ethanol. Remove slides from 
ethanol and allow all ethanol to evaporate (aided by use of a Dust-off 
compressed air canister if possible). 
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5. Prepare 2% aminopropyl triethoxysilane (Pierce) solution in dry acetone in a 
glass beaker. Pipette with glass pipettes (the solution will react with 
polystyrene). 
6. Immerse rack of completely dry (and ethanol-free) glass slides in silane solution 
for 30 seconds. Use the handle to manually agitate the rack. 
7. Remove and immediately immerse in fresh dry acetone rinse for 1 minute. Use 
the handle to manually agitate the rack. 
8. Remove rack and blow-dry partially with compressed air (to remove the bulk of 
the acetone). 
9. Completely air-dry and store under vacuum at RT. 
10. When cleaning beakers containing acetone and aminopropyl triethoxysilane, be 
sure to rinse with fresh acetone to remove all traces of aminopropyl 
triethoxysilane. If present, it will form a white precipitate upon evaporation of 
acetone. 
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D-5. Protocol for labeling protein with Cy3 or Cy5 
 
Materials: 
 
 Protein 
 0.05M Borate buffer (pH 8.5) 
 DyLight 549 or 649 microscale antibody labeling kit (Pierce) 
 Illustra microspin column (GE) 
 
Procedure: 
 
1. Dialyze the protein sample against 0.05M Borate buffer (pH 8.5) overnight. 
2. Take 100 µl of dialyzed protein (around 1mg/ml), add to one vial of DyLight 549 
or 649 dye (DyLight 549 equals Cy3, DyLight 649 equals Cy5), pipet to mix. 
3. Incubate the mixture at room temperature for 1 hour. 
4. Take 100 µl of purification resin (from the labeling kit), add to an Illustra 
microspin column (GE). 
5. Spin the resin at 1000g for 30 seconds. 
6. Change collection tube, apply the protein-dye mixture onto the center of the 
resin column. 
7. Spin the column at 1000g for 30 seconds. 
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8. Collect the flow through, measure protein concentration and label efficiency by 
UV-Vis absorption. 
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